Studies of Aphthovirus Subunits and Synthetic Peptides Relevant to Their Use as Vaccines Against Foot and Mouth Disease. by Murdin, Andrew David.
STUDIES OF APHTHOVIRUS SUBUNITS AND SYNTHETIC 
PEPTIDES RELEVANT TO THEIR USE AS VACCINES AGAINST 
FOOT AND MOUTH DISEASE.
A Thesis submitted to the University of Surrey 
for the Degree of Doctor of philosophy 
in the Faculty of Biological and Chemical Sciences
by
ANDREW DAVID MURDIN
January, 1986.
ProQuest Number: 27696204
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 27696204
Published by ProQuest LLO (2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
ABSTRACT
Laboratory animals and cattle were vaccinated with 
the aphthovirus capsid protein VPl or with 
aphthovirus-specific synthetic peptides. The 
peptides used copied either the sequence of amino- 
acids 141-160 from the VPl of aphthovirus strains 
OIBFS 1860 and 01 Kaufbeuren (the 0 peptide) or the 
equivalent sequence from aphthovirus strain A24 
Cruzeiro (the A peptide). VPl was isolated by 
chromatofocusing from aphthovirus strains OlBFS 
1860, A24 Cruzeiro and Asia 1 Iran 1/73.
The 0 peptide and the VPls were poorly immunogenic, 
even when coupled to keyhole limpet haemocyanin 
(KLH), and conferred little or no protection 
against challenge with infectious virus. In 
contrast KLH-A peptide had good immunogenicity and 
vaccinated guinea-pigs were protected from 
challenge. All animals vaccinated with KLH-peptide 
demonstrated considerable diversity in their 
responses, both between strains and between 
individuals of the same strain. These results may 
reflect differences between 0 and A serotype 
viruses and variations in the immune response genes 
of the animals studied.
The immune responses were long-lasting. Guinea- 
pigs and rabbits possessed significant levels of 
antibody a year after vaccination, though the 
specificity of the antibody varied with species and 
peptide. In some species KLH-peptide stimulated an 
anamnestic immune response. However, in vitro
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experiments with mouse splenocytes showed that 
peptides were less effective than virus in this 
respect.
KLH-peptide was less immunogenic, in terms of 
conferring protection and generating neutralizing 
antibodies, than virus. Sera from KLH-peptide- 
vaccinated guinea-pigs were relatively inefficient 
at forming immune complexes with virus and at 
neutralizing virus. Peptide-induced neutralizing 
antibodies appeared to correspond to a weakly- 
neutralizing sub-population of virus-induced 
neutralizing antibodies.
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ABBREVIATIONS
The following abbreviations are used in the text:- 
AEI Acetylethyleneimine
AH Aluminium hydroxide adjuvanted
AVRI Animal Virus Research Institute
BHK Baby hamster kidney
BSA Bovine serum albumin
CB Carbonate buffer
CMI Cell mediated immunity
DNFB Dinitrofluorobenzene
ELISA Enzyme linked immunosorbent assay
F-AH Freund's complete adjuvant plus aluminium
hydroxide
FCA Freund's complete adjuvant
FMD Foot-and-mouth disease
Ir genes Immune response genes 
KLH Keyhole Limpet Haemocyanin
LPS Lipopolysaccharide
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tétrazolium bromide 
PBS Phosphate buffered saline
p.i. post infection
p.v. post vaccination
poly A polyadenylic acid 
poly C polycytidylic acid 
SDS Sodium dodecyl sulphate
SNT serum neutralization titre (serum titre
of virus neutralizing antibody)
SPB Sorensen's phosphate buffer
TCID50 Tissue culture 50% infectious dose
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TCPU Tissue Culture Production Unit
TEMED Tetramethylethylenediamine
VRD Vaccine Research Department
See section 2.7.1. for a list of animal strains in 
this study.
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INTRODUCTION
1.1. Overview.
Foot and mouth disease {FMD), a highly infectious 
viral disease of cloven hooved animals, is a major 
cause of economic loss to the livestock industry. 
Typically, the disease is not fatal but causes a 
reduction in productivity, principally as weight 
loss and decreased milk yields. Additional costs 
may be incurred due to control programmes which 
require constraints on movement, slaughter of stock 
and export restrictions.
The causative agent of FMD is aphthovirus, commonly 
still referred to as foot-and-mouth disease virus. 
It is a member of the family picornaviridae and 
consists of a RNA genome enclosed in a protein 
capsid.
The disease has a global distribution, occurring 
widely throughout Asia, Africa, Europe and south 
America. vaccination is widely used in those 
countries with endemic disease, though other 
control measures may be used in countries which are 
generally disease free.
Modern vaccines are produced by inactivation of 
virus grown in tissue culture and these have been 
very effective in helping to control the disease in 
many parts of the world. Nevertheless, instability 
and incomplete inactivation can cause problems with 
such vaccines. Because of this much attention has 
been devoted to alternative vaccines in which the 
antigen is based upon an immunogenic subunit of the 
virus. Ideally, subunit or synthetic vaccines
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should be cheap and inocuous products, of 
standardised and defined composition, which are of 
comparable immunogenicity to conventional vaccines. 
While much has been hoped for from these 
alternative vaccines they are not yet competitive 
with conventional vaccines, either in terms of 
price or protection conferred, and further studies 
are clearly required. This thesis seeks to
contribute to such studies by examining some 
properties of aphthovirus proteins and of synthetic 
peptides mimicking parts of those proteins in 
relation to their use as vaccines against FMD.
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1.2. Foot and Mouth Disease.
1.2.1. Symptoms and Effects.
The most important domestic animals susceptible to 
FMD are cattle, pigs, sheep and goats. The disease 
is typically acute and the usual symptoms are fever 
with accompanying vesicles, the location of which 
varies between species. In cattle vesicles occur 
in the mouth, on the udder and on the feet. In 
pigs the lesions are mainly restricted to the feet 
and snout, while in sheep and goats they are 
usually confined to the feet alone.
The disease is highly infectious, with morbidities 
approaching 100% in susceptible herds. Although 
mortality is generally less than 5% amongst adult 
animals, heart lesions in calves and piglets 
contribute to mortality rates as high as 50% 
amongst young animals.
It is not, however, the deaths due to the disease 
but the reduced productivity of infected herds that 
constitutes the major economic effect. The loss of 
productivity is generally estimated at 25%. 
Infected animals lose weight, some develop chronic 
lameness and metabolic disorders, milk yield is 
reduced and pregnant animals may abort. A 
secondary, but no less important, effect is that 
control measures may require the slaughter of 
valuable stock and place severe restrictions upon 
trade (see section 1.2.4.).
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1.2.2. History.
A disease with symptoms strikingly similar to those 
of FMD was described by the Italian author 
Fracastorius (1546) as having infected many herds 
of cattle in Italy in 1514. Certainly the disease 
was endemic throughout Europe in the 19th century, 
though rather overshadowed by more serious diseases 
such as rinderpest (Brooksby, 1982).
Loeffler and Frosch (1897) recorded the 
filterability of the causative agent of FMD, the 
first demonstration that an animal disease could be 
caused by a filterable agent. Indeed, the only 
previous description of a filterable infectious 
agent was of tobacco mosaic virus by Ivanovsky 
(1892) .
An early observation concerning FMD outbreaks was 
that recent infection did not necessarily confer 
immunity to the disease. This was not explained 
until Vallee and Carre (1922) showed, from cross­
protection studies in convalescent cattle, that 
there was more than one form of aphthovirus. This 
observation was unprecedented in virology. The two 
'serotypes' that they found were designated 0 
(Oise) and A (Allemagne). A third serotype, 
designated C, was found shortly afterwards by 
Waldman and Trautwein (1926), and by 1954 seven 
immunologically distinct but clinically identical 
serotypes had been found. The four new serotypes 
were South African Territories (SAT) 1, 2 and 3,
and Asia 1 (Brooksby, 1958).
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1.2.3. Geographical Distribution.
FMD occurs worldwide, though the distribution of a 
given serotype may be relatively restricted. Types 
0 and A, the most widespread, occur throughout 
Europe, the Middle East, southern Asia, Africa and 
South America. Type C has been reported from
Europe, India, South America and some areas in 
Africa. Types SAT 1 and SAT 2 are usually found 
only in sub-Saharan Africa, though outbreaks 
further north are not unknown and SAT 1 spread as 
far as Turkey in 1963. SAT 3 has a very limited 
distribution in southern Africa. Asia 1 occurs 
throughout the Middle East and southern Asia but 
shows no sign of spreading to Africa or Europe 
(Rweyemamu et a l , 1982; Brooksby, 1982).
Three levels of disease situation have been 
described (Rweyemamu et al, 1982). Firstly, many 
countries are presently entirely free from the 
disease. Included in this category are the whole 
of Australia, Central and North America,
Scandinavia and many island nations such as the UK, 
Japan and the Caribbean states. Secondly, in most 
European countries FMD occurs only sporadically and
is effectively excluded by programmes of
vaccination. Thirdly, the disease is endemic 
throughout much of South America, Africa and Asia, 
though control schemes of varying efficiency may 
have been implemented. It should be noted that in 
parts of the Middle East, S.E. Asia, the USSR and 
China comprehensive information is difficult to 
aquire.
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1.2.4. control Programmes.
Ideally, the ultimate aim of any control programme 
would be the creation and maintenance of a totally 
disease free state. practical considerations 
usually result in more modest programmes designed 
to reduce the incidence of disease or to confine it 
to restricted areas. Measures taken to control FMD 
vary according to which of the above disease 
situations prevails.
Those countries free from the disease seek to 
maintain this state by imposing strict controls 
upon the import of animals and animal products. In 
the event of an outbreak of disease all infected 
animals and contacts are slaughtered and strict 
controls are imposed upon stock movement 
(Northumberland Committee, 1969; Sellers, 1972). 
Since most countries free from FMD are 
geographically isolated import controls are usually 
effective, though outbreaks may occur despite such
controls. For instance the most recent UK
outbreak, which affected Jersey and the Isle of
Wight in 1981, was most probably caused by the 
airborne spread of virus from the French mainland 
(Donaldson et a l , 1981).
The policy of exclusion and slaughter avoids the 
heavy and recurrent expense of vaccination, but in 
the UK and some other countries a strategic reserve 
of vaccine is maintained. This could be used for 
ring vaccination around an infected area to 
reinforce a slaughter policy (Sellers, 1972; 
Rweyemamu et a l , 1982), though the large number of
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aphthovirus subtypes and the limited cross 
protection that each affords means that any reserve 
vaccine must be chosen with care. In addition 
stored vaccines may have a limited shelf life (Doel 
and Baccarini, 1981; Doel and Collen, 1982). For 
these reasons the concept is emerging of a vaccine 
reserve based on concentrated virus stored over 
liquid nitrogen that can be formulated at very 
short notice (Doel, T.R., 1984, personal
communication).
In countries where only sporadic outbreaks of FMD 
occur the usual control measure is routine 
vaccination. In the event of an outbreak a 
slaughter policy comes into effect, reinforced by 
stringent zoosanitary precautions and, possibly, 
ring vaccination.
TWO control situations can be discerned in those 
countries where FMD is enzootic. All South 
American and some African and Asian countries carry 
out vaccination programmes which are supported by 
zoosanitary procedures of varying efficiency. At 
the worst this has restricted the disease to mainly 
young animals and in many cases has led to virtual 
eradication of the disease (Rweyemamu et al, 1982). 
In most African and Asian countries vaccination is 
sporadic, with the intention of protecting selected 
herds rather than controlling an enzootic disease 
(Rweyemamu et al , 1982). In many parts of the
world FMD control schemes are often neglected 
because of political instability, war, corruption 
or merely insurmountable logistical problems.
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Bachrach (1968) has aptly stated that control 
measures adopted by a particular country must take 
into account that country's geography, climate, its 
patterns of trade and livestock production, the 
degree of technological and economic development 
and the prevailing cultural, political and 
psychological attitudes.
1.3. Aphthovirus.
1.3.1. Classification.
Aphthoviruses constitute one entire genus, 
aphthovirus, of the family picornaviridae, which 
also includes the genera rhinovirus, cardiovirus 
and enterovirus. Features common to the family are 
small size, the possession of a single stranded RNA 
genome, icosahedral morphology and lack of a lipid 
envelope. The family is currently divided into 
four genera according to buoyant density, 
sensitivity to acid pH and genomic structure 
(Report of International Enterovirus Study Group, 
1963; Cooper et al , 1978).
The aphthovirus virion comprises a protein capsid 
containing one copy of a single-stranded positive 
sense RNA genome and its distinguishing features 
are a diameter of 23-35nm, a buoyant density in 
CsCl of 1.43-1 *45gm/cm^ and extreme instability 
under acid conditions. The RNA genome is 31.5% of 
the virion by weight and, in common with the 
cardioviruses, contains a polycytidylic acid (poly 
C) tract near the 5' terminus.
1.3.2. Genome structure.
The genome of aphthovirus has a molecular weight of 
about 28,000kd (Wild and Brown, 1970) which 
corresponds to a length of approximately 8000 
nucleotides. The main structural features of the 
genome are shown in figure 1.1.
A small protein, V P g , is covalently bound to the 5' 
terminus of the aphthovirus genome (Sangar et a l ,
1977), as is the case for many other RNA viruses 
(Lee et al, 1977; Flanegan et al , 1977; Hruby and 
Roberts, 1978). The picornavirus genome is
apparently synthesized with this protein attached 
(Nomoto et al , 1977), but its function is not fully 
understood. It may be that VPg acts as a primer 
for RNA synthesis, as poliovirus RNA can be 
elongated but not initiated in vitro in the absence 
of VPg (Caliguiri, 1974). The protein is not 
required for infectivity in picornaviruses, though 
it is in some other RNA viruses (Rothberg et al , 
1980). Harris (1979b) speculated that the protein 
may be required for encapsidation Of the RNA.
The VPg of aphthovirus is polymorphic. King et al 
(1980) demonstrated that a heterogenous VPg 
population could be obtained from plaque-purified 
aphthovirus preparations. The reason for this was 
determined by Forss and Schaller (1982) who found 
that there were three closely related tandem repeat 
genes for VPg in the aphthovirus genome, the first 
time that this had been observed in a picornavirus. 
The significance, if any, of the polymorphism is 
unknown. ^
The S (short) fragment, a region some 250-400 bases 
long, lies at the 5' end of the aphthovirus genome 
(Rowlands et al, 1978; Harris, 1979a; Harris,
1980). This fragment is apparently non-coding, 
insofar as it is not translated in vitro and it 
does not appear to code for any of the viral 
proteins known to be produced in vivo (Sangar et al 
, 1980). There is an AUG start codon near the 5'
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end of the S fragment of aphthovirus type AlO 
(Harris, 1979a) but this is not a conserved feature 
of RNA's from the other serotypes and probably has 
no functional significance (Harris, 1980). The 
sequence at the 5 ' terminus is conserved to a 
considerable extent between serotypes and has the 
potential to form a stable secondary structure, 
perhaps because this region must interact in some 
way with VPg, with ribosomes or with the RNA 
polymerase (Harris, 1980; Harris et al , 1980).
The poly C tract links the S fragment to the L 
(long) fragment (Brown et a l , 1974). It is a
conserved feature of aphthovirus, though its length 
may vary between isolates (Harris and'Brown, 1977;
Black et a l , 1979; La Torre et 1982). The
function of the tract is not known, though Harris 
and Brown (1977) have suggested that its length may 
be related to virulence. It is not required for 
translation, as isolated L fragments lacking both 
poly C and the S fragment can be translated in 
vitro (Harris et al, 1980; Sangar et al , 1980).
The only known coding region of the aphthovirus 
genome is the L fragment. This contains a major 
initiation site at its 5' end and some minor 
initiation sites at other points throughout its 
length. The minor sites are not thought to have 
any significance in vivo (Sangar et a l , 1980). The 
products of translation are shown in figure 1.1 
(see also section 1.3.5.).
The 3 ' end of the genome is occupied by a 
polyadenylic acid tract 40 to 100 residues long.
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The function of this region, too, is not fully
understood though it seems to be connected with 
infectivity in some picornaviruses (Sangar, 1979). 
Several groups have used ribonuclease Tl mapping or 
hybridization studies to detect homologies between 
the genomes of various strains of aphthovirus 
(Harris et a l , 1980; Robson et al , 1980; Marquardt, 
1982). Excluding the region coding for the capsid 
proteins they found up to 80% homology within
serotypes and up to 65% homology between serotypes. 
In contrast, the capsid protein coding sequences
were far more heterologous, particularly the VPl 
and VP 3 coding sequences which showed as little as 
10% homology between some serotypes. The
variability of this region of the genome, and of
the length of the poly C tract, is sufficient to
allow one- and two-dimensional ribonuclease Tl maps 
to be used as diagnostic tools for the
differentiation of aphthovirus subtypes (King et al 
, 1981; La Torre et a l , 1982).
Much of the L fragment, especially that part coding 
for the capsid proteins, has been sequenced. This 
has revealed many homologies, even within the
capsid protein coding sequences. Section 1.3.4.
reviews this and other data concerning the capsid 
proteins.
1.3.3. capsid structure.
The aphthovirus capsid is approximately 70% of the 
virion by weight and is constructed of 60 copies 
each of four proteins, VPl, VP2, VP3 and VP4 
(Burroughs et a l , 1971; Brown, 1979). A few
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molecules (two by analogy with other 
picornaviruses, Rekosh, 1977) of VPO, the uncleaved 
precursor of VP2 and VP4, may be present. It has 
been reported that the virion also contains three
non-structural proteins. These are the virus coded
RNA polymerase, p56a, (sangar et al , 1976), a 
ribonuclease of unknown origin (Denoya et al , 1978) 
and a protein kinase, also of unknown origin, able 
to phosphorylate some of the structural proteins 
(Grubman et al , 1981).
The sedimentation coefficient of the aphthovirus 
virion has been determined to be 145.2S +/- 1.5S
(Strohmaier and Adam, 1976). The commonly accepted 
value is 146S. Disruption of the 146S virus 
particle by acid or heat treatment releases free 
RNA, 12S particles containing VPl, VP2 and VP3 in 
equimolar amounts and an insoluble precipitate of 
VP4 (Burroughs et al, 1971). Strohmaier and Adam 
(1976) proposed that the 12S particle contained 
three molecules of each of VPl, VP2 and VP3, and 
that the virion was formed from twenty 12S
particles located at the faces of the icosahedral 
particle. The most recent model for the
aphthovirus capsid is that of Vasquez et al (1979), 
who suggested that the capsid was composed of 
twelve 12S subunits. In this model the 12S 
subunits are pentamers of a further subunit 
containing one molecule each of VPl, VP2 and V P 3 
and are located at the twelve vertices of the 
icosahedral 146S particle. VP4 is loosely bound 
within the particle and is not part of any
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suggested structural unit. This agrees with the 
proposed structures of several other picornaviruses 
(reviewed by Rekosh, 1977; Putnak and Phillips,
1981) and with the molecular weight determined for 
12S by Brown and Morrell (1980).
In addition to the 146S virion other viral
particles may be. produced in infected cells. The
75S ('natural empty') particles are RNA-free 
capsids (Graves et al , 1968a) which contain a
higher than usual proportion of VPO (Rowlands et al 
, 1975). Natural 12S particles, the composition of 
which has not yet been determined (Brown, 1980), 
are also thought to occur. A particle sedimenting 
at 3S, the "virus Infection Associated" (VIA)
antigen, co-electrophoreses with P56a and is 
probably an inactive form of the molecule (Sangar 
et a l , 1976; Newman et al, 1979).
Vasquez et al (1981) isolated several virus related 
structures with sedimentation coefficients ranging 
from 50S to 190S. These were obtained during the 
purification of aphthovirus and, with the 
exceptions of the 146S virion and of the 75S empty 
particle, were present in very small quantities. 
Some of the structures could be purified 
sufficiently for examination in the electron
microscope and for analysis of their constituent 
proteins. Structures of 90S, 85S and 55S contained 
the four capsid proteins and VPO in similar 
proportions to those found in 75S particles and, in 
addition, contained other polypeptides of uncertain 
origin. On the basis of this data the authors
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proposed a role for the 90S particle in the 
morphogenesis of FMDV, but this has yet to be 
confirmed.
1.3.4. The capsid proteins.
Burroughs et al (1971) first reported that 
aphthovirus possessed four capsid proteins, VPl, 
VP2, VP3 and VP4. The molecular weights of these 
proteins were originally determined, by gel 
electrophoresis, to be 34,000, 30,000, 26,000 and
13,500 daltons respectively (Talbot and Brown, 
1972), but more recent estimates, calculated from 
the amino acid sequences, are lower. Boothroyd et 
al (1981) calculated molecular weights for the 
capsid proteins of aphthovirus strain AlO 61 as 
23,248 for VPl, 24,649 for VP2, 24,213 for VP3 and 
7,360 for VP4. Whilst these values are more
accurate than the earlier estimates it is possible 
that they are too low, as there is some evidence 
that all of these proteins are phosphorylated (La 
Torre et al, 1980; Grubman et al , 1981).
King and Newman (1980) found the isoelectric points 
of the capsid proteins of 01 Pacheco to be 8.3 for 
VPl, 6.2 to 6.6 for VP2, 5.6 to 5.1 for VP3 and 4.7 
for VP4. These were approximate values determined 
under non-equilibrium conditions. Their
electrofocusing technique was primarily designed to
detect charge differences rather than to determine
absolute pi values, and was sufficiently sensitive 
to detect single charge changes in the proteins 
VPl, VP2 and VP3. When used diagnostically
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electrofocusing was able to demonstrate charge 
differences between the capsid proteins of closely 
related strains of aphthovirus (King and Newman, 
1980; King et a l , 1981). This was thought to
represent differences in amino acid sequence rather 
than degrees of phosphorylation (Lowe et al , 1981). 
During the last five years several laboratories 
have developed experimental cloned protein vaccines 
against FMD (see section 1.6.3a.). In the course 
of this work much information was obtained about 
the capsid proteins. The existence of cDNA copies 
of the viral genome allowed the amino acid 
sequences of VPl and of other viral proteins to be 
determined (Boothroyd et al , 1981; Kurz et a l , 
1981; Boothroyd et al, 1982; Makoff et al , 1982;
Beck et a l , 1983). Cheung et al (1983) determined 
two VPl sequences (from aphthovirus strains 01 
Campos and C3 Indaial) and compared these with the 
eight previously published sequences (all from 
serotypes A, 0 or C). They found that although 
most of the amino acid sequence was conserved the 
protein contained two highly variable regions. The 
amino acids at sequence positions 42-60 varied 
among serotypes but were conserved within serotypes 
whereas the amino acids at positions 134-158 tended 
to be highly variable among all strains examined. 
These conclusions were in accord with earlier 
comparisons based on fewer available sequences. 
Though some sequences have been determined for the 
other capsid proteins (Boothroyd et al 1981, 1982)
too few sequences are available for meaningful
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comparisons to be made. However Meloen and Briare 
(1980) showed anti-VP2 sera was completely cross- 
reactive between 12S particles from a type A and a 
type 0 virus. They concluded that identical 
antigenic regions of the VP2 were exposed on the 
12S particles of each serotype, though this did not 
necessarily mean that the amino acid sequences of 
these regions were wholly conserved. Their results 
also showed anti-VP3 sera to be partially cross­
reactive, though the degree of sequence homology 
between the two serotypes could not be determined. 
Talbot et al (1973) examined the antigenicity of 
VP4. Anti-VP4 sera was found to react similarly 
with homologous or heterologous VP4, suggesting 
conserved antigenic sites on the protein.
The precise arrangement and structure of the capsid 
proteins within the aphthovirus capsid has not yet 
been determined, but it is known that portions of 
VPl are exposed on the surface of the virion. The 
protein is sensitive to the action of trypsin upon 
the native particle (Burroughs et a l , 1971) and 
carries the immunogenic and cell attachment sites 
of the virus (Rowlands et al , 1971; Bernard et al , 
1975; cavanagh et al , 1977), properties which are
consistent with a surface location. More recently 
Robertson et al (1983) have identified a region of 
VPl, sequence positions 136 - 144, which is exposed 
on the virion surface.
Meloen and his colleagues (Meloen et al , 1979; 
Meloen and Briare, 1980) used antisera against each 
of the capsid proteins to probe 146S virions and
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artificial 75S (formed by treating the virus with 
EDTA) and 12S subunits. They found that only VPl 
antigens were exposed on the intact virion, whereas 
75S particles exposed VPl and VP2 antigens and 12S 
exposed antigens of VPl, VP2 and VP3. Talbot et al 
(1973) were similarly unable to demonstrate VP4
antigens on the surface of intact virus particles, 
though VP4 could be iodinated after the virus was 
treated with trypsin. This suggests that VP4 is
buried within the intact virion.
Two groups have attempted to predict the molecular 
structure of parts of VPl. Pfaff et al (1982), 
using several methods, identified seven probable 
helical regions within the VPl of aphthovirus
serotype 01 Kaufbeuren. Two helices, occurring 
between sequence positions 143 and 182, were 
predicted to possess both hydrophobic and 
hydrophilic faces and hence to lie on the surface 
of the virus (see also section 1.6.3b.). Rowlands 
et al (1983) proposed structures for the 141 to 160 
regions of four VPl's and they, too, predicted that 
these regions would be substantially helical. They 
attempted to correlate their predictions with 
studies on the antigenicity of synthetic peptides 
copying the sequences of these regions. However, 
the validity of all such structural predictions has 
recently been challenged. Kabsch and Sander (1984) 
examined a diverse group of proteins of known 
structure and found that identical pentapeptides 
displayed a marked variability in conformation from 
protein to protein. They concluded that the
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accurate prediction of structure from sequence data 
required a new approach.
The classic probe of protein structure is X-ray 
crystallography. Aphthovirus has been crystallized 
(Rowlands, 1985) but no results are yet available, 
some studies of poliovirus crystals have been made 
(Finch and Klug, 1959; Hogle, 1983). To date only 
the nature of the packing of the virus within the 
crystals has been determined but it is thought that 
it will be possible to determine the structure of 
poliovirus with a resolution of at least 2.9A 
(Hogle, 1983). Rhinovirus crystals similar in 
structure to poliovirus crystals have also been 
described (Erickson et al , 1983), but once again 
the fine structure of the virion is not yet known.
1.3.5. infection and Replication.
The course of infection of a host cell by a 
picornavirus and the subsequent replication of the 
virus can be briefly summarised as follows. After 
the virus attaches to the cell surface the capsid 
releases the genome into the cell. The genome is 
replicated and capsid proteins synthesized at the 
expense of normal cellular functions. The newly 
synthesized proteins are thought to be assembled 
into capsid protomers which in turn are assembled 
into virions, incorporating a copy of the genome in 
the process. The new virions are then released by 
lysis of the host cell. In this respect 
aphthovirus appears to be a typical picornavirus, 
though it has not been studied as extensively as 
some members of the family. For recent reviews of
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picornaviral replication see Rueckert (1976), 
Rekosh (1977), Sangar (1979), Agol (1980) and
Putnak and Phillips (1981).
The aphthovirus virion first attaches to a cell by 
a non-specific electrostatic mechanism requiring 
di-valent cations (Brown et al, 1962). In the case 
of other picornaviruses the attached virion is then 
bound more tightly as receptors are recruited from 
the cell membrane (Lonberg-Holm and philipson,
1974). The attachment site on picornaviruses is 
located on VPl (for the case of aphthovirus see 
section 1.3.4.), though loss of VP4 from the virion 
will prevent binding, presumably by causing
conformational changes in the capsid (Lonberg-Holm 
and Korant, 1972). The receptor on the cell has 
not been identified.
The process by which the picornavirus genome enters 
the cell is still not completely understood.
Virions tightly bound to the membrane are 
subsequently dissociated into 12S particles,
releasing the genome. Cavanagh et al (1978), 
working with aphthovirus, found that this occurred 
within the cell, but their data does not preclude 
the possibility that the virus is dissociated at a 
protected site on or within the membrane. Within 
three to four hours (depending on the virus) of the 
genome entering the cell, synthesis of cellular 
protein ceases and synthesis of cellular RNA and 
DNA is reduced (Rekosh, 1977; Agol, 1980).
The genome serves two functions, acting both as a 
template for its own replication and as a message
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for the synthesis of viral proteins. Replication 
of the picornavirus genome takes place in two 
stages. Because the genome is a positive strand of 
RNA the first stage is the synthesis of a 
complementary negative strand. This is then used 
as à template for the production of new positive 
strands (Agol,1980). Replication of aphthovirus 
RNA occurs in a structure known as the 'replication 
complex , located on the rough endoplasmic 
reticulum (Lazarus and Barzilai, 1974). The 
complex contains positive and negative RNA strands 
plus several proteins, of which the major component 
is the virus coded RNA polymerase, p56a (Newman et 
al / 1979). In the case of poliovirus the RNA is
present in the replication complex as the 
replicative intermediate form, a full length strand 
plus several partially complete complementary 
strands (Baltimore, 1968). There is presumably a 
control mechanism governing the ratio of positive 
to negative strands and their fate (transcription 
templates, mRNA or encapsidation), but its nature 
is unknown.
Synthesis of cellular proteins is greatly reduced 
within thirty minutes of picornaviral infection and 
cellular ribosomes are recruited into viral 
polyribosomes for translation of the viral genome 
(Baltimore, 1969). Translation of poliovirus RNA 
apparently requires the removal of VPg (Nomoto et 
al, 1977) and at least some aphthovirus mRNA lacks 
this protein (Sangar, 1979). The aphthovirus 
genome contains one major initiation site close to
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the 3 ' side of the poly C tract (see section
1.3.2.). Translation of the aphthovirus genome 
yields four primary products which are then 
cleaved, either autolytically or by the virus coded 
protease (Rueckert et a l , 1980), following one of
the several alternative pathways (see fig. 1.1). 
Most of the work on assembly of picornavirus 
particles has been conducted with polio or EMC 
viruses, though some data is available for 
aphthovirus. viral particles produced in
aphthovirus infected cells are fully described in 
section 1.3.3.. Briefly, these may include 75S 
particles, which are RNA-free capsids, and 12S
particles, subunits of the capsid. By analogy with 
the data for other picornaviruses these have 
several possible roles in the morphogenesis of the 
virion (Rekosh, 1977; Putnak and Phillips, 1981). 
The 12S particles may self-assemble into 75S 
capsids, which then incorporate a RNA molecule to 
form a complete virion. Alternatively, the 12S
particles themselves may interact with the.RNA to 
form virions, bypassing the 75S particle. In this
model the 75S particle is seen either as a means of
storing 12S particles or as a by-product of the 
assembly process without any function. As a third 
alternative the 75S and 12S particles may have no 
role at all in morphogenesis, the capsid proteins 
(or their precursor, P88) forming the capsid 
directly around the genome. Sangar (1977) favoured 
the last mechanism as the likely means of assembly. 
However, the data obtained by Yafal and Palma
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(1979), whilst not conclusive, suggest that the 75S 
particle of aphthovirus is a direct precursor of 
the virion, consistent with the first of these 
possible mechanisms.
Once assembly has occurred, virions are released 
from the infected cell by lysis. There is some 
indication that this process is controlled by the 
virus (Rekosh, 1977), but the mechanisms involved 
are unknown.
- 23 -
Figure 1.1. The genome of aphthovirus and its 
translation products. Note that the intermediate 
and mature products of translation are formed via 
several alternative cleavage pathways not indicated 
in the figure. Based on McCahon (1981) and King et 
al (1983).
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1.4. Antigenicity and Immunogenicity of 
Aphthovirus.
1.4.1. Overview.
Antigenicity, the ability to bind antibody, and 
immunogenicity, the ability to induce an immune 
response, has been defined by Shinnick et al (1983) 
in the following terms:
"An immunogenic site of a protein is 
defined as a region of the protein that 
can induce an immune response against 
that region. The response can result in 
either humoral (circulating antibodies) 
or cellular (T-cell mediated) immunity.
An antigenic site of a protein is defined 
as the region that interacts specifically 
with humoral antibodies or immune T- 
cells."
Clearly there can be a considerable degree of 
overlap between antigenicity and immunogenicity but 
the distinction is an important one. When animals 
encounter a protein it is the immunogenicity of 
that protein which determines the immune response. 
Subsequent action of the immune system upon the 
protein is determined by the antigenicity of the 
protein.
This section is concerned with the antigenicity of 
aphthovirus and the presence or absence of 
antigenic sites as determined by reaction with 
antibody in vitro. Immunogenicity will be dealt 
with as it bears upon antigenicity, for instance
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the ability of subunit immunogens to induce 
antibody capable of recognising vital antigens, 
section 1.5 will consider further the
immunogenicity of the virus in terms of the immune 
response it induces.
1.4.2. Serology.
Aphthovirus occurs as seven main serotypes (0, A,
C, Asia 1, SAT 1, SAT 2 and SAT 3 - see section
1.2.2.), each composed of multiple subtypes. The
first serotypes described were originally 
distinguished by cross-immunity tests in cattle 
(Waldmann and Trautwein, 1926), but the serotypes 
and subtypes of the virus may also be distinguished 
by neutralizing antibody tests (Galloway et al, 
1948) and by complement fixation assays (Rice and 
Brooksby, 1953). Biochemical techniques have also 
been used for distinguishing strains of the virus. 
King and Newman (1981) used electrofocusing to 
compare the isoelectric points of the capsid 
proteins and La Torre et a^ (1982) used RNase Tl 
maps of the genome as a diagnostic aid. Both 
techniques were used to determine the origin of the 
virus responsible for the 1981 Jersey and Isle of 
Wight outbreaks (King et al 1981). Currently, in 
the World Reference Laboratory at the Animal Virus 
Research Institute, serotypes and subtypes are 
distinguished by complement fixation tests. In 
this way the relationship of an unknown strain of 
virus to one or more reference strains may be 
established (Arrowsmith, A., 1984, personal
communication). New subtypes may arise by
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antigenic drift (Henderson, 1970; Arrowsmith, 1975; 
Robson et al , 1979), and 61 subtypes are currently 
recognised by the World Reference Laboratory for 
FMD (Arrowsmith, A., 1984, personal communication). 
These comprise 10 0 subtypes,30 of A, 5 of C, 6 of 
SAT 1, 3 of SAT 2, 4 of SAT 3 and 3 of Asia 1.
It is important to realise the functional 
significance of the immunological tests used to 
distinguish serotypes of the virus. During the 
course of infection each subtype generates immunity 
primarily, but not exclusively, to that subtype. 
Immunity may be conferred to other subtypes of the 
same serotype, but by definition immunity is not 
conferred against other serotypes. This fact has a 
considerable influence on the epidemiology and the 
control of FMD, since neither prior infection nor 
vaccination necessarily prevents spread of the 
disease.
1.4.3. Antigenicity of the virus and its subunits. 
The native picornavirus virion has characteristic 
antigenic properties and is defined as the D 
(dense) or N (native) antigen. Other viral 
structures, for instance empty particles and 12S 
subunits, may have either D antigenicity or altered 
antigenic properties which are defined as C 
(coreless) or H (heated) antigenicity. The switch 
from D to C antigenicity is associated with the 
loss of VP4 and the loss of ability to attach to 
host cells. For recent reviews see Rueckert (1976) 
and putnak and Phillips (1981).
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The native virions of each aphthovirus serotype 
have, by definition, D antigenicity. They induce 
serotype specific neutralizing antibodies (see 
section 1.4.1.). It has been shown for several 
picornaviruses that the virion exists in two 
interconvertible forms having high (A form, pi 
>6.0) and low (B form, pi <5.0) isoelectric points 
(Mandel, 1971; Chlumecka et a l , 1973; Korant et a l ,
1975). There appears to be a strong correlation
between the A form and D antigenicity. This
interconvertibility of forms has not been 
demonstrated for aphthovirus, though the extreme 
acid-sensitivity of the virion would be expected to 
render any B form unstable.
Natural empty, 75S, particles have the same
antigenic properties as the intact virion, despite 
their different protein composition. Artificial 
75S particles, formed by treating virus with EDTA, 
are antigenically quite distinct from the virus. 
They have C antigenicity, with properties very 
similar to 12S particles (Rowlands et a l , 1975; 
Rweyemamu et a l , 1979).
Artificial 12S particles having C antigenicity may 
be produced,„„._by^ .. acid or heat treatment of whole 
virus. They stimulate the production of 
precipitating and complement fixing antibody but 
show cross reaction between serotypes in complement 
fixation, ELISA and other serological tests and 
usually induce only low levels of neutralizing 
antibody (Cartwright et a l , 1980; Doel and Chong, 
1982; Haresnape and McCahon, 1983). Haresnape and
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McCahon (1983) have reported high neutralizing 
antibody titres in rabbits after a single 
vaccination with 12S, but this appears to be 
exceptional. However, artificial 12S will
stimulate a secondary, neutralizing, antibody 
response in animals primed with virus (Cartwright 
et a l , 1980) or with 12S (Meloen et a l , 1979; 
Cartwright et a l , 1982).
Natural 12S particles, thought to be produced
during the course of infection, are little studied 
for technical reasons. However, there are some
indications of antigenic differences between 
natural and artificial 12S particles. McCullough 
and Butcher (1982) have reported monoclonal 
antibodies that can distinguish between 12S
produced by acid degradation of virus and 12S 
harvested from infected cell lysates, which might 
be expected to contain a proportion of natural 12S 
particles. The 12S particles derived from natural 
75S particles by heat and acid degradation, which 
might be expected to resemble natural 12S, confer 
higher levels of immunity than 12S derived from 
virus in the same way (Doel and Chong, 1982). 
Studies have also been made of the antigenicity of 
the capsid proteins. Burroughs et al (1971)
established that the capsid of apthovirus contained 
four different proteins, VPl, VP2, VP 3 and VP4. 
When intact virus was treated with trypsin only one 
protein, VPl, was cleaved but the virus lost its 
ability to bind to susceptible cells and was no 
longer able to immunise vaccinated animals (Wild et
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al, 1969; Burroughs et a l , 1971). The conclusion 
that VPl carried the immunizing determinants and 
cell attachment sites of the virus was subsequently 
confirmed by several groups (Rowlands Gt a1 , 1971, 
Bernard et a l , 1975; cavanagh et a l , 1977).
Laporte et al (1973) showed that isolated VPl could 
stimulate serotype specific neutralizing
antibodies. However, the antigenicity of VPl is 
quite distinct from that of the virus. The 
neutralizing activity of some anti-VPl sera is not 
serotype specific and there is good evidence that 
the neutralizing epitopes expressed on the isolated 
protein are not the same as those expressed on the 
virus. Thus Meloen and Briare (1980) found that 
anti-sera to VPl from virus of strain 01 BPS 1860 
had weak but definite neutralizing activity against 
an AlO strain of virus, whereas antisera to VPl 
from AlO did not neutralize 01 BPS. Cartwright et 
al (1982) compared the neutralizing activity of 
antisera against 146S, 12S and VPl. They found
that the virus elicited a spectrum of neutralizing 
antibodies which could be absorbed to a very 
limited extent by 12S but not at all by VPl. In 
contrast virus absorbed all of the neutralizing 
activity induced by VPl.
Antisera raised against isolated V P 2 react with 
artificial 12S and artificial 75S but not with
intact virus (Meloen et aJ., 1979; Meloen and
Briare, 1980). Meloen and Briare (1980) showed 
that, for two viruses from serotypes A and 0, anti- 
VP2 sera was completely cross-reactive between
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heterologous and homologous 12S particles. They 
concluded that identical epitopes were exposed both 
on the VP2 and on the 12S particles of each 
serotype and that these epitopes were largely
responsible for the cross-reactivity of anti-12S 
sera. Their results also showed anti-VP3 sera to 
be partially cross-reactive between 12S particles 
from the two serotypes. Anti-VP4 sera cross reacts 
with heterologous VP4 (Talbot et al , 1973).
Monoclonal antibodies have recently been used to
examine the antigenicity of the virus and VPl in 
more detail. Some virus-neutralizing monoclonals 
raised against intact virus also recognised VPl 
(Duchesne et a l , 1984) and 12S (McCullough et a l ,
1985), whereas others recognised 12S to a slight 
degree but did not recognise isolated VPl at all 
(Meloen et a l , 1983; Baxt et a l , 1984; Ouldridge e_t 
al, 1984). On the basis of this data there appear 
to be at least three neutralizable sites on the 
virus, a sequential site identified by Duchesne et 
al (1984), a conformational site identified by 
Ouldridge et al (1984) and a trypsin resistant site 
identified by Meloen et al (1983) and Ouldridge et 
al (1984). McCullough et al (1985) identified four 
neutralizable sites on 01 Suisse, on the basis of 
competition between monoclonals, but it is unclear 
how these relate to the sites described by other 
workers.
Robertson et al ( 1984), using five virus-
neutralizing monoclonals raised against type A12 
VPl, reported two neutralization epitopes on the
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VPl, at 145-168 and 169-179. They also postulated 
the presence of at least one more such epitope. In
a related paper, Baxt et aJ. ( 1984), also working
with A12 antigens, produced three sets of virus- 
neutralizing monoclonals. They concluded that 
there were three neutralizable sites on the surface 
of the virus and were able to provisionally 
identify two with the neutralization epitopes on 
VPl located by Robertson et al (1984).
The relationship of these sites to each other on 
the virion surface is still a matter for
speculation. When using polyclonal anti-viral sera 
and examining immune complexes under the electron 
microscope Brown and Smale (1970) were able to
visually identify three areas on the capsid which
bound antibody. It is not known whether there is 
any correspondence between these sites and either 
the sites identified by anti-viral monoclonals or 
the sites identified by anti-VPl monoclonals.
McCullough et aJ (1985) have discussed the
distribution of epitopes on the virion, but their 
proposed epitope map is as yet unconfirmed.^
There is some evidence that the distribution of 
neutralization epitopes varies between serotypes. 
In a preliminary study of the binding of 
neutralizing monoclonals to the virus, Meloen and 
Barteling (1983) described differences between the 
numbers of neutralization epitopes on 0 and A type 
viruses. It remains to be seen whether the use of 
a wider range of antibodies will support this 
result.
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studies with poliovirus also lead to the conclusion 
that there are multiple neutralization epitopes
upon the virus. Uhlig et al (1983) described
eleven neutralizing monoclonal antibodies which 
could be divided into four groups according to 
their reaction with various poliovirus antigens.
Crainic et aJ. ( 1983), examining a range of
poliovirus isolates, found both serotype-specific 
and strain-specific neutralizing epitopes as 
defined by a panel of neutralizing monoclonals. By 
definition these are not covariable and must 
represent distinct sets of epitopes upon the virus 
surface. similar results have been described by 
Humphrey et al (1982).
Interestingly, the distribution of neutralizing 
epitopes appears to vary between the poliovirus
types. Thus Emini et ^  ( 1982 ) produced two
monoclonal antibodies which reacted with
qualitatively different neutralizing sites on
poliovirus type 1. Both sites were contained in 
VPl, and other workers also found that VPl of
polioviruses types 1 and 3 carried poliovirus 
neutralizing sites (Blondel et a l , 1982; Chow and
Baltimore, 1982; Evans et a l , 1983; Minor et— a l , 
1983; van der Marel et al , 1983). In the case of
poliovirus type 1, but not type 3, neutralizing 
sites have also been reported in V P 2 and VP3 
(Dernick et a l , 1983; Emini et al , 1983a; van der
Marel et al, 1983; Emini et a l , 1984).
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1.4.4. Synthetic peptides.
Synthetic peptide immunogens have been in use as a 
research tool for a number of years. protein- 
reactive antibodies may be induced by peptides 
synthesized according to amino-acid sequences 
determined from nucleotide sequences. Such 
antibodies may be used as reagents for identifying 
and purifying proteins about which nothing is known 
other than the deduced amino-acid sequence (see 
e.g. Sutcliffe et a l , 1980).
The first suggestion that synthetic immunogens 
could be used in vaccines was provided by the work 
of Anderer and Schlumberger (1965) who found that 
short peptides copying the C-terminal amino-acid 
sequence of tobacco mosaic virus protein were able 
to stimulate the production of virus-neutralizing 
antibodies in rabbits. The effective exploitation 
of this finding was prevented by the lack of an 
easy method for sequencing proteins. Similar 
results were obtained with synthetic peptides 
copying the sequences of portions of the coat 
protein of bacteriophage MS-2 by Langbeheim et al 
(1976), but it was not until the advent of 
effective DNA-sequencing techniques in the late 
1970's (see Maxam and Gilbert, 1980) that the use 
of synthetic immunogens became widespread. Since 
then, studies have encompassed infectious diseases 
as diverse as malaria (Godson et a l , 1983),
diphtheria (Audibert et a l , 1982), cholera (Sela et
a l , 1984 ), hepatitis (Gerin et a l , 1984 ), influenza
(Arnon and Shapira, 1984), poliomyelitis (Emini et
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al, 1983b) and FHD (Bittle et a l , 1982; see section
1.6.4b.). Shinnick et ^  ( 1983) have recently
reviewed the subject.
It is clear from these and other studies that a 
high proportion of synthetic peptides induce 
antibodies capable of recognising the native 
protein (Niman et a l , 1983; Palfreyman et a l , 1984) 
and that the antigenicity and immunogenicity of 
some synthetic peptides closely reflects that of 
the native protein (Rowlands et a l , 1983; Shinnick 
et a l , 1983; Alexander et a l , 1983). However, the 
complete antigenic structures of only a relatively 
few proteins have been determined (see e.g. Atassi, 
1975; Atassi, 1978; Wiley et a l , 1981) and there 
are still no firm rules either for predicting the 
location of immunogenic sites within proteins or 
for constructing immunogenic peptides.
Consequently, for proteins of unknown structure, 
various methods have been used to identify likely 
immunogenic sites as a guide for the production of 
synthetic peptide immunogens (Shinnick et a l , 1983, 
Brown, 1984). comparison of amino-acid sequences, 
whilst not widely applicable, is useful when 
multiple antigenic forms of a protein exist. 
Immunogenic sites are likely to occur within 
regions of high sequence variability, though not 
all such regions are immunogenic. predictions of 
structural and physical properties from amino-acid 
sequences are of more general use and immunogenic 
sites have been located on the basis of 
hydrophilicity and probable three-dimensional
— 3 6 —
structure. Functional tests, screening a range of 
peptides for biological activity, are useful for 
locating immunogenic sites and in addition provide 
a body of information to support predictions based 
on structural or physical considerations. The 
application of these methods to aphthovirus is 
described in section 1.6.4b.
Several studies have been made of the antigenicity 
and immunogenicity of synthetic peptides copying 
the amino acid sequence of parts of the aphthovirus 
capsid protein VPl. Bittle et al (1982) selected 
several peptides on the basis of sequence variation 
and found that antisera to peptides copying the 
sequence of amino acids 141-160 from VPl of 01 
Kaufbeuren recognised not only the homologous virus 
but viruses of serotypes A and c, albeit weakly. 
Pfaff et al (1982) made use of a slightly shorter 
peptide, copying amino acids 144-159 from the same 
VPl but selected largely on the basis of predicted 
structure. Antisera to this peptide also reacted 
to some extent with a virus of serotype C but were 
unable to recognize an A serotype virus.
Rowlands et al (1983) examined the immunogenicity 
of the 141-160 region in more detail. Four 
antigenic variants of virus strain A12 119 were
obtained and the VPl's sequenced. Differences were 
detected at amino acids 148 and 153, and peptides 
copying the 141-160 region of each variant were 
synthesized. Both anti-viral and anti-peptide 
sera, when assayed in a cross-neutralization test, 
were able to distinguish between the variant
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viruses. Geysen et al (1984) aoopteo the converse 
approach and examined the antigenicity of variants 
of the 146-152 peptide of an 01 virus by probing 
them with anti-viral sera. They found that amino 
acids 148 and 151 were most important in 
determining antigenicity, with a lesser
contribution being derived from amino acids 149 and 
152.
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1.5, The Immune Response to Aphthovirus.
1.5.1. overview.
Host defences against aphthovirus comprise innate 
physical or chemical barriers to infection together 
with defences induced by infection or vaccination, 
of which neutralizing antibody is accepted to be an 
important component. Animals may be passively 
immunised against the disease with convalescent 
serum (see e.g. Brooksby, 1949; Galloway, 1954), 
and many workers have established a correlation 
between serum titres of virus-neutralizing antibody 
(SNT) and resistance to disease (including Martin 
and Chapman, 1961; Fish et a l , 1969; Graves et a l , 
1972; Chapuis and Moreau, 1972). Neutralizing 
antibodies can also be detected in bodily 
secretions, such as saliva and pharyngeal fluid 
(Hyslop, 1965; Garland, 1974) and it is possible 
that these, too, have a role to play in resistance 
to the disease. The antibody response to viral 
antigens, including aphthovirus, has been reviewed 
by Cowan (1972). Garland (1974) has reviewed both 
specific and non-specific host defences against 
aphthovirus.
1.5.2. cattle.
Early studies by a number of workers, including 
Brown and Crick (1958), Brown and Graves (1959), 
Brown et al (1964) and Cowan (1966), established 
the pattern of an early IgM response at three to 
five days post-infection (p.i.) followed by an IgG 
response about two weeks p.i. . IgM remained
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detectable for up to thirty days p.i., whereas IgG 
could still be detected after several months. 
Cunliffe (1964) reported detectable SNT fifty-four 
months p.i., while Gomes et al (1972), in a shorter 
study, found that SNT remained high for at least 
eighteen months p.i. and showed little sign of
declining after this time. In contrast, cunliffe
found that complement fixing antibody persisted no 
longer than ninety days p.i. . A similar rapid 
decline of complement fixing antibody relative to 
neutralizing antibody was noted by Cowan (1966). 
The specificity of the antibodies has also been 
found to change with time. This seems due in part
to the class switch from IgM to IgG, and in part to
changes in the composition of the IgG population 
(Brown and Graves, 1959; Wagner and Cowan, 1971; 
Meloen, 1979a, 1979b).
The kinetics of the antibody response of cattle to 
inactivated vaccines were found to be broadly 
similar to those described following infection. 
The SNT of most adult cattle given multiple doses 
of formaldehyde inactivated aluminium hydroxide 
adjuvanted (F-AH) vaccine persisted for at least 
forty-nine months after the last vaccination (van 
Bekkum et a l , 1963; 1969; Fish et a l , 1969). At
least 56% of the animals, depending on virus 
serotype, were protected against challenge at this 
time (van Bekkum et a l , 1969). Lobo (1975) found
that the SNT of adult cattle were sustained at a 
high level for at least fifteen months following 
several vaccinations with an F-AH vaccine. Cattle
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given a single dose of an oil adjuvanted vaccine 
had low but detectable SNT thirty months after 
vaccination, though whether animals were protected 
at this stage was not reported (Auge de Mello et al, 
1980). The SNT of animals given two doses of the 
oil vaccine at six month intervals remained at high 
levels for the entire thirty month trial. In 
similar studies, over 80% of cattle were protected 
six months after one or more vaccinations with oil 
adjuvanted vaccines (Plum Island Animal Disease 
Center and pan American Foot-and-Mouth Disease 
Center, 1976; McKercher and Giordano, 1967). 
Graves et al (1968b) studied the onset of immunity 
and found that most cattle were protected from 
contact challenge within three to four days of 
vaccination with an oil vaccine.
Generally, the responses to F-AH vaccines, oil 
vaccines and infection have similar kinetics. The 
magnitude of the SNT response seems to increase in 
the order F-AH vaccines, oil vaccines and 
infection, though different ways of expressing 
titres means that results from different 
laboratories must be compared with caution.
Several groups have examined the SNT of cattle 
given attenuated vaccines. Geering et al (1965) 
reported that the response peaked at twenty-one to 
twenty-eight days and persisted for at least 
eighteen months. A few cattle maintained peak 
titres throughout this period, but less than 50% of 
animals were protected from challenge after 
eighteen months. Similar results were described by
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Kemron and Goldsmit (1961), who found that SNT 
persisted for at least fourteen months, though 
titres declined over this period.
More recently a number of workers have used more 
sophisticated analytical techniques to study the 
response in more detail. Using ion-exchange 
chromatography, Chappuis and Moreau (1972) were 
able to detect an increased proportion of 
neutralizing IgGl after revaccination (F-AH 
vaccine). Abu Elzein and Crowther (1981), using an 
ELISA, detected specific IgG four days after 
vaccination, considerably earlier than previously 
reported. They were also able to detect 
differences between the serum antibody response to 
infection and to inactivated vaccines. Vaccinates 
tended to produce higher and more sustained levels 
of IgM and serum igA and to produce lgG2 four to 
five days later than infected animals. The SNT of 
vaccinated cattle were lower by a factor of ten 
than titres of infected animals, though all were 
protected. Meloen (1979a, 1979b) found that,
though the kinetics of production of neutralizing 
and precipitating antibodies were similar after 
infection and vaccination, there were quantitative 
and qualitative differences between the responses. 
The level of the response to infection was greater 
by an order of magnitude than that to vaccination, 
and the antibodies of infected animals showed a 
characteristically different spectrum of activity. 
The papers cited in the preceding paragraphs have 
all concentrated on serum antibody. Fewer studies
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have been made of local immunity to aphthovirus. 
However, it is known that the most common sites at 
which aphthovirus infection starts are the nasal 
passages, oral cavity, pharynx and lower 
respiratory tract (Sutmoller and McVicar, 1976; 
Donaldson, 1979). The extent to which circulating 
antibody protects these areas from viral infection 
is unclear. For instance animals with high SNT may 
become carriers, shedding virus produced by
persistent oropharyngeal infection (Sutmoller et al, 
1968; Hedger, 1970). Saliva, nasal and
pharyngeal secretions also contain specific 
neutralizing antibody (Hyslop, 1965; Figueroa et al,
1973). Garland (1974) examined the role of local 
immunity against the disease. He found that 
secretory antibody, predominantly IgA, could be
detected within three to six days p.i. and that
peak titres of secretory virus-neutralizing 
antibody were reached by twenty-one to twenty-eight 
days p.i.. Neutralizing antibody was detectable in 
serum and secretions for at least five and a half 
years p.i., with titres generally, but not always, 
lower in the secretions than in the serum.
In contrast, animals given an inactivated vaccine 
did not produce detectable secretory antibody until 
two or three doses had been administered. In this 
case the predominant secretory antibody was IgGl,
though some IgA was present, and titres were always 
lower than serum titres. Both convalescent and 
vaccinated animals were protected against the 
disease, though vaccinates were more likely to shed
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virus following challenge, consistent with lower 
levels of secretory, neutralizing, IgA.
Interestingly, the vaccinated animals had received 
a dose of vaccine no more than twenty-one days 
before challenge whereas the convalescent group had 
not been exposed to the virus since their infection 
five and a half years previously. It was concluded 
that the presence of neutralizing antibody in the 
secretions had a definite bearing on the course of 
infection.
More recent work has largely confirmed these 
findings. McVicar and Sutmoller (1974) and 
Francis et al (1983) studied the antibody response 
in serum and pharyngeal fluid after infection or 
vaccination and obtained results similar to those 
of Garland (1974) and Abu Elzein and Crowther
(1981). Matsumoto et ^  (1978) agreed in most
respects with these four studies, but reported that 
secretory antibody was barely detectable in 
pharyngeal fluid and occurred mainly in saliva and 
nasal secretions. This discrepancy was attributed 
to the poor specificity of earlier tests, but the
results of Francis et ^  ( 1983) would tend to
discount this. On balance the evidence indicates 
the presence of significant levels of secretory 
antibody in pharyngeal fluid.
A feature of the response to both attenuated and 
inactivated vaccines is the decline with time of 
protection afforded by virus-neutralizing serum 
antibody. A greater antibody titre seems to be 
required to protect animals challenged six months
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or more after vaccination than to protect those 
challenged within three months of vaccination 
(Borgen et a l , 1962; Geering et a l , 1965; van
Bekkum et a l , 1969; Chappuis and Moreau, 1972). It 
is not known whether this is also a feature of the 
response to infection. The cause of the phenomenon 
is unknown, though some workers have made
observations which may be relevant. Garland (1974) 
reported that, after two doses of vaccine, 
neutralizing antibody could be detected in serum 
for at least a year but could not be detected in 
secretions after four months. Complement fixing 
antibody declines to undetectable levels within 
three months of infection (Cunliffe, 1964). The 
time scale of both these observations is highly
suggestive but without a proper understanding of 
the mechanism of neutralization in vivo it is 
difficult to speculate further.
The kinetics of the immune response appear to be 
independent of virus serotype. However, the 
serotype can exert a profound effect on the quality 
of the response. Many groups have reported direct 
comparisons of two or more serotypes in trials of 
inactivated vaccines (see e.g. van Bekkum et a l , 
1963; Fish et a l , 1969; van Bekkum et a l , 1969;
Chappuis and Moreau, 1972; Graves et al, 1972;
Mowat, 1972; Plum Island Animal Disease Center and 
Pan American Foot-and-Mouth Disease Center, 1976; 
Institute Nacional de Tecnologia Agropecuaria and 
Plum Island Animal Disease Center, 1976; Pay et al, 
1983). Serotypes 0, A and C are the most commonly
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studied and the general consensus of opinion is 
that type A viruses induce immunity more 
effectively than type 0 viruses, with type C 
viruses falling somewhere between the two. 
However, many of the studies must be interpreted 
with caution because of the problems of accurately 
measuring virus concentrations experienced by 
earlier workers.
Pay et al (1983) found that equivalent doses of 0, 
A and C viruses induced comparable SNT, but that a 
higher SNT was required to give a comparable level 
of protection against challenge with the 0 virus. 
Chapuis and Moreau (1972) and Sutmoller et al 
(1980) have also described differences between the 
levels of antibody required for a given percentage 
protection against different serotypes. The cause 
of these differences is unknown, but it would 
appear that protection is not solely a function of 
antibody titre.
1.5.3. Other Domestic Animals.
Studies have been made of the response of pigs to 
aphthovirus, though the data is not as extensive as 
that available for cattle. Additionally, some data 
is available concerning the response of sheep. 
Cunliffe (1962) reported that, following infection, 
pigs produced a peak of neutralizing antibody at 
seven to ten days. Titres declined slightly by
twenty-eight days but were then maintained at a 
more or less constant level for at least four 
months. Whereas all animals were protected at 
twenty-eight days p.i., five animals challenged at
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128 days p.i. were not protected. McKercher and 
Giordano (1966) found that only 50% of convalescent 
pigs were protected 90 or 178 days p.i..
Anderson (1971) has reviewed the response of pigs 
to vaccination with aphthovirus. Briefly,
conventional F-AH vaccines, with or without 
saponin, require at least two doses to generate 
immunity lasting a few months. Vaccines adjuvanted 
with DEAE-Dextran perform only slightly better. 
(See also Anderson et a l , 1971b). Attenuated
vaccines have not been successful, as the vaccine 
strains tend to revert to virulence. However, oil 
vaccines can protect pigs for six months to a year 
(see also Anderson et a l , 1971a). Graves et al
(1968b) studied the onset of immunity after 
vaccination with an oil vaccine and found that most 
pigs were protected from contact challenge within 
three to five days of vaccination.
The antibody subclasses involved in the response to 
oil vaccines were studied by Ouldridge et al 
(1982), who found the expected pattern of an early 
IgM response and a later, sustained, IgG response. 
Neutralizing antibody was first detected eight days 
post vaccination (p.v.), at which stage it was 
present only in the IgM serum fraction. By ten to 
fourteen days neutralizing igG was also present and 
after thirty-five days neutralizing IgM could no 
longer be detected. The SNT peaked at twenty to 
twenty-five days then declined slightly to a 
plateau which was maintained for at least 100 days 
p.v.. This is in close agreement with the results
of Anderson (1971), who found that high SNT could 
be maintained for at least 280 days in response to 
certain vaccine virus subtypes. The response to 
DEAE-Dextran vaccines was broadly similar (Anderson 
et a l , 1971b), but of decreased magnitude. In
contrast, the primary response to saponin- 
adjuvanted vaccines consisted entirely of IgM and 
lasted no more than twenty-one days (Anderson et al  ^
1971b), though the animals were primed and 
responded well to a booster vaccination.
Despite the fact that secretory antibody appears to 
be an important component of the immunity of cattle 
to FMD, there are no data to suggest that this is 
true of pigs. Wittman (1972) was unable to detect 
specific secretory antibody, of any class, in pigs 
immune to FMD.
The vaccine virus serotype has been shown to 
influence the quality, but apparently not the 
kinetics, of the immune response in pigs. In one 
study (Plum Island Animal Disease Center and Pan 
American Foot-and-Mouth Disease Center, 1976) A24 
Cruzeiro induced a moderate response whereas C3 
Resende and 01 Caseros were much less effective. 
However Ouldridge et al (1982) found very little 
difference between the responses to vaccine strains 
of A24 Cruzeiro, 01 Campos and C3 Indaial. Mowat 
(1972) compared the immunogenicity of subtypes of 
A22, SAT 2 and Asia 1 and found the response to A22 
to be markedly inferior to the response induced by 
the other viruses. Anderson (1971) examined the 
response of pigs to vaccination with strains of
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each of the seven aphthovirus serotypes. A22, 
C997, Asia 1 and SAT2 induced strong responses. 
The response to 01 was moderate, while SAT 3 and 
SAT 1 stimulated very weak responses. However, as 
noted for cattle vaccines, many of these studies 
must be interpreted with caution because of the 
problems of reliably measuring virus concentration 
experienced by earlier workers.
Relatively few data are available concerning the 
response of sheep to aphthovirus. ' Oral et al 
(1970) examined the immunological status of sheep 
following vaccination with a formaldehyde 
inactivated, saponin adjuvanted vaccine. After one 
vaccination sheep were protected for up to seven 
months. Second and subsequent vaccinations
protected the animals for at least a year after the 
last vaccination. These results compared well with 
cattle included in the study, but appeared to 
contradict those of Gomes Urquizo (1969), who found 
that SNT of sheep given a F-AH vaccine began to 
decline within four months even if a booster 
vaccination was given. However, since the
correlation of SNT with protection is unknown in 
the case of sheep, a reliable comparison can not be 
made between the two studies.
1.5.4. Guinea-pigs.
Because the course of the disease in guinea-pigs 
corresponds closely to the course of the disease in 
cattle, they have been widely used for many years 
as a model system for the study of aphthovirus
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infection and immunity (Bedson et a l , 1927 ).
Several studies (Brown, 1960; Brown et a l , 1964; 
Cowan and Trautman, 1965) have established the 
response of guinea pigs to infection with 
aphthovirus. There is an early IgM response which 
peaks at seven to ten days and is followed by an 
IgG response which predominates after fourteen 
days. Animals are immune to challenge for at least 
eight months after recovery from infection (Bedson 
et a l , 1927). The same sequence of events occurs
in animals vaccinated with inactivated virus 
(Graves et a l , 1964). Provided that sufficient
antigen is administered the response remains high 
for at least eighty-four days after vaccination 
(Morgan et a l , 1968; Morgan et a l , 1969). The use 
of an oil adjuvant does not necessarily increase 
peak antibody titres, but may maintain them for 
longer than an aqueous vaccine (Morgan et a l , 
1968).
Knudsen et al (1979) reported that guinea pigs 
developed cell-mediated immunity (CMI) as well as 
humoral immunity to aphthovirus, although the CMI 
response was not strong. The involvement of CMI 
has not been reported in other animals, and is not 
thought to be relevant to protection (Garland,
1974).
1.5.5. Other Laboratory Animals.
Mice are the laboratory animals most commonly used 
in studies of aphthovirus. For example, extensive 
use is made of newborn mice in virus neutralization 
assays. However, despite a considerable body of
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work concerning such assays, few studies have been 
made of the immune response of mice to the virus. 
Subak-Sharpe (1961) studied the susceptibility of 
adult mice to aphthovirus and found great variation 
in response to infection, with susceptibility 
dependent on a number of factors including the 
strain of mouse and the strain of virus used. 
Additionally, he reported significant qualitative 
differences between the susceptibilities of adult 
and juvenile mice. However, no attempt was made to 
study the nature or kinetics of the immune response 
of susceptible animals.
Though guinea-pigs or large animals are preferred 
for studies of vaccines some groups have assessed 
the use of mice for vaccine potency tests (Gayot et 
al, 1964; Shevetsov et a l , 1969; Bechmann, 1969). 
The potency of vaccines in mice showed a good 
correlation with their potency in cattle, but once 
again the nature and kinetics of the immune 
response were not investigated.
1.5.6. The Role of Antibody.
Hardy and Moore (1981, 1982) examined the
neutralization of aphthovirus serotype Al2 119 by 
polyclonal sera. They found that two populations 
of antibodies could be derived from such sera, one 
specific for the intact virion and one cross­
reactive with 12S subunits. The virion-specific
antibody neutralized the virus effectively and the 
degree of neutralization was proportional to 
antibody concentration. The cross-reactive
- 51 -
antibody was relatively ineffective at neutralizing 
virus and left a non-neutralized virus fraction 
even at high antibody concentrations. This non­
neutralized fraction consisted of virus-antibody 
complexes which could be neutralized by the 
addition of anti-globulin antibody. The authors 
concluded that the two antibody populations acted 
upon the virus in different ways. It was suggested 
that specific antibody acted in an unspecified 
manner at a few critical sites whilst the cross 
reactive antibody acted by blocking the surface of 
the virion with antibodies bound to non-critical 
sites. Neutralizing antibody induced by VPl was
entirely of the cross reactive type.
Baxt et al (1984), also working with Al2, produced 
three sets of neutralizing monoclonal antibodies. 
These neutralized the virus in three ways, either 
preventing adsorption to cells with or without
aggregating the virus, or acting in an unspecified
manner after penetration of the virus into the 
cell.
The exact mechanism (or mechanisms) by which 
antibody neutralizes aphthovirus remains obscure. 
However, some further information is available for 
other picornaviruses, especially poliovirus. 
Mandel (1971) had found that poliovirus existed in 
two isoelectric forms, with pi's of 7.0 (the A 
form) and 4.5 (the B form). He subsequently 
observed that neutralization by antibody was 
associated with stabilization in the B form and 
proposed that neutralization could be a result of
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such stabilization following antibody induced 
conformational changes in the capsid. The apparent 
effect of stabilization was inhibition of either 
penetration into the cell or of uncoating of the 
genome. Evidence for conformational changes in the 
capsid of a picornavirus after neutralization was 
also provided by carthew (1976), who observed that 
the pattern of radiolabelled virion polypeptides 
obtained after iodination of a bovine enterovirus 
depended upon whether iodination was performed 
before or after neutralization.
Recent studies with monoclonal antibodies and with 
antisera to the capsid proteins have shown that not 
all neutralizing antibodies cause conformational 
changes in poliovirus. Thus Emini et al (1983c) 
found that, of thirteen monospecific neutralizing 
antibodies, one antibody neutralized the virus 
without an associated change in pi. This seemed to 
be a general feature of antibody raised against 
capsid protein V P 3 (Emini et a l , 1983d). Some of
these antibodies partially inhibited binding of 
virus to cells and all of them prevented 
transcription of the viral genome by some means. 
Icenogle et al (1981, 1983) examined the mode of
action of two poliovirus neutralizing monoclonal 
antibodies. One apparently acted by causing a 
conformational change in the virion and it was 
suggested that the other acted by cross-linking 
pentameric capsid subunits. This antibody also 
recognized 70S "natural empty" particles and 14S 
capsid subunits. Relatively few antibodies per
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virion were required for effective neutralization 
and virus aggregation did not appear to be 
important. In contrast Brioen et al (1983) 
described a poliovirus neutralizing monoclonal 
which acted solely by aggregating virus, the 
reduction in infectivity being proportional to the 
degree of aggregation. In a further study Brioen 
et al (1985) found that not only could 
neutralization occur without a pi shift but that 
even when a pi shift was associated with 
neutralization there was not a quantitative 
correlation between the two phenomena.
On the basis of the information currently available 
it would seem that poliovirus (and by extrapolation 
aphthovirus) is neutralized by a multiplicity of 
mechanisms including inhibition of binding to host 
cells, inhibition of penetration and inhibition of 
viral transcription. A conformational change in 
the capsid (as manifested by a pi shift) may be 
associated with neutralization by any of these 
mechanisms, but the association has not been proved 
to be causal.
However, it is important to note that all of the 
preceding data relates to the neutralization of 
virus in in vitro tests. Clearly, the
correspondence between in vitro neutralization of 
aphthovirus and in vivo protection from disease is 
not complete. Protective mechanisms such as 
opsonization do not function in vitro but are 
undoubtedly of protective importance, while the 
effect of factors such as complement which can
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function in vitro may not be measured reliably by 
in vitro assays (Ferris and Donaldson, 1983).
It is known that some in vivo neutralisation assays 
are more sensitive than in vitro ones (Bradish et 
a l , 1962) which certainly implies a role for
factors such as complement and opsonization. The 
passive transfer of opsonizing antibody is a 
possible explanation for the results of Knudsen e^ 
al (1983), who compared the infectivity of 
infectious immune complexes in various in vivo and 
in vitro systems. They found that complexes 
capable of infecting cell monolayers were not 
infectious when inoculated intraperitoneally or 
intracardially. Such complexes were infectious 
when inoculated into the tongue or heelpad. In 
this latter case the passive transfer of immune 
serum was able to prevent systemic spread of the 
disease and, at very high levels, to give complete 
protection.
As neutralizing and protective monoclonal 
antibodies to aphthovirus become available it may 
be possible to establish more precisely the 
relationship between the two phenomena.
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1.6. Vaccines.
1.6.1. Introduction.
In the early years of this century FMD in Europe
was controlled by a combination of quarantine and
deliberate spread of the disease within infected
areas. This policy was designed to shorten the
duration of an outbreak and to establish an immune
population. Especially valuable animals were
sometimes passively immunised with convalescent
serum. Much work was carried out during the 1920's
and early 1930's with the aim of producing an
effective foot-and-mouth disease vaccine. Belin
had limited success in developing an attenuated
vaccine strain of the virus, whilst other workers,
notably Schmidt, Trautwein, Vallee and Waldmann,
were trying to develop an inactivated but
immunogenic preparation of the virus. Although
some promising results were obtained during this
period a reliable and effective vaccine was not
produced until 1937 (Waldmann et al , 1937). This
vaccine provided the basis for the development of
modern vaccines, and worldwide FMD control
programmes now consume some 1500 million doses of
vaccine annually. For reviews see Mowat et al
(1978), Brooksby (1982), Mebus and McKercher
(1982), Rweyemamu et ^  (1982) and Della-Porta
( 1983) .
1.6.2. Attenuated Vaccines.
The first attempts to develop such a vaccine were 
described by Belin (1927), who was able to produce
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aphthovirus strains of reduced virulence for cattle 
by co-cultivation of aphthovirus and vaccinia virus 
on the skin of cattle. Results in the field were 
disappointing (Belin, 1939) and the method was not 
developed further, though inactivated vaccines 
prepared from virus cultivated in this manner were 
used for many years (see section 1.6.3.).
Later workers attempted to attenuate aphthovirus by 
passage through abnormal host species. Strains 
with reduced virulence for cattle were produced in 
guinea pigs (Henderson, 1949; Brooksby, 1982), mice 
(Skinner, 1951), chicks (Gillespie, 1954), rabbits 
(Paraf et a l , 1958) and in tissue culture (Mowat,
1964a). Though some strains produced in each 
system were found to be capable of stimulating an 
effective immune response in cattle without causing 
clinical signs of disease the use of attenuated 
vaccines in the field was relatively limited.
There are several accounts in the literature of the 
succesful use of attenuated FMD vaccines under 
field conditions (see, for example, Galloway, 1962; 
Mowat, 1964b; viljoen, 1964; Martin and Edwards, 
1965), but these must be set against several 
serious deficiencies. For example, vaccines 
adapted for cattle may cause disease in swine or 
even in cattle under stress (Mowat et a l , 1969;
1978). Pay and Bracewell (1966) reported a live 
vaccine that was entirely avirulent in beef cattle 
but which caused clinical lesions in lactating 
dairy cattle. The immunogenicity of attenuated
strains was found to vary in different breeds of
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cattle (Mowat and Prydie, 1962; Cunha et al, 1962). 
Not only were some virus strains unsuitable for
attenuation but the process of attenuation could 
cause loss of immunogenicity (Mowat et al , 1969). 
This meant that it was not possible to produce a 
comprehensive range of attenuated, vaccine, 
strains. Furthermore, attenuation of the virus was 
a lengthy process, regardless of the time needed 
for testing and development (Mowat et al, 1969).
These deficiencies, when set against the
considerable success of inactivated vaccines, led
to the abandonment of attenuated vaccines.
The possibility of producing recombinant 
aphthovirus strains for .use as vaccines has been 
suggested by McCahon et al (1980). They showed 
that a recombinant having the growth 
characteristics of one subtype combined with the 
antigenic characteristics of another subtype could 
be produced. They also located regions of the 
genome coding for such biological properties as 
mouse virulence and good growth in BHK cells. It 
is possible that a proper understanding of the 
genetics of the virus will allow a more controlled 
approach to the development of attenuated vaccines 
in the future.
1.6.3. Inactivated Vaccines.
The first effective FMD vaccine was described by 
Waldmann et al (1937), who obtained virus from 
tongue epithelium and vesicle fluid of infected 
cattle and inactivated it with formalin in the
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presence of an aluminium hydroxide gel. Similar 
vaccines were described by Graub et al (1939), who 
obtained his virus from viraemic blood, and by
Rohrer et al ( 1950). A formaldehyde inactivated
vaccine was also developed by Belin (1939). Belin 
cultivated his vaccine virus on the skin of live 
cattle using a process of co-infection with 
aphthovirus and vaccinia virus. Pustular material 
containing both viruses could be scraped from the 
skin in large quantities (Belin, 1957).
Although inactivated vaccines of the Waldmann and 
Belin types were relatively effective and were 
widely used for a number of years, the use of 
deliberately infected cattle as a source of virus 
posed serious problems. Not the least of these was 
the risk of disease spreading from the holding 
compounds and abbatoirs where cattle were infected 
and slaughtered. The development of techniques for 
the production of virus in tissue culture, 
potentially more convenient and economic, 
eventually led to the abandonment of this method of 
virus production.
The earliest tissue culture production method was 
developed by Frenkel (1947), who grew virus in 
bovine tongue epithelium collected from recently 
slaughtered healthy cattle. This proved to be a 
highly effective method of producing virus, and 
once early doubts about the immunogenicity of 
tissue culture virus had been resolved (Henderson 
and Galloway, 1953) it was rapidly adapted to 
routine vaccine production. virus could be grown,
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harvested and inactivated under conditions which 
greatly reduced the risk of dissemination of
disease. Since this was a primary culture system
there was no need for virus to be adapted and any
isolate from cattle could rapidly be grown in
quantities suitable for vaccine production.
The method had the disadvantages of requiring a 
regular supply of tongue epithelium and its large 
scale aseptic handling, but these were not 
sufficient to stop its use. This type of vaccine 
is currently in use by the French and Dutch, 
amongst others. However, the finite supply of 
bovine tongue epithelium eventually led to a 
requirement for alternative substrates for virus 
growth. Ubertini et al (1960, 1963) described an
alternative primary tissue culture system using 
calf kidney cells, but the method was cumbersome, 
using large numbers of roller bottles as culture 
vessels. Although their method is still in use it 
did not solve the problem of limited tissue 
supplies. What was required was a continuous cell 
line susceptible to aphthovirus.
Although initial studies of pig kidney cell lines 
were disappointing, a hamster kidney cell line, 
BHK21/C13, was found to support the growth of 
several strains of aphthovirus (Mowat and Chapman,
1962) and to be suitable for the production of 
vaccine (Mowat et a l , 1962). The cells of this
line were monolayer cells and therefore required a 
solid substratum for growth. However, the large 
scale culture of anchorage dependant cells was not
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well developed in the early 1960's (Spier and
Whiteside, 1976a). The roller bottle systems of
Ubertini et al (1960, 1963) and of Polatnick and
Bachrach (1964) were capable of producing
significant quantities of virus but were awkward to
use on a large scale. consequently it was
necessary to adapt the BHK21/C13 cell line to
suspension growth. This was achieved without loss
of susceptibility to virus by Capstick et al (1962)
and allowed the production of cells and virus to be
carried out on a large scale in fermenter vessels
(Telling and Ellsworth, 1965). The system has
limitations, in that only selected strains of
aphthovirus grow well in BHK suspension cells 
and Spier,
(ClarkeA 1980) and the susceptibility of the cells 
may vary with a number of factors (Clarke, 1981). 
Nevertheless, it rapidly became the dominant FMD 
vaccine production system, until in 1980 it 
accounted for up to two-thirds of the world's FMD 
vaccine output (Mowat, 1981).
Spier and Whiteside (1976a; 1976b), in an attempt
to circumvent some of the problems associated with 
using BHK suspension cells, developed the use of 
BHK monolayer cells in large scale unit systems 
based on packed beds of glass beads or on Sephadex 
bead microcarriers. Such cultures have been used 
for the industrial scale production of vaccine 
virus (Meigner, 1978) but these systems have yet to 
make a significant impact on the commercial 
manufacture of FMD vaccines.
The first effective FMD vaccines were prepared
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using formalin inactivated virus as the antigen 
(Waldmann et a l , 1937). Formalin inactivated
adsorbed vaccines were widely used for many years 
despite doubts about the complete effectiveness of 
the method. Inactivation of picornaviruses by 
formaldehyde was found to be slow and not to follow 
first order kinetics (Gard, 1957; Graves J.H.,
1963), with the consequent risk that a residuum of 
infectious virus could remain in any vaccine 
prepared this way, and so alternative methods of 
inactivation were examined. The use of
acetylethyleneimine (AEI) as an inactivant was 
described by Brown and Crick (1959) and by Brown e^ 
a l , ( 1963) who found it to compare favourably with
formaldehyde. Inactivation was rapid and followed 
first order kinetics. AEI largely replaced
formaldehyde as the method of choice for 
inactivation and was itself superceded, for reasons 
of safety and availability, by the closely related 
chemical binary ethyleneimine (Bahnemann, 1975). 
More recently Scodeller et al (1984) have described 
a method whereby the virus may be inactivated via 
the action of the endogenous ribonuclease. The 
subject of FMD virus inactivation has been 
extensively reviewed by Simms (1971).
The vaccine of Waldmann et al (1937) was adjuvanted 
with aluminium hydroxide. This adjuvant,
supplemented with saponin, is still in current use, 
as are oil-adjuvanted vaccines. The effect of 
adjuvants on the immunogenicity of aphthovirus is 
discussed in section 1.5..
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1.6.4. Experimental Vaccines.
considerable interest has been aroused by the 
prospect of sub-unit or synthetic f m d  vaccines, for 
such products offer a number of advantages over 
conventional vaccines (Beale, 1982). The absence 
of infectious viral r n a  would eliminate the risk of 
the vaccine causing infection. Whereas
conventional FMD vaccines require refrigeration due 
to the instability of the virus, cloned or 
synthetic vaccines should be sufficiently stable to 
permit storage at ambient temperature. Finally, it 
may be possible to develop synthetic vaccines into 
a thoroughly standardised and defined product 
containing no extraneous biological material. This 
should reduce the risk of allergic reactions and 
other side effects sometimes associated with 
conventional vaccines.
These potential advantages have stimulated research 
aimed at identifying the immunogenic portion of 
aphthovirus and subsequently developing a vaccine.
a) Cloned protein vaccines.
The immunogenicity of isolated VPI was first 
investigated by Laporte et al (1973), who 
demonstrated that pigs inoculated with VPI from a 
type 0 aphthovirus were stimulated to produce 
neutralizing antibodies. The neutralizing activity 
was specific for type o, consistent with the 
response to whole virus. it was subsequently shown 
that VPI was also capable of inducing protection in 
pigs (Bachrach et al, 1975; 1977; 1978) and cattle
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(Bachrach et a l , 1982). To achieve this, VPl was
typically given as two 100 pg doses. This compares
poorly with the whole virus, which can induce 
effective protection in cattle with a single dose 
of between 1 and 5^g (Rweyemamu et a l , 1982, 
Bachrach et a l , 1982). Under experimental
conditions one PD50 may be as little as 32 ngm of
purified virus for cattle and 5.8 ngm for pigs,
although larger doses may be required for pigs
under field conditions (Mowat, 1972).
The VPl used in these studies was isolated from 
purified whole virus and it was clearly not
economically viable to use VPl prepared by this
method in a commercial vaccine. Bachrach et al
(1978) considered three possible alternative 
methods for the production of large quantities of 
VPl, namely cell free protein synthesis programmed 
by aphthovirus RNA, chemical synthesis and the use 
of recombinant DNA techniques. The first of these 
methods is strictly a laboratory technique, with 
potential yields too low to be of any practical 
use, and chemical synthesis of the whole protein 
would have been prohibitively expensive.
The most promising method of synthesis at the time 
was the use of recombinant DNA techniques. The 
construction and analysis of recombinant plasmids 
containing cDNA copies of portions of the 
aphthovirus genome (Kupper et a l , 1981; Kurz et a l , 
1981 and Boothroyd et a l , 1981) was soon followed 
by expression of various bacterial fusion proteins, 
containing most or part of the sequence of VPl, in
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B.subtilis (Hardy et a l , 1981) and in E.coli (Kleid 
et al , 1981 and Hofschneider et a l , 1981). When 
used as vaccines these fusion proteins were able to 
stimulate cattle (Kleid et al , 1981), pigs (Kleid 
et a l , 1981) and goats (Hofschneider et a l , 1981)
to produce neutralizing antibodies. The animals 
were also protected from challenge. However, the 
necessary dosage of fusion protein was similar to 
that required for VPl (i.e. 2 doses of lOO^g each)
and thus the fusion protein still compared 
unfavourably with whole virus vaccines.
b) Synthetic peptide vaccines.
Despite the disappointing performance of cloned 
protein vaccines the work resulting in their 
production had yielded much useful information. 
The existance of cDNA copies of the viral genome 
allowed the amino acid sequences of VPl and of 
other viral proteins to be determined (Boothroyd et 
al, 1981; Kurz et al , 1981; Boothroyd et a l , 1982; 
Makoff et a l , 1982; Beck et a l , 1983; Cheung et a l , 
1983).
It had already been demonstrated that some peptides 
derived from VPl by CNBr cleavage could induce 
neutralizing antibodies in guinea pigs (Kaaden et 
1977; Adam et a l , 1978) and further work upon 
peptides derived from VPl by chemical or enzymic 
cleavage (Bachrach et a l , 1982 ; Strohmaier et a l , 
1982; Haresnape et a l , 1983) indicated that certain 
regions of VPI were responsible for inducing
neutralizing antibodies. Strohmaier et al (1982) 
were able to align their VPl derived peptides with
- 6 5 —
the amino acid sequence of the protein and identify 
two such areas, sequence positions 138-154 and 200- 
213.
By comparing the sequences of six different VPl 
molecules, from viruses of serotypes 0, A and c, 
Makoff et al (1982) were able to identify two 
highly variable regions, sequence positions 129-160 
and 193-204. Because of this variability they 
regarded these regions as potentially immunogenic. 
Similarly, by comparing three VPl's from two viral 
serotypes Beck et al (1983) were also able to 
locate two highly variable regions, sequence 
positions 40-60 and 130-160. Cheung et al (1983) 
compared the eight previously published sequences 
(serotypes 0, A and c) with two newly determined 
sequences and they too found a pair of highly 
variable regions. Sequence positions 134-158
varied from strain to strain and sequence positions 
42-60 varied between serotypes.
Additional evidence for the immunogenicity of one 
of these regions was provided by Robertson et al
(1983). They found that sequence positions 136-144 
were included within a region of VPl exposed on the 
virion surface and thus were potentially part of an 
antigenic site.
Once it was confirmed that there were only a 
limited number of potentially immunizing sites 
within VPl and the sequences of several forms of 
the protein were known, chemically synthesised 
peptides were again considered for use as vaccines. 
Rather than synthesise the whole protein, as
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Bachrach et al (1978) had originally suggested, 
Bittle et al (1982) synthesized several peptides 
copying, in total, 35% of the sequence of the VPl 
of 01 Kaufbeuren. When coupled to a carrier 
protein, keyhole limpet haemocyanin (KLH), two 
peptides were found to produce neutralizing 
antibodies in rabbits. One of these peptides, 
copying the sequence of amino acids 141 to 160, 
stimulated neutralizing antibodies in guinea pigs 
and eleven of fifteen such guinea pigs were 
protected from challenge with infectious virus. 
More recently, this peptide has been reported to 
stimulate the production of neutralizing antibody 
in cattle (Bittle et a l , 1984).
Similar results have been obtained independently by 
other groups. Pfaff et al (1982) synthesized three 
01 Kaufbeuren VPl peptides selected on the basis of 
predicted three dimensional structure. One of 
these, copying the sequence of amino acids 144 to 
159 and also coupled to KLH, stimulated high titres 
of antibody (neutralizing and ELISA) in rabbits. 
Yansura et al (1983) have described the synthesis, 
using recombinant DNA technology, of a peptide 
copying the sequence of amino acids 130 to 157 of 
A24 Cruzeiro VPl. The peptide was obtained as a 
fusion protein combining the peptide and sequences 
coded for by the E.coli tryptophan operon. cattle 
given two 250 ^g doses of the fusion protein 
produced high levels of neutralizing antibody and 
were protected when challenged with infectious 
virus.
-  67 -
Several patents have been granted for synthetic 
aphthovirus peptide antigens to be used as vaccines 
or diagnostic reagents, but the information 
presented is of a rather general nature (Biogen, 
1982; Bittle, 1983; Nicholson, 1984). However, as 
far as information is available, it seems that 
there is little difference in immunogenicity 
between VPl and peptide, whether synthesized 
chemically or produced in transformed bacteria. 
This being so, factors such as price and ease of 
production will determine which, if any, is chosen 
for use in a commercial vaccine.
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MATERIALS AND METHODS
2.1. Baby Hamster Kidney (BHK) cells.
BHK21 C13 monolayer cells were provided by the 
Tissue Culture Production Unit (TCPU) at the Animal 
Virus Research Institute (AVRI). The cell line was 
established by Macpherson and Stoker (1962) and 
maintained for routine use by serial passage in 
Roux flasks.
BHK21 C13 Clone AC9C suspension cells were provided 
by the Vaccine Research Department (VRD), AVRI. 
BHK21 C13 monolayer cells were adapted to 
suspension growth by Capstick et al (1962). The 
AC9C clone was derived at AVRI (Clarke, 1981) and 
maintained by serial passage in suspension culture.
2.2. Virus.
2.2.1. Strains.
BHK cell-adapted strains of aphthoviruses A5 Pando, 
A24 cruzeiro, C3 Resende, 01 Campos, 01 BPS 1860, 
01 Kaufbeuren, Asia 1 Iran 1/73, SATl Bot 1/68, 
SAT2 Bot 3/77 and SAT3 Bee 1/65 were provided by 
the VRD and the World Reference Laboratory, AVRI. 
All strains had been passaged repeatedly in BHK 
monolayer or suspension cells, as appropriate, 
before their use in this study.
Guinea-pig and cattle challenge strains of A24 
Cruzeiro and 01 BPS 1860 were provided by the VRD.
2.2.2. Growth and purification.
Aphthovirus was grown at 37 °C in suspension 
cultures of BHK cells maintained in Eagles medium
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plus 0 .02% tryptose phosphate, 1% polyethylene
glycol-precipitated ox serum and 65uM NaHCOg
Approximately 10® plaque forming units (pfu) of 
virus were used to infect a 6 litre culture 
(approximately 2 x 10® cells/ml). Cultures were 
sparged with air at a flow rate of 400ml/minute. 
The medium was harvested 48 hours after infection 
and cellular debris removed by centrifugation at 
450g for 15 minutes. After the addition of 7% w/v 
polyethylene glycol and O.lM NaCl (final 
concentrations) the harvest was stirred for 2 hours 
at 4 °C to precipitate the virus. The precipitate
was pelleted by centrifugation at 450g for 1 hour
and the pellet suspended in 0.15M NaCl, 0.05M Tris- 
HCl pH 7.6 (Tris-Nacl buffer).
Fatty material was extracted with two volumes of 
trichlorethylene. After centrifugation at 450g for 
30 minutes the upper, aqueous layer was removed and 
retained. In some cases the remaining non-aqueous 
layers were extracted a second time with Tris-NaCl 
buffer.
The aqueous extract was clarified by centrifugation 
at 10,000g for 30 minutes and the virus in the 
supernatant pelleted by centrifugation at 100,000g 
for 2 hours. The pellet was suspended in Tris-NaCl 
buffer and centrifuged at 70,000 g for 2 hours in a 
density gradient of 5% to 30% sucrose in the same 
buffer. The gradient was harvested through a 
continuous flow UV spectrophotometer measuring 
absorbance at 260nm and the fraction containing 
146S virus particles retained. Aliquots were
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stored at -70°C prior to use.
Virus for use in vaccines or ELISA was inactivated 
with acetylethyleneimine (AEI, see section 1.6.3) 
prior to precipitation from the tissue culture 
medium. 0.05% AEI v/v was added to the medium, 
which was held at 37 °C for 16 hours before further 
processing.
2.2.3. Radiolabelled virus.
Radioactive aphthovirus was prepared in Roux-bottle 
cultures of BHK monolayer cells. One Roux culture 
was infected with 10^ pfu of virus in 25ml of 
Eagle's medium and incubated at 37°C for 20 hours. 
The supernatant from this culture was then decanted 
onto a fresh Roux culture, which was incubated for 
30 minutes at 37°C before the infecting medium was 
removed. The infected cell sheet was washed three 
times in phosphate buffered saline (PBS) and 
incubated at 37 °C in methionine-free Eagle's 
medium. lOOjiCi of S-methionine were added after 
2 hours and incubation continued overnight.
The supernatant medium was clarified by 
centrifugation at 10,000g for 30 minutes, then the 
virus in the supernatant was pelleted by 
centrifugation at 100,000g for 2 hours. The pellet 
was suspended in Tris-NaCl buffer and centrifuged 
at 500,000g for 70 minutes in a density gradient of 
5% to 30% sucrose in the same buffer. Fractions of 
1ml were taken from the gradient and radioactivity 
determined by counting 10/Jl from each fraction in 
2ml Lumagel (LKB Instruments Ltd) in a Kontron
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MR300 liquid scintillation counter.
Labelled virus was stored at +4°C until use, 
usually within a few days of preparation.
2.2.4. Virus capsid proteins.
Capsid proteins were prepared from whole virions. 
Sucrose density gradient fractions containing 
radiolabelled and unlabelled virus were pooled, 
then two volumes of ethanol were added to the pool 
and the virus precipitated at -20°C for 48 to 72 
hours. The precipitate was pelleted by
centrifugation at 450g for 30 minutes and dissolved 
in dissociation buffer (see sections 2 .3.1 and 
2.3.2) for use.
2.2.5. Virus precursor proteins.
Precursor proteins were prepared from BHK cells 
infected with virus in the presence of zinc 
acetate. The effect of the zinc is to inhibit 
proteolytic cleavage and thus cause an accumulation 
within infected cells of the primary products of 
translation of the viral genome (Polatnick and 
Bachrach , 1978) .
Ten roux cultures of BHK monolayer cells were 
infected with virus (see section 2.2.3.). After 24 
hours the supernatant medium was collected, pooled 
and clarified by centrifugation at 450g for 15 
minutes. BHK suspension cells were sedimented from 
an 8 litre culture and the culture medium removed. 
The cells were infected by suspension in the Roux 
culture supernatant. The volume was adjusted to 1 
litre with Eagle s medium at 37 °C and the pH was
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adjusted to 7.3 with bicarbonate buffer. After 
incubation at 37 °C for 30 minutes the cells were 
centrifuged at lOOg for 5 minutes. The infecting 
medium was discarded, then the cells were washed 
once in Eagle s medium at 37°C, centrifuged as 
before and suspended in 1 litre of Eagle's medium 
at 37°C. After incubation at 37°C for a further 3 
hours, 50ml of 5M NaCl and 10ml of 0.02M zinc 
acetate were added to the culture. Incubation was 
continued for 1 hour 45 minutes then the cells were 
centrifuged at 450g for 15 minutes and washed twice 
in PBS at 4°C. The washed pellet was dissolved by 
boiling in 8M urea, O.OOIM dithiothreitol and 10% 
Triton X-100 and the solution stored at -20°C prior 
to use.
Radiolabelled precursors were prepared using the 
same protocol, with the following modifications. 
One half or one quarter as many cells were used and 
all volumes were reduced accordingly. Eagle's 
medium was replaced by methionine-free Eagle's 
medium, and l^Ci/ml of ®®S-methionine was added 
to the culture 45 minutes prior to harvesting the 
cells.
2.2.6. Assays.
a )146S antigen. The mass of antigen in sucrose 
gradient harvests was calculated from the 
absorbance at 260nm using the method of Doel et al 
(1982).
b )Infectivity. The titre of infectious virus in a 
culture, in pfu/ml, was determined by plaque assay 
on BHK monolayer cells. Serial ten-fold dilutions
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of the virus were prepared in PBS. BHK cell 
monolayers in 9cm Petri dishes were infected with 
0.2ml of diluted virus, then incubated at 37°C in a 
humidified, 5% C02/air, incubator. After 30 
minutes the cells were overlaid with Eagle's 
overlay medium containing 1% agar, 1% ox serum, 25 
units/ml of mycostatin, 100 units/ml of penicillin 
and 10 ^g/ml of neomycin sulphate. After 48 hours 
the plates were stained for 2 hours with 5ml 
0.0001% neutral red in PBS. Visible plaques were 
counted and the titre (pfu/ml) of infectious virus 
in the sample was calculated (Sellers, 1959) .
2.3. . Chromatographic purification of viral 
proteins.
2.3.1. Ion exchange chromatography of capsid 
proteins.
Three ion exchange systems were used:-
a) Sulphopropyl sephadex was equilibrated with 
0.02M citric acid, pH 3.97, 8M urea, 1% 2- 
mercaptoethanol and 1% Nonidet NP40 then packed in 
a 1.0 X  23cm column. The virus was dissociated in 
the equilibration buffer plus 2% SDS at 56°C for 90 
minutes followed by boiling for 2 minutes and was 
layered onto the column. Elution was carried out 
with 100ml of buffer forming a linear gradient of 
0.02M citric acid, pH 3.97, to 0.5M citric acid pH 
3.3 in 8M urea, 1% 2-mercaptoethanol and 1% Nonidet 
NP40 at a flow rate of 15ml/hour.
b) DEAE Sephadex A50 and c) DEAE Biogel A were 
equilibrated with O.OIM N a d  in 8M urea, 1% 2-
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mercaptoethanol, 1% Nonidet NP40, O.OlM Tris pH
8 .8 , and packed in a 1.0 x 30cm column. The virus 
was dissociated in the equilibration buffer by 
incubation at 56 °C for 2 hours. Elution was 
carried out with 100ml of buffer forming a linear 
gradient of O.OlM NaCl to 0.3M NaCl in 8M urea, 1%
2-mercaptoethanol, 1% Nonidet NP40, O.OlM Tris pH
8 .8 , at a flow rate of approximately 5ml/hour. 
Fractions of 4 to 5 ml were collected. Samples of 
0.5ml or 0.25ml from each fraction were counted in 
4ml or 2ml of Lumagel respectively.
2.3.2. Chromatofocusing of capsid proteins.
This was carried out using a modification of the 
technique first described by Sluyterman and 
Elgersma (1978). Proteins are focused in a pH
gradient generated by the elution of a buffered 
ion-exchange column with a mixed-ampholyte buffer.
A 1.0 X 40cm column was packed with Pharmacia 
Polybuffer Exchanger 94, and equilibrated with 
200ml of 0.025M imidazole, pH 7.4 followed by 100ml 
of 8M urea, 1% Triton X-100, ImM dithiothreitol, 
0.025M Imidazole, pH 7.4. Virus was dissociated in 
8M urea, 10% Triton X-100, 5mM dithiothreitol, 
0.025M imidazole, pH 7.4, by boiling for 10 to 15 
minutes, then cooled and loaded onto the column. 
Elution was carried out with 8M urea, 1% Triton X- 
100, ImM dithiothreitol, 10% Pharmacia Polybuffer 
74, pH 4.0, at a flow rate of 12ml/hour. Fractions 
of approximately 4ml were collected and the pH of 
fractions 1 , 5, 10, 15, 20, and every tenth
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fraction thereafter was measured as soon after 
collection as possible. Samples of 0.5ml or 0.25ml 
from each fraction were counted in 4ml or 2ml of 
Lumagel respectively.
2.3.3. Chromatofocusing of precursor proteins. 
Aliquots of labelled and unlabelled precursors were 
pooled, then dialysed twice against 100 volumes of 
0.1% SDS, 0.1% 2-mercaptoethanol. The dialysis 
tubing used for this step had a molecular weight 
cutoff of 50kD (Spectrum Medical Industries Inc., 
Los Angeles, USA). The dialysed pool was 
concentrated by evaporation at 60°C under a stream 
of oxygen-free nitrogen to a final volume of 2 to 
3ml. Two volumes of ethanol were added to the 
concentrate and the protein precipitated at -20°C 
for 48 to 72 hours.
A 1.0 X  40cm column was packed with Pharmacia 
Polybuffer Exchanger 94, then equilibrated with 
200ml of 0.025M histidine, pH 6.2 followed by 100ml 
of 8M urea, 1% Triton X-100, ImM dithiothreitol, 
0.025M histidine, pH 6.2. Precipitated precursors 
were pelleted by centrifugation at 450g for 15 
minutes, dissolved by boiling in 8M urea, 10% 
Triton x-100, 5mM dithiothreitol, 0.025M histidine 
pH 6.2, then cooled and loaded onto the column. 
Elution was carried out with 8M urea, 1% Triton X- 
100, ImM dithiothreitol, 10% Pharmacia Polybuffer 
74, pH 4.0 at a flow rate of 12ml/hour. Fractions 
of approximately 4ml were collected and the pH of 
fractions 1 , 5, 10, 15, 20, and every tenth
fraction thereafter was measured as soon after
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collection as possible. Samples of 0.5ml or 0.25ml 
from each fraction were counted in, respectively, 
4ml or 2ml of Lumagel.
2.3.4. Recovery of proteins.
Fractions associated with peaks of radioactivity 
were pooled and dialysed twice against 100 volumes 
of 0.1% SDS, 0.1% 2—mercaptoethanol. The dialysed 
pools were concentrated by evaporation at 60°C 
under a stream of oxygen-free nitrogen to a final 
volume of 2 to 3ml. Two volumes of ethanol were 
added to the concentrate and the protein 
precipitated at -20°C for 48 to 72 hours.
The identity of precipitated proteins was 
determined by polyacrylamide gel electrophoresis 
(section 2.3.6.). The quantitative recovery of 
protein was estimated by the recovery of 
radioactivity or by a Lowry protein assay, using 
the method of Bensadoun and Weinstein (1976).
2.3.5. Polyacrylamide gel electrophoresis.
a)Reagents.
i)Acrylamide stock solution. 30% acrylamide, 0 .8% 
bis-acrylamide in distilled water. The solution 
was filtered before use.
ii)Reservoir buffer. 0.025M tris pH 8.5, 0.05M 
glycine, 0.1% SDS.
iii)Sample buffer. 0.5M urea, 2% SDS, 10% 
glycerol, 2% 2-mercaptoethanol, 0.0625M tris, pH
6 .8 , coloured with bromophenol blue.
iv) Stain. Coomassie blue R250, 0.25% w/v in 45.4% 
methanol, 9.2% glacial acetic acid.
_ 'in
b )Protocol.
A discontinuous gel, 0.15cm thick, was cast between 
two glass plates. The separation gel (10% or 7.5% 
acrylamide, 5M urea, 0.1% SDS, 0.05% ammonium
persulphate (freshly prepared), 0.375M tris, pH
8 .8 . with 0.05% tetramethylethylenediamine (TEMED) 
as catalyst) was overlaid with a 2cm dep^h of 
stacking gel (2.2% or 1.7% acrylamide, 5M urea, 
0.1% SDS, 0.05% ammonium persulphate (freshly
prepared), 0.125M tris, pH 6 .8 . with 0.05% TEMED) 
cast around a shaped spacer to form sample 
application wells.
The cast gel/plate assembly was sealed into a 
vertical electrophoresis tank and the upper and 
lower reservoirs filled with reservoir buffer. 
Approximately lOO^g of protein, dissolved by
boiling in sample buffer, was loaded into each 
sample application well (located in the upper, 
cathodic, reservoir). Electrophoresis conditions 
were 30 volts for 16 hours at 15 to 20°C.
The gel was released from the plate assembly and 
stained with the Coomassie blue stain for 45
minutes. Protein bands were revealed by destaining 
with several changes of 5% methanol, 7.5% acetic 
acid. Destained gels were washed in water then 
dried under vacuum onto cellophane sheets.
A24 Cruzeiro
Ac-SER-GLY-ARG-***-ARG-GLY-ASP-MET-GLY-SER-
LEU-ALA-ALA-ARG-VAL-VAL-LYS-GLN-LEU-PRO-LYS
01 BFS/01 Kaufbeuren
Ac-VAL-PRO-ASN-LEU-ARG-GLY-ASP-LEU-GLN-VAL-
LEU-ALA-GLN-LYS-VAL-ALA-ARG-THR-LEU-PRO-LYS
Figure 2.1. Sequences of the A24 and 01 peptides. 
These are based on the sequences of amino-acids 
141-160 of the VPl proteins of A24 Cruzeiro, OlBFS 
1860 and 01 Kaufbeuren as described by Makoff et al 
(1982). The C-terminal lysine present in both 
peptides is not part of the VPl amino-acid sequence 
but was added to aid conjugation to carrier 
proteins. Both peptides were blocked by
acétylation at the N-terminus. There is a deletion 
(***) in the A24 sequence equivalent to position 
144 of the 01 sequence.
For the purposes of this study the 0 peptide was 
treated solely as an 01 BFS peptide. All 
appropriate assays of sera from 0 peptide- 
vaccinated animals and all challenge experiments 
involving such animals utilised 01 BFS virus.
2.4. Synthetic peptides.
Custom made synthetic peptides were purchased from 
the Macromolecular Analysis Service, University of 
Birmingham. These copied the sequence of amino- 
acids 141 to 160 of VPl from aphthovirus serotypes 
01 BFS and 01 Kaufbeuren, and the equivalent region 
from A24 Cruzeiro, as shown in Figure 2.1.
2.5. Carrier molecules.
2.5.1. Serum immunoglobulins.
Guinea-pig, rabbit and chicken immunoglobulins were 
prepared from non-immune serum by sodium sulphate 
precipitation (Stenos, 1967). The serum was made 
to 18% w/v with sodium sulphate and stirred for 15 
minutes. The precipitate was pelleted by 
centrifugation at lOOOg for 15 minutes then 
dissolved in PBS, made to 13% w/v with sodium 
sulphate and stirred for 15 minutes. The 
precipitate was pelleted as before, dissolved in 
the buffer of choice and dialysed overnight at 4°C 
against the same buffer. Any precipitate present 
after dialysis was removed by centrifuation. The 
supernatant, when examined on a Beckman Model E 
analytical ultracentrifuge, contained one major 
peak sedimenting at IS.
2.5.2. Egg yolk immunoglobulins.
Antibody to guinea-pig spleen cells was purified 
from the eggs of immune chickens.
Spleens were taken from non-immune DH guinea pigs
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and splénocytes prepared in the same way as mouse 
splenocytes (section 2.10.3). Hens were immunised 
intramuscularly with 1.5x10^ cells in 1ml of
Freund's complete adjuvant (FCA), and boosted at 25 
days with the same number of cells in 1ml of 
Al(0H)3 (see section 2.8.1.). Eggs laid between
seven and twenty-eight days after boosting were 
collected and the yolks pooled.
20ml of yolk were diluted to 100ml with PBS then 
clarified by centrifugation at 10,000g for 15 
minutes. The supernatant was diluted with an equal 
volume of PBS and fatty material extracted with 2 
volumes of trichlorethylene. After centrifugation 
at 450g for 60 minutes the upper, aqueous layer was 
removed and retained. In some cases the remaining 
non-aqueous layers were extracted a second time 
with PBS. Immunoglobulins were prepared from the 
aqueous extract by sodium sulphate precipitation as 
per section 2 .5 .1 .
2.5.3. Other proteins.
Keyhole limpet haemocyanin (KLH) was purchased from 
Calbiochem (La Jolla, USA). Bovine serum albumin 
(BSA) was purchased from Sigma (Poole, England). 
Tetanus toxoid was kindly provided by Dr. Frank 
Sheffield of The National Institute for Biological 
Standards and Control, London.
2.6. Preparation of antigen-carr1er conjugates.
Three methods were used to prepare conjugates. All 
reactions, regardless of the method, were carried 
out in PTFE coated vessels.
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2.6.1. Glutaraldehyde conjugates.
The carrier protein was prepared at 1 to 2 mg/ml in 
O.IM Sorensen's phosphate buffer (SPB), pH 7.7. 
Glutaraldehyde was added to a final concentration 
of O.OIM and the mixture was gently shaken on a 
rotary mixer for 1 hour at 37 °C. Unreacted 
glutaraldehyde was removed by dialysis at 4 ° C 
against 0.005M phosphate buffer (1/20 dilution of 
SPB). The protein remaining after dialysis was 
determined by Coomassie blue protein assay (see 
section 2.6.4a.).
Peptide or VPl was diluted to 2mg/ml with SPB and 
added weight for weight to the carrier- 
glutaraldehyde conjugate. The mixture was shaken 
on a rotary mixer for 1 hour at 37°C, then stored 
at -20°C prior to use.
2.6.2. Polysaccharide conjugates.
Dextran of molecular weight 40kd was prepared at 5 
mg/ml in 0.3M NaHCOg , pH 8.0, then mixed with an 
equal volume of 0.03M NalO, . The reaction was 
allowed to proceed, with occasional shaking, for 30 
minutes at 20°C. Glycerol was added to a final 
concentration of 0.16M and incubation at 20°C 
continued for 1 hour, following which the activated 
dextran was dialysed against O.OIM carbonate buffer 
(CB) (0.007M NaHCOa , 0.003M N a 2 CO 3 , pH 9.6). 
Carrier protein was prepared at 10 mg/ml in CB. 
The dextran was mixed with an equal weight of 
protein and the mixture incubated, with occasional 
shaking, for 5 hours at 20°C. Unbound dextran was
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removed from the carrier-dextran conjugate by 
dialysis against CB at 4 ° C . The dialysis tubing 
used for this step had a molecular weight cutoff of 
50k (Spectrum Medical Industries Inc., Los 
Angeles, USA). Protein remaining after dialysis 
was measured by Coomassie blue protein assay (see 
section 2.6.4a).
An equal weight of peptide or VPl, 2 mg/ml in CB, 
was mixed with the carrier-dextran conjugate. The 
mixture was incubated, with occasional shaking, for 
4 hours at 20°C before the reaction was halted and 
the conjugate stabilised by the addition of NaBH 
(weight for weight of carrier). The conjugate was 
held at 4°C overnight, then stored at -20°C prior 
to use.
Conjugates crosslinked with a shorter dextran (MW 
lOkd) or with inulin (MW 6kd) were also prepared 
using this method.
2.6.3. Direct conjugation to immunoglobulins. 
Peptide was linked directly to the carbohydrate 
moieties on immunoglobulin molecules using a 
modification of the method of Nakane and Kawaoi 
(1974).
Immunoglobulins were prepared at 5mg/ml in 0.3M 
NaHCOg , pH 8.0. Dinitrofluorobenzene (DNFB) stock 
solution (1% DNFB v/v in ethanol) was added, to a 
final concentration of 0.1% DNFB, and the mixture 
was incubated for 1 hour at 20°C, with occasional 
shaking. 0.08M NalO* was then added and incubation 
continued for 30 minutes, after which glycerol was 
added to a final concentration of 0.16M. Following
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incubation for a further hour, with occasional 
shaking, the reaction mixture was dialysed against 
O.OIM CB at 4°C. Protein remaining after dialysis 
was determined by Coomassie blue assay (see section 
2 .6 .4a . ) .
An equal weight of peptide, 5mg/ml in O.OIM CB, was 
added to the activated immunoglobulin and 
conjugation allowed to proceed for 5 hours at 20°C. 
The reaction was halted and the conjugate 
stabilised by the addition of Img NaBH per mg of 
carrier protein. The conjugate was held at 4 °C 
overnight, then stored at -20°C prior to use.
2.6.4. Assays.
a) Coomassie blue protein assay. Doubling
dilutions of the assay sample were made in flat 
bottomed 96-well microtitre plates (Nunc-Immuno 
Plate II-96F), 100^1 per well. Distilled water or
PBS was used as the diluent. lOO/il of coomassie
blue G250, 0.06% in 0.6N HCl, were added and the
colour allowed to develop for 10 to 15 minutes. 
The O.D. at 620nm was measured and protein 
concentration determined by reference to 
simultaneously assayed bovine serum albumin 
solutions of known concentration.
The assay was most reproducible at protein 
concentrations between 20 and lOO^g/ml. Preparing 
doubling dilutions of the sample to be assayed 
ensured that at least two measurements could be 
made within this range.
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b) Sedimentation coefficients. The sedimentation 
coefficients of selected carriers and conjugates 
were measured using a Beckman Model E analytical 
ultracentrifuge fitted with Schlieren optics. 
Samples were prepared in a dilute, aqueous, buffer 
and all measurements were made at 22°C.
c ) ELISA. Selected batches of conjugate were 
tested for the presence of peptide bound to the 
carrier protein by an ELISA (see section 2.8). 
Plates were coated with a 1/100 dilution of rabbit 
antiserum to the carrier protein, then serial 
dilutions of conjugate were made across the coated 
plates. controls of peptide, carrier or a non­
conjugated mixture of the two were included at this 
stage. The trapped antigen was probed for peptide 
with either guinea-pig anti-peptide serum, guinea- 
pig anti-conjugate serum (positive control) or 
normal guinea-pig serum (negative control), diluted 
1/100 in dilution buffer plus 3% BSA for use. 
Bound antibody was detected using HRPO-conjugated 
rabbit antiserum to guinea-pig immunoglobulins, 
diluted 1/5000 in dilution buffer plus 3% BSA.
2.7. Immunisations.
2.7.1. Animals.
Dunkin-Hartley randomly bred (DH), Strain 2 inbred 
(S2) and Strain 13 inbred (S13) guinea-pigs.
New zealand/Dutch cross (NZ/D) rabbits.
Charles Rivers (CR) and pirbright (P) randomly bred 
and Balb C, C3H, C57 Black (C57B), Parkes 
surgically derived (PSDi) and Charles Rivers (CRi)
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inbred mice.
All small animals were bred at AVRI.
Devon red steers were purchased locally.
2 .7 .2 . vaccination.
The various antigens were formulated with one of 
three adjuvants.
a)Freund's complete adjuvant (FCA)^ Antigen, 
diluted in PBS, was emulsified with an equal volume 
of FCA (Difco Laboratories, Detroit, USA) by 
repeated passage through a 16 gauge syringe needle.
b ) A l u m i n i u m  hydroxide (Al(OHlgJ_^ Four volumes of 
antigen diluted in PBS were mixed with one volume 
of 3% Al(OH)g (sold as "Alhydrogel" by Superfos 
Export CO., Denmark). The vaccine was held at 4°C
for at least 16 hours prior to use.
c)Aluminium hydroxide and saponin^ saponin was
incorporated in Al(0H )3 vaccines at 1.7mg/ml final
concentrât ion.
unless otherwise stated vaccines were administered
as follows.
Rabbits and guinea-pigs were given 1ml of vaccine, 
inoculated sub-cutaneously on the flank. This 
contained 10/ig of virus or 100/ig of peptide or VPl, 
together with an equal weight of carrier if used. 
Mice received one fifth of a rabbit/guinea-pig 
dose, also inoculated sub-cutaneously on the flank. 
Initial vaccinations were made with antigen in FCA. 
Booster vaccinations, when given, were adjuvanted 
with A l (O H )3 .
Cattle were vaccinated subcutaneously with 3ml of
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vaccine.
2.7.3. Challenge.
Guinea-pigs were inoculated with 10^ '^  ID50 of virus 
in the left rear footpad. They were deemed 
protected if generalised lesions did not develop. 
Cattle were inoculated with 10^'° ID50 of virus 
intradermolingually. Severity of tongue lesions
and spread to the feet was assessed.
2.8. Enzyme linked immunosorbent assay (ELISA).
The following protocol was the basis for all ELISA 
assays used in the course of this investigation, 
specific uses of the assay are described in 
sections 2.6.4c., 2.9.1., 2.9.2. and 2.10.4b.
2.8.1. Antisera.
Horseradish peroxidase (HRPO) conjugated anti­
species sera (rabbit anti-mouse immunoglobulin, 
rabbit anti-guinea-pig immunoglobulin, rabbit anti- 
bovine immunoglobulin, swine anti-rabbit
immunoglobulin) were purchased from Dakopatts 
(Woking, England).
Rabbit anti-KLH and anti-BSA sera were the gift of 
Mr. R.F.Staple, AVRI. Rabbit anti-serum to chicken 
serum was purchased from Dakopatts. Rabbit
antisera to guinea-pig IgGl or lgG2 were purchased 
from Nordic Immunology (London, England). Rabbit 
antiserum to guinea-pig igM was purchased from 
Miles scientific (Slough, England).
Rabbit, guinea-pig or mouse antisera to virus, 
peptide, peptide-carrier conjugates or VPl were 
produced in accordance with the protocols described
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in section 2.7.2.
2.8.2. Protocol.
Flat-bottomed 96-well microtitre plates (Nunc- 
Immunoplate II-96F) were coated with lOO/il per well 
of antigen or antiserum diluted in coating buffer 
(0.015M Nag CO3 , 0.035M NaHC03 , pH 9.6). Plates 
were incubated at 20°C overnight then washed three 
times by immersion in wash buffer (M25 buffer 
containing 0.15M NaCl and 0.05% v/v Tween 20, final 
concentrations).
Antiserum or antigen, diluted in dilution buffer 
(M25 buffer containing 0.15M NaCl and 1.0% v/v 
Tween 20, final concentrations) plus 3% BSA, was 
added to each well. The plates were incubated for 
1 hour at 37°C, during which time they were shaken 
gently on an orbital shaker, then washed three 
times. This step was repeated, if necessary, for 
any successive antisera used in the assay.
Finally, HRPG-conjugated anti-immunoglobulin serum, 
diluted in dilution buffer, was added to the 
plates. The plates were incubated for 1 hour at 
37°C on an orbital shaker then washed three times 
as before. lOOyul of substrate solution (0- 
phenylenediamine, 0.42mg/ml in 0.051M citrate,
0.022M Na 2 HPO4 , pH 5.0, plus 0.4% 30vol H gOg 
added immediately before use) were added to each 
well and the colour allowed to develop for 5 
minutes before the reaction was halted by the 
addition of lOO/il of 25% Hg S O 4 . Absorption at 
492nm was determined using a Titertek Multiskan
plate reader.
2.9. Serum assay.
2.9.1. Total specific antibody.
All sera were assayed by ELISA (see section 2.8.) 
for antibody against virus and peptide. In 
addition some sera were assayed for antibody to 
VP l .
Plates were coated with antigen diluted to lyag/ml 
in coating buffer. Serial dilutions, in dilution 
buffer, of the sera under assay and of standard 
positive and negative sera were made on the plates. 
Bound antibody was detected with HRPO-conjugated 
anti-immunoglobulin sera.
2 .9 .2 . specific antibody subclasses.
Selected guinea-pig sera were assayed by ELISA (see 
section 2.8) for virus- and peptide-specific IgGl, 
IgG2 and IgM.
Plates were coated with antigen diluted to lyug/ml 
in coating buffer. Serial dilutions, in dilution 
buffer, of the sera under assay and of standard 
positive and negative sera were made on the plates. 
Specific antibody was then probed with rabbit 
antisera to guinea-pig IgGl, lgG2 or IgM. Rabbit 
anti-lgGl or lgG2 was diluted as required in 
dilution buffer plus 3% BSA. Rabbit anti-igM was . 
diluted in dilution buffer plus 3% BSA and l;ig/ml 
chromatographically purified guinea-pig igG 
(Pharmacia, 1982) to remove any anti-igG activity. 
Bound rabbit antibody was detected with HRPO- 
con jugated swine antisera to rabbit
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immunoglobulins.
2.9.3. Neutralizing antibody. .
Neutralizing antibody titres (SNT) were determined
using a microtitre assay as described by Golding et 
al (1976). Briefly, this was a tissue-culture 
microneutralization assay in which doubling 
dilutions of serum were tested against a standard 
100 TCID50 of virus over a 48 hour period. A 50% 
neutralization end-point was determined.
2.9.4. Plaque reduction assays.
samples for assay were prepared in one of two ways. 
Either dilutions of serum were prepared in PBS 
containing 500pfu/ml of virus or dilutions of 
peptide were prepared in PBS containing 500pfu/ml 
of virus and to which was added a freshly prepared 
standard concentration of serum. The samples were 
incubated in a waterbath at 37 ° C  for 1 hour prior 
to assay.
BHK cell monolayers in 9cm Petri dishes were 
infected with 0.2ml of the samples, then incubated 
at 37°C in a humid, 5% C02/air, incubator. After 
30 minutes the cells were overlaid with Eagle's 
overlay medium containing 1% agar, 1% ox serum, 25 
units/ml of mycostatin, 100 units/ml of penicillin 
and 10 ^g/ml of neomycin sulphate. After 48 hours 
the plates were stained for " 2 hours with 5ml 
0.0001% neutral red in PBS and any visible plaques 
were counted.
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2.9.5. Complexing antibody.
The ability of serum to form immune complexes with 
virus was determined by sucrose density gradient 
analysis.
The serum for assay was diluted as required in non- 
immune horse serum, then radiolabelled virus added 
at c.4^g/ml final concentration. After incubation 
overnight at 4°C the mixture was loaded onto a 9 ml 
gradient of 15% to 45% sucrose in Tris-NaCl buffer. 
A 2ml cushion of CsCl, 1.6g/ml in Tris-NaCl buffer, 
was layered beneath the gradient immediately before 
use. The gradient was centrifuged at 500,000g for 
70 minutes, then 1ml fractions were collected. A 
250/11 sample from each fraction was counted in 4ml 
of Lumagel.
2.10. Mouse splenocytes.
2.10.1. Mice.
C57B mice were immunised with virus or KLH- 
glutaraldehyde-peptide conjugate in FCA as per 
section 2.8.1. The animals were revaccinated after 
28 days with an equivalent dose of antigen on 
A1 (0H )3 and were used for experiments after 56 or 
more days.
2.10.2. Culture medium.
Complete medium was RPMI 1640 (supplied by the TCPU 
at AVRI), plus 2mM glutamine, ImM pyruvate, 50/iM 2- 
mercaptoethanol, 20mM HEPES pH 7.0, 500 units/ml
penicillin, 500 /ig/ml streptomycin, 10% foetal calf 
serum and non-essential amino acids at the
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following final concentrations:- alanine, 0.89 
mg/ml; asparagine, 1.5 mg/ml; glycine, 0.75 mg/ml; 
glutamic acid, 1.47 mg/ml; proline, 1.15 mg/ml; 
serine, 1.05 mg/ml; aspartic acid, 1.33 mg/ml. The 
foetal calf serum was an endotoxin free batch 
(Gibco Ltd, Scotland) selected for its ability to 
maintain cells in culture and for its lack of 
innate mitogenic activity. 2-mercaptoethanol was 
prepared and added immediately before use. 
Incomplete medium was RPMI 1640 plus 20mM HEPES pH
7.0, 500 units/ml penicillin and 500 /ig/ml
St reptomycin.
2.10.3. Splenocyte culture.
Spleens were taken aseptically and the cells 
prepared after the method of Collen et al (1984). 
Individual spleens in 2 to 3 ml of cold incomplete 
medium were ground in a tissue grinder to produce a 
cell suspension free of visible clumps. The 
suspension was made to 10ml with cold incomplete 
medium and the cells pelleted by centrifugation at 
250g for 5 minutes. The pellet was taken up in 
10ml of ice-cold 0.83% NH^Cl and held on ice for 5 
minutes to lyse the erythrocytes. After lysed 
cells and debris had sedimented the supernatant was 
mixed with an equal volume of cold incomplete 
medium and the cells recovered by centrifugation as 
above. The cells were washed three times in cold 
incomplete medium, suspended in complete medium and 
counted. One spleen typically produced 10® viable 
cells, as determined by trypan blue exclusion. 
Splenocytes were cultured in complete medium
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containing various concentrations of antiaen 
(virus, peptide, KLH or KLH-glutaraldehyde-peptide 
conjugate). Control cultures were grown in either 
complete medium only, complete medium plus 7.5/ig/ml 
lipopolysaccharide (LPS) or complete medium plus 
5/jg/ml Concanavalin A. Cultures were maintained in 
96 well tissue culture plates (Nunc Microwell Plate 
96F), 10® cells in 200/il of medium per well,
sealed with adhesive plastic sheets and incubated 
at 37°C in a humid atmosphere of 5% C02, 95% air.
2.10.4. Assays.
a) MTT reduction. The level of cellular metabolic 
activity was assessed at intervals by measuring 
reduction of the tétrazolium salt MTT (3-(4,5- 
dimethylthiazol-2-yl)-2 ,5-diphenyl tétrazolium
bromide), after the method of Mosmann (1983).
100/il of medium was removed from each well and 
discarded, leaving the cells for assay in lOO/il of 
medium per well. lO/il of MTT stock ( 5mg/ml in PBS, 
filter sterilized) was added to each well, then the 
plates were resealed and incubated as above. After 
4 hours acid-isopropanol (0.04M HCl in isopropanol) 
was added (100/:1 per well) and mixed thoroughly to 
dissolve any blue crystals formed by cleavage of 
the MTT. Absorbance was determined using a 
Titertek Multiskan plate reader. The absorbance 
due to blastogénie activity of the cultures was 
read at 550nm. Blank absorbance was determined 
from medium-only control cultures read at 620nm.
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b) ELISA. The culture medium was assayed for
specific antibody by ELISA (see section 2.8) after 
eight days. Plates were coated with antigen, 
l^g/ml in coating buffer, then 75/il of tissue 
culture supernatant was added to each well. The
supernatant was used neat or diluted with an equal 
volume of dilution buffer. Serial dilutions were 
not made, preliminary experiments having shown this 
to be unneccesary. Control sera (mouse anti-virus, 
mouse anti-conjugate and normal mouse serum), 
diluted 1/100 in dilution buffer plus 3% BSA, were
included at this stage. Specific antibody was
detected with HRPO-conjugated rabbit antiserum to 
mouse immunoglobulins, used at a dilution of 1/800 
in dilution buffer plus 3% BSA.
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RESULTS
3. ISOLATION OF VPl AND STUDIES OF ITS USE AS A 
VACCINE.
3.1. Introduction.
Vaccines prepared from the aphthovirus capsid 
protein VPl have recently been the subject of 
several investigations (see section 1.6.) which 
indicate that further development of such vaccines 
may be useful. The use of P88, the precursor of 
the capsid proteins, as an alternative immunogen 
also merits consideration. It is possible that the 
presence of all the capsid proteins as one molecule 
may favourably affect the conformation and 
immunogenicity of VPl.
Such studies require the preparation of large 
quantities of the immunogen and various techniques 
have been used to isolate these and similar 
proteins. These include preparative polyacrylamide 
gel electrophoresis (Bachrach et al, 1978), ion- 
exchange chromatography (Adam and Strohmaier, 1974; 
Bernard et al, 1974) and isoelectric focusing in 
urea-sucrose gradients (Wiegers and Drzeniek, 
1980). Each of these methods has its advantages, 
but the simplest and potentially the most versatile 
of the three is ion-exchange chromatography, which 
was selected for further evaluation.
Another method which appeared to have considerable 
potential was chromatofocusing. In this technique, 
first described by sluyterman and Elgersma (1978), 
proteins are focused in a pH gradient generated by
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the elution of a buffered ion-exchange column with 
a mixed ampholyte buffer and are eluted in the 
order of their isoelectric points. The resolution 
is reported to be similar to that of 
electrophoretic isoelectric focusing (Sluyterman 
and Wijdenes, 1978).
In preliminary experiments to evaluate the use of 
chromatofocusing and ion-exchange chromatography 
for the isolation of VPl from aphthovirus it was 
found to be necessary to include Triton X-100, urea 
and dithiothreitol in the elution buffer in order 
to minimise precipitation of the capsid proteins 
within the column. Determination of the protein 
concentration in the eluate by measuring the 
absorbance at 280nm was not practical under these 
conditions and therefore a quantity of 
radiolabelled marker virus was incorporated into 
each sample. Unfortunately, under these conditions 
conventional ion-exchangers were prone to 
mechanical collapse, which caused high back­
pressures and much reduced flow rates,
consequently, ion-exchange chromatography was not 
investigated further.
3.2. isolation of VPl by chromatofocusing.
The isolation by chromatofocusing of proteins from 
viruses of each serotype of aphthovirus was
assessed. The elution profiles obtained by
monitoring radioactivity in the fractions collected 
are shown in Fig. 3.1, together with the pH 
gradients measured during elution. The virus 
capsid proteins eluted in the order VPl (first, at
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high pH), VP2 and VP3, as determined by 
polyacrylamide gel electrophoresis.
The bulk of the VPl of aphthovirus types A5 Pando, 
C3 Resende and SAT 2 Bot 3/77 was excluded from the 
column and frontally eluted (pool 'a' on the 
profiles), though small quantities could be 
detected eluting from the column at a pH of 
approximately 6.5. Most of the VPl of the other 
aphthovirus types studied was apparently retained 
on the column for a short time and eluted at a pH 
of 6.5 to 7.0 (generally pools 'b' or 'c' on the 
profiles).
The last protein to be eluted, VP3, did so 
relatively late in the pH gradient with all 
aphthovirus types examined (pools 'f' and 'g' on
the profiles). There was a definite tendency for
this protein to form broad or poorly defined peaks 
and this was particularly evident with A5 Pando, 01 
Campos and SAT3 Bee 1/65.
In all cases the pH gradient was essentially linear 
during the course of elution, though some variation 
was observed between runs.
Fig. 3.2 shows the PAGE analysis of proteins
isolated after the chromatofocusing of SAT2 Bot 
3/77. VPl was obtained in pure form, whereas VP2 
and VP3 were contaminated with traces of VPl or VPl 
and VP2 respectively. This result is
representative of those obtained with other 
preparations of virus.
Other viral proteins were occasionally detected. 
VPlL and VPlS, the cleavage products of VPl, were
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found to elute shortly after VPl. VPO, the 
precursor of VP2 and VP4, was sometimes evident as 
a minor component eluting between VP2 and VP3.
The recovery of radioactivity after the elution of 
aphthovirus type SAT2 Bot 3/77 is shown in Table
3.1. 80% of the marker was recovered, contained
mostly in pools 'a', 'c', 'à' and 'f'. Pool 'a'
contained VPl, pools 'o' and 'd' VP2 and pool 'f' a 
mixture of VP2 and VP3. Pool 'g' contained VP3 
(Fig. 3.2). VP4 could not be recovered from the 
column under the conditions used, so the recovery 
of 80% of the total label represents some 96% of 
the potentially recoverable label. The recovery of 
radioactivity after chromatofocusing of the other 
virus preparations was also monitored and the 
results are summarised in Table 3.2. The recovery 
declined to approximately 50% with an initial load 
of 10 to 15mg of virus. The recovery of VPl also 
declined as the initial protein load increased 
(Table 3.3), but even so the gain in production of 
VPl from the use of a larger sample compensated for 
the reduced efficiency of recovery.
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Figure 3.1. Elution profiles of seven preparations 
of aphthovirus during chromatofocusing. One virus
from each serotype was used, as follows: A5 pando, 
01 Campos, Asia 1 Iran 1/73, C3 Resende, SATl Bot 
1/68, SAT2 Bot 3/77, SAT3 Bee 1/65. The solid line 
shows the elution of the ^^S-Methionine label, the 
broken line the pH of the eluate. The bars 
indicate pools from which protein was recovered.
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Table 3.1. Recovery of S-methionine after 
chromatofocusing of aphthovirus type SAT2 Bot 3/77. 
The pools referred to are marked on the SAT2 
elution profile in Figure 3.1.
Pool Radioactivity present 
(dpm X 10” )^
a 145
b 45
c 374
d 250
e 88
f 425
g 92
Total (all pools) 1419
Initial virus preparation 2000
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Figure 3.2. SDS-PAGE analysis of proteins 
recovered after chromatofocusing of SAT2 Bot 3/77. 
The pools referred to are marked on the elution 
profile shown in Fig. 3.1. Bovine serum albumin 
fraction V was used as a carrier protein to aid the 
recovery of viral proteins by ethanol 
precipitation. This is the source of the high 
molecular weight proteins visible on the gel.
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l^ hiP ?,?. i O^T^ ry of ^^ S-nethicnine after diroratofioaising of se\m 
pr^ar^icns of cçhthcvirus. The pools referred to are narked cn the 
elution profiles in Figure 3.1.
Virus Quantity mlioætivity Radioactivity reœvered
(ng) loaded onto colurm {dgm X 10 ®)
v“ 6 v In pools m  total
A5 lando 12 4.28 1.83 2.01
01 Canpos 15 9.30 3.30 4.72
C3 I^ sencte 1 3.50 1.96 2.73
Asia 1 Iran 1/73 10 5.20 2.60 3.30
SATl Bot 1/68 7 0.64 0.24 0.30
SŒ2 Bot 3/77 ra"^ 2.00 1.42 1.61
SAG ^  1/65 10 1.00 0.48 0.56
RA = Radioactive virus only.
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lable 3.3» RBOcveiry of the innunc^ aiic capsid protein VPl fran four 
pr^araticns of aphthovirus.
Virus Quantity of 
virus loaded 
onto œlurm (mg)
VPl reoovered 
(ng)
VPl reoovered^  
(%)
Asia 1 Iran 1/73 4 0.76 100
A5 lendo 11.4 1.48 70
A5 Eando 17 1.63 53
Asia 1 Iran 1/13 60 2.78 30
 ^assunnrg 60 ccpies per virion
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3.3. Response of guinea-pigs to vaccination with 
VPl.
DH guinea-pigs were vaccinated with various VPl 
vaccines, then bled and challenged after 28 days. 
The results are shown in Fig. 3.3, together with 
results from virus vaccinated animals for 
comparison. Single vaccinations with these
vaccines induced moderate to low levels of anti­
viral antibody as measured by ELISA, but did not 
induce neutralizing antibody. The A24 and 01 VPl 
vaccines were not protective, whereas the Asia 1 
VPl vaccines induced a low level of protection 
despite the absence of detectable neutralizing 
antibody. The use of a carrier enhanced the ELISA 
antibody response to Asia 1 VPl only. Neutralizing 
antibody titres and protection were not affected.
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Figure 3.3. The response of guinea-pigs to 
vaccination with VPl or whole virus vaccines. DH 
guinea-pigs were vaccinated with lOOpg of VPl, with 
or without an equal weight of carrier, or with 10/ig 
of virus, in FCA. The animals were bled and 
challenged 28 days after vaccination. Anti-viral 
antibody titres were measured by ELISA, 
neutralizing antibody titres by the microtitre 
neutralization test. The error bars show standard 
deviation. Sera were considered negative when 
titres of <= 1.7 in the ELISA or <= 1.04 in the
neutralization test were obtained.
Some vaccines included KLH as a carrier. The 
conjugates were formed with glutaraldehyde (gl) or 
with 40kd dextran (dx).
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VACCINE
O^BFS 
O^BFS VPl 
O^BPS VPl-dx-KLH 
O^BFS VP1-gl-KLH
A24 Cruzeiro 
■ Ag^ Cruzeiro VPl 
A^4 VP1-di-KLH 
A24 VPl-gl-KLH
Asia 1 Iran l/73 
Asia 1 VPl 
Asia 1 VPl-dx-KLH
LOG^  ANTIBODY TITRE 
ELISA
anti-virus SNT
1 2  3 4 5 6 1 2
PROTECTION
-i----- 1----- 1 I
5/6
0/6
0/5
0/5
5/5
0/5
0/5
0/5
6/ 6 
1/6 
2/8
* No. protected/no. challenged
Figure 3.3.
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3.4. Discussion.
The use of chromatofocusing made it possible to 
prepare relatively large quantities of VPl. The
theoretical capacity of a 1 x 40cm column of PBE 94 
is ca. 300mg of protein and thus the limit to the 
use of this method has been the availability of 
virus. Typically, two 8 litre cultures of BHK
suspension cells were used for the production of 
virus, yielding 15 to 20mg of purified virus. This 
quantity of virus contains ca. 4mg of VPl, of which 
1.5 to 2mg could be recovered after all
purification steps were carried out.
This performance compares favourably with
alternative systems used for the isolation of
aphthovirus proteins. Several groups have reported 
the use of preparative PAGE systems (Bachrach et 
al, 1978; Kleid et al, 1981) with capacities of up 
to 5mg of viral protein (Matheka and Bachrach, 
1975), equivalent to ca. Img of VPl. More 
recently, commercial PAGE systems with higher 
capacities have become available but these systems 
are considerably more expensive than a simple 
chromatographic column. conventional ion-exchange 
systems are theoretically comparable with
chromatofocusing and have been used succesfully in 
the past (Adam and Strohmaier, 1974; Bernard et al, 
1974) but in this instance were found to suffer 
from serious practical problems. Isoelectric
focusing in a urea-sucrose gradient has been used 
to prepare poliovirus capsid proteins (Wiegers and 
Drzeniek, 1980). The system gave excellent
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resolution and had a large capacity for protein but 
was technically complex.
It has been reported by Cantrell et al (1981) that 
protein load can affect the pH gradient during
isoelectric focusing. Since no attempt was made to 
standardise the protein load applied to the column 
this is a probable cause of the variation between 
runs observed in Figure 3.1. The effects described
by Sluyterman and Elgersma (1978) concerning the
difference between the true pi of a protein and the 
pH at which it elutes during chromatofocusing mean 
that pi cannot be accurately determined by this 
method. The isoelectric points of aphthovirus
capsid proteins determined by analytical 
isoelectric focusing (King and Newman, 1980) are 
higher than the pH values at which these proteins 
were observed to elute during chromatofocusing. 
This is not crucial for a preparative technique, 
but data concerning isoelectric points derived by 
this method must be interpreted with care. 
Chromatofocusing was not so effective when used to 
isolate precursor proteins of aphthovirus strain 
from infected BHK suspension cells. In the course 
of this work two attempts were made to purify A5 
Pando precursors (data not shown) but viral 
proteins could neither be satisfactorily resolved 
nor obtained free from cellular contaminants. In 
retrospect, a combination of gel filtration and 
affinity chromatography might have provided a more 
appropriate strategy for purification of proteins 
that were a minor component of an infected cell
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lysate. The object of attempting to use 
chromatofocusing was to determine whether this 
method could provide a relatively simple 
purification system able to handle large quantities 
of protein. Whilst meeting these criteria for the 
purification of VPl the system did not appear to 
have the potential to purify P88 in useful 
quantities.
The limited investigation of VPl vaccines reported 
here produced results consistent with earlier 
studies, which indicated that single doses of VPl 
vaccines were ineffective at inducing neutralizing 
antibody or protection (Bachrach et al, 1975; 1977; 
1978; 1982). The presence of a carrier did not
usefully enhance the response to VPl. Taken 
overall, these results gave no indication of an 
improvement on the findings of other groups working 
with VPl, nor did it appear that the production of 
P88 in BHK cells offered a useful alternative 
source of immunogen since the protein could not be 
isolated without undue difficulty. For these 
reasons, and because of the growing interest in 
synthetic peptide vaccines, VPl and P88 were not 
investigated further.
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4. PRELIMINARY STUDIES OF PEPTIDE-PROTEIN 
CONJUGATES AND OF THEIR USE AS VACCINES.
4.1. Introduction.
Several recent studies have examined synthetic 
peptide vaccines against a number of diseases (see 
sections 1.4.4. and 1.6.4b.). Whilst many 
different peptides have been examined, relatively 
few studies have directly compared multiple 
formulations of the same peptide. Thus preliminary 
investigations were carried out to assess the 
effect of a range of carrier molecules, cross- 
linking agents and adjuvants on the immunogenicity 
of the 01 and A24 peptides.
Furthermore, there is little published information 
concerning batch to batch variation of peptide- 
protein conjugates, which can be significant 
(Beuvery et a l , 1983). Whilst this may not be a
problem in laboratory investigations where one 
batch of conjugate can provide all the antigen 
necessary (as was usually the case in this study), 
it would certainly be necessary to have a means of 
standardising the production of conjugates for any 
commercial application. This chapter describes an 
ELISA which may be used to compare the quantity of 
peptide in various peptide-carrier conjugates.
4.2. Physical properties of the conjugates.
The efficiency of coupling of peptide to various 
carrier molecules was assessed by ELISA. The 
carrier was trapped with an appropriate anti­
carrier antibody and then probed with an anti-
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peptide antibody for the presence of peptide. Non­
conjugated mixtures of peptide and carrier protein 
showed no sign of peptide associated with the
trapped protein (Fig. 4.1), whereas all of the
conjugated preparations contained significant 
quantities of peptide bound to the carrier protein 
(Fig 4.2). Glutaraldehyde appeared to be the most 
effective of the cross-linking agents used, though 
panels C, D and E in Fig. 4.2 indicate that there 
was batch to batch variation with this procedure. 
Some conjugates were examined in a Beckman model E 
analytical ultracentrifuge and were found to
contain both material sedimenting at an ' s '  value 
consistent with the monomeric carrier (Table 4.1) 
and rapidly sedimenting, aggregated, material of 
very high ' s '  value. ELISA of fast and slow
sedimenting fractions showed peptide to be 
associated with both (Fig. 4.3). Studies carried 
out in this laboratory indicated that the fractions 
were of equivalent immunogenicity (T.R. Doel, 1984, 
personal communication) and conjugates were not, 
therefore, fractionated prior to use.
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Figure 4.1. ELISA for peptide covalently bound to 
a carrier protein. Four preparations were assayed:
A) KLH-glutaraldehyde-A peptide (batch 21.6)
B) KLH
C) A peptide
D) a mixture of KLH and A peptide
KLH was trapped with an antibody bound to the solid 
phase, then probed with three guinea-pig sera as 
follows: anti-KLH-glutaraldehyde-peptide (O) as a 
positive control, anti-peptide ( □) as a test serum 
and normal serum (A) as a negative control. The 
assay is not quantitative but the amount of peptide 
bound to the carrier is related to the area 
between the lines of the test serum and the 
negative serum (shaded).
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Figure 4.2. ELISA for peptide covalently bound to 
a carrier protein. Eight batches of peptide- 
protein conjugates were assayed:
KLH-glutaraldehyde-0 peptide 
KLH-40kd dextran-0 peptide 
KLH-glutaraldehyde-A peptide (batch 21.6) 
KLH-glutaraldehyde-A peptide (batch 12.7) 
KLH-glutaraldehyde-A peptide (batch 2.84) 
chicken IgG-glutaraldehyde-A peptide 
chicken lgG-40kd dextran-A peptide 
chicken IgG-A peptide (Nakane and Kawaoi type
conjugate)
The carrier protein was trapped by an appropriate 
antibody bound to the solid phase, then probed with 
three guinea-pig sera as follows: anti-conjugate
(O) as a positive control, anti-peptide ( □ )  as a 
test serum and normal serum (A) as a negative 
control. The amount of peptide bound to the 
carrier is\ related to the area between the 
lines of the test serum and the negative serum 
(shaded).
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Table 4.1. Sedimentation coefficients'of various 
carrier proteins and carrier-peptide conjugates.
Preparation S-value^
KLH 7.0
KLH-glutaraldehyde-A peptide 6.4
KLH-glutaraldehyde-0 peptide 6.6
BSA 4.4
BSA-glutaraldehyde-A peptide 4.3
BSA-glutaraldehyde-0 peptide 4.0
Guinea-pig igG 7.1
Guinea-pig IgG-glutaraldehyde-A peptide 6.9
Bovine IgG 7.2
Bovine JgG-40kd dextran-0 peptide 7.4
 ^mean of two determinations
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Figure 4.3. ELISA for peptide covalently bound to 
soluble and insoluble fractions of a peptide- 
carrier conjugate. KLH-glutaraldehyde-A peptide 
(batch 2.85, lOOpg/ml) was assayed as prepared (A), 
or after centrifugation at 10,000g for 10 minutes 
(B). The pellet formed by centrifugation was 
washed, restored to the original volume of the 
centrifuged aliquot, then assayed (C). KLH was 
trapped with an antibody bound to the solid phase, 
then probed with three guinea-pig sera as follows: 
anti-KLH-glutaraldehyde-peptide ( O) as a positive 
control, anti-peptide ( □ )  as a test serum and 
normal serum (A) as a negative control.
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4.3. Response of guinea-pigs to vaccination with a 
range of peptide-carrier conjugates.
A range of different conjugates were used to 
vaccinate guinea-pigs. Sera were taken at 28 days 
post vaccination (p.v.) and some animals were 
challenged with infectious virus. The results are 
shown in Figs. 4.4, 4.5 and 4.6. The use of a
carrier protein generally enhanced the immune 
response to the A peptide whereas the results were 
inconclusive with the 0 peptide. In similar 
experiments with rabbits (Fig. 5.3) the response to 
either peptide was clearly enhanced by the use of a 
carrier.
There was little indication that any particular 
carrier was greatly superior to the others, 
although KLH linked to the A peptide gave the best 
response overall. In this regard it should be 
noted that there was no consistent relationship 
between anti-viral ELISA titres, anti-peptide ELISA 
titres and neutralizing antibody titres. That is 
to say, high titres by one assay did not mean 
necessarily that similar titres would be obtained 
in the other assays. Because KLH was generally a 
satisfactory carrier and has been used widely by 
other workers it was adopted as the carrier of 
choice for subsequent studies.
With respect to the adjuvant used, there was little 
to distinguish between 0 peptide vaccines 
adjuvanted with FCA, Al(0 H )3 or Al(0H )3 + Saponin. 
In contrast, FCA appeared to be the superior 
adjuvant for A peptide vaccines.
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None of the guinea-pigs vaccinated with the 0 
peptide were protected against live virus 
challenge, whereas the KLH-glutaraldehyde-A peptide 
vaccine was protective. This result has been 
confirmed on a number of occasions and with other 
carriers (Staple and Doel, personal communication). 
Results obtained with virus and VPl vaccines are 
shown (Figs. 4.4 and 4.6) for comparison. See also 
chapter 3.
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Figure 4.4. The response of DH guinea-pigs to 
vaccination with the 0 peptide coupled to a range 
of carrier molecules. Groups of six animals were 
vaccinated according to section 2 .7 .2 ., then bled 
and challenged 28 days later. Anti-viral and anti­
peptide antibody titres were measured by ELISA, 
neutralizing antibody by the microtitre 
neutralization test. The error bars show standard 
deviation. Sera were considered negative when 
titres of <= 1.7 in the ELISA or <= 1.04 in the 
neutralization test were obtained.
The carriers used were KLH, BSA, 40kd dextran (dx) 
or IgG from rabbits (Rb), guinea-pigs (Gp) or 
chickens (Ch). One chicken IgG preparation was 
made from chickens immunised with guinea-pig spleen 
cells (ChlgGaGp). Conjugates were formed with 
glutaraldehyde (gl) or 40kd dextran (dx), or the 
peptide was simply mixed (mix) with the carrier. 
All vaccines were adjuvanted with FCA.
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Figure 4.5. The response of dh guinea-pigs to 
vaccination with the 0 peptide coupled to a range 
of carrier molecules and formulated on Al(OH) 3 
with or without saponin (sap). Groups of five 
animals were vaccinated according to section 2 .7 .2 . 
and then bled 28 days later. Sera were pooled, 
then anti-viral and anti-peptide antibody titres 
were measured by ELISA, neutralizing antibody by 
the microtitre neutralization test. Pools were 
considered negative when titres of <= 1.7 in the 
ELISA or <= 1.04 in the neutralization test were 
obtained.
The carriers used were KLH, BSA or tetanus toxoid 
(Tet. box), and all conjugates were formed with 
glutaraldehyde.
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Figure 4.6. The response of DH guinea-pigs to 
vaccination with the A peptide coupled to a range 
of carrier molecules. Groups of five animals were 
vaccinated according to section 2 .7 .2 . and then 
bled 28 days later. Some animals were challenged 
at this time. Anti-viral and anti-peptide antibody 
titres were measured by ELISA, neutralizing 
antibody by the microtitre neutralization test. 
The error bars show standard deviation. Sera were 
considered negative when titres of <= 1.7 in the 
ELISA or <= 1.04 in the neutralization test were 
obtained.
The carriers used were KLH, or IgG from rabbits 
(Rb), guinea-pigs (Gp) or chickens (Ch). The 
conjugates were formed with glutaraldehyde (gl), 
40kd dextran (dx) or via the carbohydrate residues 
of IgG (NK). The vaccines were adjuvanted with 
either FCA or Al(OH)-
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4.4. Dose response of guinea-pigs to peptide-KLH 
conjugates.
DH guinea-pigs were vaccinated with different 
concentrations of KLH-glutaraldehyde peptide in 
FCA. Fig. 4.7 shows the results. There was a 
considerable difference between the responses of 
the guinea-pigs to the A and 0 peptide conjugates, 
the former being at least ten-fold more effective 
than the latter. Whereas the ELISA anti-viral 
antibody response to the A peptide was superior to 
the anti-peptide response the reverse was the case 
for the 0 peptide.
Finally, several of the dose response curves are 
sigmoid in form. Thus doses of the A peptide 
conjugate in excess of lOO^g, and doses of the 0 
peptide conjugate in excess of Img might not be 
expected to produce significant increases in 
antibody titre. However, the inability of 0 
peptide conjugates to protect animals from 
challenge (Fig. 4.4) did not appear to be related 
to the dosage. In a separate experiment five
guinea-pigs were vaccinated with 2mg of KLH- 
glutaraldehyde-0 peptide. None were protected when 
challenged 28 days p.v.
132 -
Figure 4.7. The response of DH guinea-pigs to 
vaccination with a range of doses of KLH- 
glutaraldehyde-0 peptide ( O, •) or KLH-
glutaraldehyde-A peptide ( □ , ■ ) .  Groups of five 
animals were bled twenty-eight days after 
vaccination and anti-viral (open symbols) and anti­
peptide (closed symbols) antibody titres were 
measured by ELISA (upper panel). Neutralizing 
antibody titres (SNT) were measured by the 
microtitre neutralization test. Sera were
considered negative when titres of <= 1.7 in the 
ELISA or <= 1.04 in the neutralization test were 
obtained.
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4.5. Discussion.
The ELISA used to examine conjugates offers the
potential to standardise the preparation of
peptide-carrier conjugates, a process which some
workers have found difficult (Beuvery et al, 1983).
While the ELISA in its present form is not 
quantitative, the areas under the titration curves 
may be used as an index of the degree of 
conjugation. Preliminary work with a radiolabelled 
peptide indicates that the assay may be made 
quantitative. In a series of experiments carried 
out in this laboratory approximately 10% of the 
peptide in conjugates was found to be associated 
with rapidly sedimenting, aggregated, carrier and 
25% with soluble, 'monomeric', carrier. The 
remaining 65% of peptide was apparently not bound 
to a carrier molecule (T.R. Doel, 1985, personal 
communication).
It would appear from the results presented here 
that the choice of cross-linking agent has little 
effect on the immunogenicity of conjugates of 
aphthovirus peptide. This is in broad agreement 
with results presented by other workers, though no 
comprehensive study of cross-linking agents in this 
context has been published to date. The conjugates 
of Bittle et al (1982, 1985) were prepared either
via an N-terminal cysteine or by the use of 
glutaraldehyde, but no data was presented to enable 
a direct comparison to be made. Pfaff et al (1982) 
and Schaller and Pfaff (1983) reported that there 
were no major differences between conjugates formed
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with glutaraldehyde or with carbodiimide. This is 
interesting because the different modes of action 
of the two agents, conjugating via amino-amino and 
amino-carboxy1 groups respectively, represent the 
two most obvious routes available for cross- 
linking .
With regard to the choice of carrier there was 
little to choose between the various 0 peptide 
conjugates, whereas KLH seemed superior to other 
carriers for the A peptide. Immunoglobulins 
appeared generally less effective as carriers. 
This was particularly interesting in the case of 
the homologous IgG, which it had been hoped would 
mimic an immune complex. Similar results have been 
reported in a number of studies. Bittle et al 
(1983, 1985) used KLH and tetanus toxoid, and found 
both to be acceptable. Pfaff et al (1982) and 
Schaller and Pfaff (1983) compared KLH, BSA and 
bovine thyroglobulin, and found KLH to be the 
superior carrier. Schaller and Pfaff (1983) also 
used succinylated carriers, but found these to be 
inferior to the underivatised parent molecules. 
BSA and KLH have been used as carriers for
poliovirus peptides (Emini et a l , 1983b) and
tetanus toxoid has been used as a carrier for
influenza peptides (Arnon and Shapira, 1984) but 
neither group presented any comparative data. 
Various synthetic carriers have also been used in 
peptide vaccines. These include muramyl dipeptide- 
poly-DL-ala-poly-L-lys, used to carry diphtheria 
toxin peptides (Audibert et a l , 1982), and
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dipalmityl lysine, used to carry hepatitis-B 
peptides (Hopp, 1984). Synthetic carriers were not 
available for use in this study but their use with
aphthovirus peptides should certainly be
investigated. A similar approach, in which the
peptide acts as its own carrier, has recently been
described by Bittle et ^  (l985). Aphthovirus
peptides polymerised with glutaraldehyde or by 
oxidation of terminal cysteine residues were found 
to be superior immunogens to free peptide and 
comparable to tetanus toxoid-peptide conjugates in 
effectiveness. Thus it would seem that the use of 
aphthovirus peptides as vaccines need not be 
limited by lack of a suitable carrier.
In contrast to this the availability of a suitable 
adjuvant may prove more restrictive. The finding 
that FCA was considerably more effective as an 
adjuvant than the conventional alternatives was
disappointing, though not unexpected. It will be 
necessary to develop an acceptable alternative to 
FCA before synthetic vaccines can be used 
commercially. Ideally, the adjuvant should be a 
synthetic product of defined composition so that 
the advantage of having a defined synthetic antigen 
in the vaccine is not compromised. Several groups 
have recently reported encouraging results using 
synthetic viral or bacterial antigens in 
association with the synthetic adjuvant muramyl 
dipeptide (Arnon et a l , 1980; Audibert and Chedid,
1984; Bittle et a l , 1985) and in some circumstances 
muramyl dipeptide or its derivatives appear to have
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the potential to act as both adjuvant and carrier 
(Arnon et a l , 1980; Audibert and Chedid, 1982). 
Despite the fact that the two peptides studied 
represent equivalent regions of the capsid protein 
VPl of two serotypes of aphthovirus, there were 
major differences in their immunogenicity. The A 
peptide induced high levels of anti-viral antibody, 
as measured by ELISA, and conferred protection from 
challenge, whereas the 0 peptide failed to induce 
antiviral antibody except at high dose levels and 
was not protective at all. It is interesting that 
a similar relationship appears to pertain to whole 
virus vaccines (see section 1.5.2) and to VPl 
vaccines in some instances (Moore, D.M., 1985,
personal communication), both in terms of the 
quantity of antigen required to induce antibody 
and, at least in the case of whole virus vaccines, 
in terms of the absolute amount of neutralizing 
antibody required to confer a given level of 
protection. While there is no obvious explanation 
for the superiority of A virus, VPl or peptide 
vaccines, further studies could prove to be of 
great value to the development of successful 
synthetic peptide vaccines against FMD.
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5. COMPARISON OF THE RESPONSES OF SMALL ANIMALS AND 
CATTLE TO SYNTHETIC PEPTIDE VACCINES.
5.1. Introduction.
In the previous chapter a variety of peptide 
vaccines were assessed in guinea-pigs. For many 
years guinea-pigs have been used as a
model system for testing conventional, whole virus, 
cattle vaccines (Bedson et a l , 1927). However
there is relatively little information available 
concerning the responses of cattle or laboratory 
animal models to synthetic peptide vaccines and it 
is not known whether guinea-pigs provide an 
adequate model system for large animals in the case 
of such vaccines. This chapter describes a series 
of experiments which compare the responses of 
guinea-pigs, mice, rabbits and cattle to peptide or 
virus vaccines.
5.2. The response of guinea-pigs.
Groups of six guinea-pigs from each of three 
strains (DH, S2 and S13) were vaccinated and 
revaccinated with KLH-glutaraldehyde-0 peptide. 
The results are shown in Fig. 5.1. Although the 
inbred S2 strain guinea-pigs gave a good anti­
peptide antibody response only the randomly-bred DH 
animals produced detectable, though low, levels of 
anti-viral or neutralizing antibody. There was no 
clear indication that the response was boosted by 
repeated vaccination, consistent with other results 
reported here (see chapter 6 ).
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Fiaure— 5 ^  The response of various strains of
guinea-pig to vaccination with a k l h -
glutaraldehyde-o peptide conjugate. The
vaccination protocol and the strains of guinea-pig
used are described in sections 2 .7 .1 . and 2 .7 .2 ..
The animals, in groups of six, were bled at 28 days
(5?), boosted with the same antigen, bled again at
56 d a j ^ (  =  ), boosted once more and bled at 84
d a y s ( U ) .  Anti-viral and anti-peptide antibody
titres were measured by ELISA, neutralizing
antibody titres by the microtitre neutralization
test. The error bars show standard deviation and
the arrow indicates 'greater than'. sera were
considered negative when titres of <= 1.7 in the
ELISA or <= 1.04 in the neutralization test were
obtained.
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5.3. The response of mice.
Mice from each of seven strains, in groups of five 
animals each, were vaccinated and revaccinated with 
either KLH-glutaraldehyde-0 peptide or OlBFS. The 
results are shown in Fig. 5.2. The highest 
response to the peptide vaccine was observed with 
the randomly-bred CR and P strains, which gave a 
response comparable to that of the DH guinea-pigs. 
Of the inbred strains, the C57B mice gave the 
strongest overall response, producing detectable, 
though low, levels of anti-viral, anti-peptide and 
neutralizing antibodies. Other inbred strains gave 
little or no neutralizing antibody and only low 
levels of anti-virus and anti-peptide antibody. In 
this respect the responses of the Balb/C, PSDi and 
CRi strains were similar to the S13 strain of 
guinea-pigs. The antibody responses to the virus 
vaccine were generally higher and more uniform, 
although the CRi mice gave a notably weak response. 
In contrast to the guinea-pig data, there was some 
evidence of an anamnestic response in mice. This 
was most marked in the case of neutralizing 
antibody titres following a low or negligible 
initial response. This aspect of the immune 
response of mice is examined in more detail in 
chapter 7.
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Figure 5.2. The response of various strains of 
mice to vaccination with OlBFS or with a KLH- 
glutaraldehyde-0 peptide conjugate. The
vaccination protocol and the strains of mice used 
are described in sections 2.7.1. and 2.7.2.. The 
animals, in groups of five, were bled at 28 days 
( 88)/ boosted with the same antigen and bled again 
at 56 days (LU). Anti-viral and anti-peptide 
antibody titres were measured by ELISA and the 
neutralizing antibody titre of pooled sera was 
measured by the microtitre neutralization test. 
The error bars show standard deviation and the 
arrows indicate 'greater than'. Sera were
considered negative when titres of <= 1.7 in the
ELISA or <= 1.04 in the neutralization test were 
obtained.
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5.4. The response of rabbits.
Rabbits, in groups of four or five, were vaccinated 
and revaccinated with either peptide, KLH- 
glutaraldehyde-peptide or virus. The results are 
shown in Fig. 5.3. The rabbits responded well in 
terms of ELISA and neutralizing antibody titres to 
both 0 and A peptide conjugates. Free peptides 
also induced ELISA and neutralizing antibodies, 
although titres were generally lower than those 
obtained with the conjugates. The responses to the 
A peptide and conjugate vaccines were comparable to 
those of DH guinea-pigs. In a marked contrast, the 
responses to the 0 peptide and conjugate vaccines 
were much broader than those of DH guinea-pigs, and 
included high titres of anti-viral and neutralizing 
antibodies. There was some evidence of an 
anamnestic response after revaccination,
particularly in the case of neutralizing 
antibodies.
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Figure 5.3. The response of rabbits to vaccination 
with virus, peptide or a KLH-glutaraldehyde-peptide 
conjugate. The vaccination protocol is described 
in section 2.7.2.. The animals were bled at 28 
days (38^), boosted with the same antigen and bled 
again at 56 days { C H  ) . Anti-viral and anti- 
peptide antibody titres were measured by ELISA, 
neutralizing antibody titres by the microtitre 
neutralization test. The error bars show standard 
deviation. Sera were considered negative when 
titres of <= 1.7 in the ELISA or <= 1.04 in the 
neutralization test were obtained.
- 145 -
5.5. The response of cattle.
Four groups of three cattle were vaccinated with 
KLH-glutaraldehyde-A peptide as follows: A) 40/jg
conjugate (=20;ag peptide) in FCA, B) 200/] g 
conjugate (=100/ig peptide) in FCA, C) Img conjugate 
(=500/jg peptide) in FCA and D) Img conjugate in 
A 1 (0H )3 plus saponin. These animals, together with 
an unvaccinated control group, were bled every 
seven days and challenged after 28 days. Sera were 
assayed by ELISA for anti-viral and anti-peptide 
antibody, and the results are shown in Fig. 5.4. 
Most animals, including two out of three controls 
possessed significant levels of anti-viral antibody 
which fluctuated without a discernable pattern 
throughout the experiment. These levels did not 
appear to be influenced by vaccination.
In contrast, all animals in the three groups 
vaccinated with Freund s adjuvanted vaccines 
responded by producing anti-peptide antibodies. 
There was no apparent relationship between anti­
virus and anti-peptide antibody titres. Anti- 
peptide titres generally rose until 21 days p.v., 
then remained stable or declined slightly. There 
was little variation between the responses of the 
cattle within each group, but animals in group C), 
vaccinated with the highest dose of conjugate, 
responded with higher titres than those in the 
other groups. Animals vaccinated with the 
Al{OH)a/saponin vaccine, together with the control 
animals, did not produce detectable levels of anti- 
peptide antibody.
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Sera were also assayed for neutralizing antibody. 
None of the fifteen animals produced detectable 
levels of neutralizing antibody at any time and 
none were protected from challenge.
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Figure 5.4. The response of cattle to vaccination 
with a KLH-glutaraldehyde-A peptide conjugate. 
Fifteen animals were divided into five groups of 
three and vaccinated as follows:
A) 40ug conjugate in FCA
B) 200ug conjugate in FCA
C) Img conjugate in FCA
D) Img conjugate in Al(OH)g plus saponin
E) unvaccinated control group.
The animals were bled every seven days after 
vaccination and were challenged on day 28. Anti­
viral and anti-peptide antibody titres were 
measured by ELISA, and the figure shows the titres 
for individual animals (0,0 ,^) in each group. 
Sera were considered negative when titres of <=1.7 
were obtained and all animals in groups D and E 
were negative for anti-peptide antibody by this 
criterion.
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5 .6 . comparison of the responses of individual 
guinea-pigs, mice and rabbits.
Considerable animal to animal variation in response 
to peptide vaccines was noted on a number of 
occasions. Tables 5.1, 5.2 and 5.3 summarise data 
obtained in the course of experiments described in 
chapters 4 and 5.
Variation was most evident in the responses of the 
various strains of mice examined (Table 5.1). Each 
group vaccinated with KLH-0 peptide, with the 
exception of the group of CR mice, contained a 
number of non-responding animals, whereas all mice, 
regardless of strain, responded to vaccination with 
virus. Furthermore, KLH-peptide vaccinated mice 
displayed a much greater range of responses than 
mice vaccinated with virus. This was especially 
evident when the anti-viral antibody titres were 
compared.
The responses of rabbits and guinea-pigs showed 
less variation than was seen in mice and there were 
no instances of non-responding rabbits or guinea- 
pigs (Tables 5.2 and 5.3). However, it was still 
apparent that the range of anti-viral antibody 
responses of KLH-peptide vaccinated animals was 
greater than the range of other responses to 
vaccination with KLH-peptide or with virus. In 
this respect there was no apparent difference 
between the response of rabbits to the 0 and A 
peptides, whereas guinea-pigs produced anti-viral 
antibodies in response to the A peptide but not to 
the 0 peptide (unless a higher than usual dose was
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administered - see Figure 4.7.)
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Table 5.1. Range of the respcnses of individual irioe of seven strains to
vaocdnatim with OlBFS or KEH-0 peptide.
Strain vaocine Range of log^  ^KISk titres Re^ xrxfers
antigen anti-virus anti-p^ ide
28 03^ 56 days 28 days 56
C3H GIBES 3.13-4.08'*’ 4.56-5.04 1.70-2.18 <1.7 5/5^
KIfi-0 p^. <1.7 <1.7 <1.7 <1.7 0/5
CS7B GIBES >5.04 >5.04 1.70-2.65 1.70-3.13 5/5
KIH-Gp^. 1.70-2.18 1.70-3.13 1.70-2.65 1.70-3.13 3/5
Balb/C GIBES 3.61-5.04 >5.04 <1.7 1.70-2.18 5/5
KLH-G P^. <1.7 <1.7 <1.7 1.70-2.65 2/5
VSDi GIBES 1.70-4.08 >5.04 <1.7 <1.7 5/5
KÜK) p^. <1.7 <1.7 <1.7 1.70-2.65 2/5
CRi GIBES 1.70-3.61 2.65-3.61 <1.7 <1.7 5/5
KEfi-G p^. <1.7 <1.7 <1.7 <1.7 0/5
CR GIBES 3.13-5.04 >5.04 <1.7 1.70-3.13 5/5
KEB-Gp^. 1.70-2.18 1.70-3.13 <1.7 2.65-4.08 5/5
P GIBES 3.61-5.04 >5.04 1.70-2.65 2.65-2.65 5/5
KEH-Gp^. 1.70-2.18 1.70-5.04 1.70-3.13 1.70-5.04 3/5
 ^lowest titre in group - hi^ iest titre in group 
 ^no. responding during oçerirnent / no. in group 
<1.7 = all titres in group <1.7 
>5.04 = all titres in group >5.04
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Table 5.2. Range of the responses of individual NZ/D
rabbits to vaccination with virus or KLH-peptide.
vaccine Range of log^Q ELISA titres
antigen anti-virus anti-peptide
28 days 56 days 28 days 56 days
OlBFS 3.73-4.6^ 4.61-5.08 <1.7 1.70-2.65
KLH-0 pep. 1.70-3.13 2.48-4.86 3.13-5.04 4.86-5.34
,A24 Cruz. 2.95-3.91 4.13-5.08 <1.7 <1.7
KLH-A pep. 1.70-4.08 2.18-5.08 3.61-4.08 4.61-5.08
lowest titre in group - highest titre in group
<1.7 = all titres in group <1.7
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Table 5.3. Range of the responses of individual DH
guinea-pigs to vaccination with virus or KLH-peptide.
vaccine Range of log^  ^ ELISA titres
antigen anti-virus anti-peptide
28 days 56 days 28 days 56 days
OlBFS 4.08-4.56'*' nd 1.70-2.65 nd
KLH-0 pep. 1.70-2.65 <1.7 3.61—4.56 4.86-5.34
A24 Cruz. 5.86-6.34 nd 2.18-3.61 nd
KLH-A pep. 2.65-5.04 3.13-4.56 3.61-4.56 4.08-4.56
^ lowest titre in group - highest titre in group
nd = not done
<1.7 = all titres in group <1.7
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5.7. Discussion.
Whilst the data presented here are not amenable to 
a useful statistical analysis they do indicate that 
there can be considerable variation in the 
responses to peptide vaccines among the various 
strains of animals studied and among individuals of 
the same strain. Relatively little has been 
published concerning this aspect of the use of 
peptide vaccines, though Emini et al (1985) and 
Ferguson et al (1985) have recently studied the 
problem. There are also indications in earlier 
reports that strain differences do occur. For 
instance, the results of Bittle et al (1982) 
suggest a difference between the responses of 
rabbits and guinea-pigs to a peptide vaccine 
similar to the ones used in this study.
The results reported here showed that rabbits 
responded comprehensively (anti-peptide, anti-viral 
and neutralizing antibody) to both peptides, 
whereas guinea-pigs responded comprehensively to 
the A peptide but gave a restricted response to the 
0 peptide. The response of mice to the 0 peptide 
was strain dependent, ranging from no detectable 
response to a comprehensive one. The response of 
cattle to the A peptide was apparently restricted 
to anti-peptide antibody only.
Similar results have been obtained with poliovirus 
peptide vaccines. Emini et al (1985), who compared 
New Zealand rabbits. Hartley guinea-pigs and Lewis 
rats, and Ferguson et al (1985) who compared 
rabbits, guinea-pigs and Balb/C mice, have both
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described considerable interspecies variation. 
Generally, rabbits responded well and rats 
responded poorly. All animals, with the exception 
of rats (Emini et al , 1985), produced high levels
of anti-peptide antibody, whereas the anti-viral 
response was species dependent. Guinea-pigs, rats 
and mice were very restricted in their ability to 
produce anti-viral antibody, similar to the 
situation observed with the 0 peptide in this 
study. Furthermore, Ferguson et al (1985) reported 
that the anti-viral antibody titres of individual 
rabbits were considerably more variable than their 
anti-peptide antibody titres, another feature of 
the response seen in this study.
Data concerning the response of cattle to synthetic 
peptides is scarce. However, the limited data of 
Bittle et al (1984) seems to indicate that although 
both guinea-pigs and cattle produced neutralizing 
antibody in response to an 01 peptide vaccine the 
response of cattle was weaker than that of guinea- 
pigs. The cattle experiment described here serves 
to emphasise the divergent response of different 
species to peptide vaccines. The A peptide vaccine 
had proven highly effective in guinea-pigs and 
rabbits, which produced anti-viral antibody and 
neutralizing antibody. Guinea-pigs were protected 
from challenge after a single vaccination. in 
cattle, however, the vaccine stimulated only anti­
peptide antibodies at even the highest dose level. 
It should be noted that in conventional vaccine 
potency tests guinea-pigs usually receive one third
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of a cattle dose (Doel, T.R., 1985, personal
communication). On this basis, the relative doses 
used in this experiment were a fair test of the 
peptide vaccine. The marked superiority of the FCA 
adjuvanted cattle vaccines follows the result in 
guinea-pigs described in chapter 4 and reinforces 
the comments made there.
The variations observed in the responses to peptide 
vaccines almost certainly reflect variations in the 
repertoire of immune response (Ir) genes of the 
animals studied . Genetic control of the immune 
response has been clearly demonstrated on numerous 
occasions and has been extensively reviewed (see 
e.g. Benacerraf and Germain, 1978). That genetic 
factors may have a major influence on the use of 
aphthovirus vaccines is clearly shown by the 
problems experienced with attenuated vaccines. In 
many instances attenuation was found to be species, 
or even strain, specific (Pay and Bracewell, 1966; 
Mowat et al, 1969) and the immunogenicity of
attenuated strains was found to vary in different 
breeds of cattle (Mowat and Prydie, 1962; Cunha et 
al, 1962). It would certainly be a major problem
if a similar situation pertained for synthetic 
peptide vaccines.
The only feature of the results which is not 
immediately explicable in terms of genetic 
variability is the marked difference in response to 
peptide vaccines observed between individual mice 
of the same inbred strain. It may be that the 
strains used were not inbred with respect to all
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relevant Ir genes, or it may be that the responses 
were affected by such factors as dose or mode of 
presentation, which are known to exert a profound 
effect on the level of the response to similar 
antigens (see e.g. Cohen et a l , 1985).
The results presented here indicate that the 
response to aphthovirus peptide vaccines can vary 
significantly between species. Thus data
concerning peptide vaccines obtained in the guinea- 
pig, the classical small-animal model for FMD, or 
in other small animals cannot be extrapolated 
confidently to cattle. conclusions based upon
studies conducted solely in small animals should 
therefore be interpreted with caution until they 
can be confirmed in cattle. The commercial 
exploitation of synthetic peptide vaccines would 
undoubtedly be facilitated if a reliable model for 
the response of cattle to peptide vaccines could be 
established.
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6 . FURTHER STUDIES IN GUINEA-PIGS AND RABBITS.
6.1. Introduction.
The results presented in chapter 5 showed that 
there could be considerable variation in the immune 
response of various laboratory animals to synthetic 
peptide vaccines. Furthermore, DH guinea-pigs in 
particular responded much more strongly to the A24 
Cruzeiro peptide than to the OlBFS peptide.
There is an obvious requirement for synthetic 
peptide vaccines to induce high and enduring levels 
of antibody if they are to be competitive with 
whole virus vaccines. It would also be useful if 
such vaccines were able to prime the immune system, 
as they have been reported to in some cases (Emini 
et a l , 1983b; Francis et a l , 1985). This chapter 
describes further studies of the antibody responses 
of guinea-pigs and rabbits to vaccination with 
synthetic peptide vaccines. The two species were 
compared to determine whether the differences 
described in chapter 5 extended to aspects of the 
response such as duration and priming. In addition 
some guinea-pig sera were assayed for specific igM, 
IgGl and lgG2 to determine whether any aspect of 
the response could be attributed to a particular 
class of antibody.
6.2. Response of guinea-pigs to single or multiple 
vaccinations with synthetic peptide conjugates.
DH guinea-pigs were vaccinated once, twice or three 
times, at 28 day intervals, with 200;ig of either 
KLH-0 peptide or KLH-A peptide. The results are
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shown in Figures 6.1 and 6.3.
Guinea-pigs vaccinated with KLH-0 peptide (Fig. 
6 .1 ) produced high anti-peptide antibody titres but 
only very low levels of anti-virus or neutralizing 
antibody. The anti-peptide antibody titre rose 
rapidly after a single vaccination to reach a peak 
after 60 to 70 days. The peak titre persisted for 
approximately 20 days and then declined, until by 
200 days post vaccination a level was reached which 
was maintained for the remainder of the experiment. 
Second or third vaccinations at 28 or 56 days did 
not affect the response significantly, either by 
increasing the peak titre or extending its 
duration.
In contrast, guinea-pigs vaccinated with KLH-A 
peptide (Fig. 6.3) produced high levels of anti­
viral and anti-peptide antibody, and moderate 
levels of neutralizing antibody. In all cases the 
titres rose rapidly after a single vaccination to 
reach a peak by 28 to 56 days post vaccination. 
Neutralizing antibody titres then declined slowly, 
but without reaching background values, for the 
remainder of the experiment. Anti-peptide and 
anti-viral antibody titres remained at peak levels 
for approximately 100 days before declining, 
rapidly at first and then more slowly, for the 
remainder of the experiment. A second vaccination 
28 days after the first did not significantly 
affect the antibody titres, but the group of 
animals which received a third vaccination at 56 
days responded by producing higher levels of anti-
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viral antibody. The higher levels declined at the 
same rate as the titres of the other groups.
Whilst the neutralizing antibody titres in the 
group of animals given three vaccinations were 
higher than those in the other groups this did not 
appear to be due to the third vaccination.
All animals were revaccinated with 40^g of the 
homologous KLH-peptide conjugate 28 days before the 
end of the experiment, that is 406 days or 343 days 
after the first vaccination (Figs. 6.1 and 6.3
respectively). There was no clear indication of a 
significant response to this final vaccination in 
any group of animals.
All sera collected during the first 100 days of the 
experiment were assayed for specific IgGl, lgG2 and 
IgM (Figures 6.2 and 6.4). Guinea-pigs vaccinated 
with either peptide produced peptide-specific 
antibody of all three classes. Guinea-pigs
vaccinated with the KLH-A peptide also produced
virus-specific IgGl, IgG2 and IgM, whereas IgM was 
the only virus-specific antibody that could be 
detected in sera from guinea-pigs vaccinated with 
KLH-0 peptide. It should be noted, however, that 
guinea-pigs vaccinated with higher doses of KLH-0 
peptide than used in this experiment did produce 
virus-specific IgGl and IgG2 (Table 8.2). As 
observed in the assays for total antibody described 
above, subsequent vaccinations 28 and 56 days after 
the first had no apparent effect on antibody 
titres.
A feature of the results for which no explanation
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is immediately apparent is the duration of the IgM 
titres. The obvious conclusion, that the assay is 
not specific for IgM, is not supported by the
evidence. Thus in the case of guinea-pigs
vaccinated with KLH-0 peptide anti-viral IgM was 
detectable when anti-viral IgG was not. 
Furthermore, although the antiserum used cross­
reacted weakly with chromatographically purified 
igG this could be abolished by carrying out the
assay with purified IgG in the diluent buffer (see
section 2.9.2).
Duplicate groups of guinea-pigs given the same 
vaccination regimens were challenged with the
homologous virus 28 days after vaccination. 
Guinea-pigs vaccinated with KLH-0 peptide were not 
protected, regardless of whether they had received 
one, two or three vaccinations, whereas fourteen 
out of fifteen guinea-pigs vaccinated with KLH-A 
peptide were protected (Table 6.1).
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Figure 6.1. Duration of the immune response of DH 
guinea-pigs vaccinated with KLH-glutaraldehyde-0 
peptide. Animals, in groups of six, were 
vaccinated either once ( □ ) ,  twice (O) or three 
times (A) according to the protocol described in 
section 2.7.2. vaccinations were administered at 
28 day intervals as marked by the appropriate 
symbols on the horizontal axis. In addition, all 
groups were revaccinated with 40pg of the 
conjugate, on Al(OH) 3 , after 406 days. The
animals were bled at intervals and anti-viral and 
anti-peptide antibody titres were measured by 
ELISA, neutralizing antibody titres by the 
microtitre neutralization test. Sera were assayed 
individually, and the results shown are the mean 
antibody titres. The average values of the
standard deviations obtained throughout the 
experiment were 0.507 +/- 0.174 logs for the ELISAs 
and 0.663 +/- 0.249 logs for the neutralization
test. Sera were considered negative when titres of 
<=1.7 in the ELISA or <=1.04 in the neutralization 
test were obtained.
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Figure 6.2. Antibody subclasses produced by DH 
guinea-pigs in response to vaccination with KLH- 
glutaraldehyde-0 peptide. Animals, in groups of 
six, were vaccinated either once ( □ ) ,  twice (O) 
or three times (A) according to the protocol 
described in section 2.7.2. Vaccinations were 
administered at 28 day intervals as marked by the 
appropriate symbols on the horizontal axis. The 
animals were bled at intervals and the anti-viral 
and anti-peptide titres of IgGl, IgG2 and igM in 
pooled sera were measured by ELISA. Pools were 
considered negative when titres of <=1.7 were 
obtained, and all animals were negative for anti­
viral IgG by this criterion.
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Figure 6.3. Duration of the immune response of DH 
guinea-pigs vaccinated with KLH-glutaraldehyde-A 
peptide. Animals, in groups of five, were
vaccinated either once { □  ), twice ( O ) or three 
times (A) according to the protocol described in 
section 2.7.2. Vaccinations were administered at 
28 day intervals as marked by the appropriate 
symbols on the horizontal axis. In addition, all 
groups were revaccinated with 40^g of the 
conjugate, on Al(0H )3 , after 343 days. The
animals were bled at intervals and anti-viral and 
anti-peptide antibody titres were measured by 
ELISA, neutralizing antibody titres by the
microtitre neutralization test. Sera were assayed 
individually, and the results shown are the mean 
antibody titres. The average values of the 
standard deviations obtained throughout the
experiment were 0.524 +/- 0.165 logs for the ELISAs 
and 0.474 +/- 0.202 logs for the neutralization
test. Sera were considered negative when titres of 
<=1.7 in the ELISA or <=1.04 in the neutralization 
test were obtained.
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Figure 6.4. Antibody subclasses produced by DH 
guinea-pigs in response to vaccination with KLH- 
glutaraldehyde-A peptide. Animals, in groups of 
five, were vaccinated either once ([]), twice (O) 
or three times (A) according to the protocol 
described in section 2.7.2. vaccinations were 
administered at 28 day intervals as marked by the 
appropriate symbols on the horizontal axis. The 
animals were bled at intervals and the anti-viral 
and anti-peptide titres of IgGl, lgG2 and IgM in 
pooled sera were measured by ELISA. pools were 
considered negative when titres of <=1.7 were 
obtained.
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Table 6.1. Protection of guinea-pigs from
challenge after vaccination with KLH-peptide.
Vaccine Mean neutralizing 
antibody titre
Protect ion
KLH-glutaraldehyde-
A peptide
1 vaccination 1.53 5/5^
2 vaccinations^ 1.83 5/5
3 vaccinations 1.95 4/5
KLH-glutaraldehyde-
0 peptide
1 vaccination 1.16 0/6
2 vaccinations 1.04 0/6
3 vaccinations 1.44 0/6
 ^ no. protected/no. challenged. Animals were
challenged 28 days after their last vaccination.
 ^Successive vaccinations were administered at 28 
day intervals.
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6.3. Response of rabbits to single or. multiple
vaccinations with synthetic peptide conjugates. 
Groups of rabbits were vaccinated once or three
times, at 28 day intervals, with 200^g of the KLH-0
peptide or once, twice or three times with the same 
quantity of the KLH-A peptide. The results are 
shown in Figures 6.5 and 6 .6 .
Rabbits vaccinated with KLH-0 peptide (Fig. 6.5) 
produced high levels of anti-peptide and antiviral 
antibody and moderate levels of neutralizing 
antibody. Titres rose rapidly after a single
vaccination to reach a peak at 50 to 60 days, 
before declining gradually for the remainder of the 
experiment. Second and third vaccinations at 28 
and 56 days did not affect the response in any way, 
either by increasing the peak titre or extending 
its duration. The rabbits were revaccinated with 
40^g of KLH-0 peptide conjugate 28 days before the 
end of the experiment, 406 or 473 days after the 
first vaccination (Fig. 6.5). Both anti-viral and 
neutralizing antibody titres were clearly boosted 
and there was some indication of an increase in the 
anti-peptide antibody titres.
Rabbits vaccinated with KLH-A peptide (Fig. 6 .6 ) 
responded in a similar manner to those vaccinated 
with the 0 peptide conjugate. They produced high 
levels of anti-viral and anti-peptide antibody, and 
moderate levels of neutralizing antibody. Antibody 
titres rose rapidly after a single vaccination to 
reach a peak by 28 to 56 days post vaccination, 
after which they remained steady or declined very
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slightly until 210 days post vaccination, when the 
experiment was terminated. There was no
significant increase in antibody titres in response 
to revaccination at 28 or 56 days after the first 
vaccination.
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Figure 6.5. Duration of the immune response of 
rabbits vaccinated with KLH-glutaraldehyde-0 
peptide. Animals, in groups of four, were 
vaccinated either once ( □ )  or three times (A)
according to the protocol described in section
2.7.2. Vaccinations were administered at 28 day 
intervals as marked by the appropriate symbols on 
the horizontal axis. In addition, both groups were 
revaccinated with 40yng of the conjugate, on A l (OH)g 
after 406 days or 473 days, as marked on the 
horizontal axis. The animals were bled at 
intervals and anti-viral and anti-peptide antibody 
titres were measured by ELISA, neutralizing 
antibody titres by the microtitre neutralization 
test. Sera were assayed individually, and the
results shown are the mean antibody titres. The
average values of the standard deviations obtained 
throughout the experiment were 0.526 +/- 0.283 logs 
for the ELISAs and 0.696 +/- 0.308 logs for the
neutralization test. Sera were considered negative 
when titres of <=1.7 in the ELISA or <=1.04 in the 
neutralization test were obtained.
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Figure 6 .6 . Duration of the immune response of 
rabbits vaccinated with KLH-glutaraldehyde-A 
peptide. Animals, in groups of five, were 
vaccinated either once ( □ ) ,  twice (O) or three 
times (A) according to the protocol described in 
section 2.7.2. Vaccinations were administered at 
28 day intervals as marked by the appropriate 
symbols on the horizontal axis. The animals were 
bled at intervals and anti-viral and anti-peptide 
antibody titres were measured by ELISA, 
neutralizing antibody titres by the microtitre 
neutralization test. Sera were assayed
individually, and the results shown are the mean 
antibody titres. The average values of the 
standard deviations obtained throughout the 
experiment were 0.748 +/- 0.456 logs for the ELISAs 
and 0.633 +/- 0.250 logs for the neutralization
test. Sera were considered negative when titres of 
<=1.7 in the ELISA or <=1.04 in the neutralization 
test were obtained.
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6.4. Response of guinea-pigs vaccinated with virus 
to revaccination with peptide or KLH-peptide.
DH guinea-pigs were vaccinated with lO^g of OlBFS
or A24 cruzeiro. After 28 days animals were 
revaccinated with the homologous peptide, either 
free or conjugated to KLH. The levels of total
specific antibody (Figures 6.7 and 6.9) and
specific IgGl, lgG2 and IgM (Figures 6.8 and 6.10)
were assayed. Revaccination had no detectable 
effect on anti-viral or neutralizing antibody 
titres in any case. There was a slight and 
transient rise in the total anti-peptide titres 
after revaccination, but this was not attributable 
to any one subclass. Overall, the response was 
similar to that seen on revaccination of guinea- 
pigs previously vaccinated with KLH-peptide.
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Figure 6.7. The response of DH guinea-pigs
previously vaccinated with OlBFS to revaccination 
with 0 peptide or with KLH-glutaraldehyde-0 
peptide. Ten animals were vaccinated with lO^g of 
OlBFS in FCA. Twenty-eight days later five were 
revaccinated with 200^g of conjugate on Al(0H )3 
(A) and five were revaccinated with lOO^g of
peptide on Al(0H )3 (B). The animals were bled
every 14 days after revaccination and anti-viral 
( # }  and anti-peptide (O) antibody titres were 
measured by ELISA, neutralizing antibody titres 
(A) by the microtitre neutralization test. Sera 
were assayed individually, and the results shown 
are the mean antibody titres. The average values 
of the standard deviations obtained throughout the 
experiment were 0.444 +/- 0.160 logs for the ELISAs 
and 0.175 +/- 0.073 logs for the neutralization
test.
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Figure 6 .8 . Antibody subclasses produced by DH 
guinea-pigs vaccinated with OlBFS then revaccinated 
with 0 peptide or with KLH-glutaraldehyde-0 
peptide. Ten animals were vaccinated with lOjig of 
OlBFS in FCA. Twenty-eight days later five were 
revaccinated with lOO^g of peptide on Al(0H )3 ( O)
and five were revaccinated with 200|ig of conjugate 
on A 1 (0H )3 ( •). The animals were bled every 14
days after revaccination and anti-viral titres of 
igGl, JgG2 and igM in pooled sera were measured by 
ELISA. (Anti-peptide titres of igGl, lgG2 and IgM 
were all <=1.7.).
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Figure 6.9. The response of DH guinea-pigs 
previously vaccinated with A24 Cruzeiro to 
revaccination with A peptide or with KLH- 
glutaraldehyde-A peptide. Ten animals were 
vaccinated with lOjjg of A24 Cruzeiro in FCA. 
Twenty-eight days later five were revaccinated with 
200;ig of conjugate on Al(0H )3 (A) and five were
revaccinated with lOO^g of peptide on Al(0H )3 (B).
The animals were bled every 14 days after 
revaccination and anti-viral ( ■) and anti-peptide 
( □ )  antibody titres were measured by ELISA, 
neutralizing antibody titres ( A) by the microtitre 
neutralization test. Sera were assayed
individually, and the results shown are the mean 
antibody titres. The average values of the
standard deviations obtained throughout the 
experiment were 0.453 +/- 0.165 logs for the ELISAs 
and 0.244 +/- 0.285 logs for the neutralization
test.
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Figure 6.10. Antibody subclasses produced by DH 
guinea-pigs vaccinated with A24 cruzeiro then 
revaccinated with A peptide or with KLH- 
glutaraldehyde-A peptide. Ten animals were
vaccinated with lO^g of A24 Cruzeiro in FCA. 
Twenty-eight days later five were revaccinated with 
lOO^g of peptide on Al(OH) 3 ( □) and five were
revaccinated with 200jag of conjugate on Al(0H )3 
( ■  ). The animals were bled every 14 days after 
revaccination and anti-viral titres of IgGl, lgG2 
and IgM in pooled sera were measured by ELISA. 
(Anti-peptide titres of IgGl, IgG2 and IgM were all 
<=1.7.).
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6.5. Discussion,
The results presented here show that KLH-peptide 
conjugates are effective immunogens in terms of 
stimulating a long-lasting anti-peptide antibody 
response following a single vaccination in guinea- 
pigs or rabbits. Long-lasting anti-viral and 
neutralizing antibodies were also detected although 
their induction was dependent upon both the peptide 
and the test species. Thus rabbits produced both 
neutralizing and anti-viral antibodies in response 
to both the A and the 0 peptides, whereas guinea- 
pigs responded in this manner to the A peptide 
only.
Anti-viral and neutralizing antibody in the guinea- 
pig appears to correlate with the presence of anti­
viral IgG, though it should be noted that there is 
not a correlation between anti-viral IgG and 
protection. Thus the guinea-pigs vaccinated with 
200pg of KLH-0 peptide in these experiments did not 
produce either anti-viral or neutralizing antibody, 
whereas both were produced by the guinea-pigs 
vaccinated with 200^g of KLH-A peptide in these 
experiments, or with 2000^g of KLH-0 peptide (Table 
8.2). Of all these, only the KLH-A peptide 
vaccinated animals were protected from challenge 
(Table 6.1 and chapter 4).
Data relating to the duration of the immune 
response following vaccination with synthetic 
peptides has not previously been reported. It is 
encouraging to note that the duration of the 
response observed in this study, at least 400 days,
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approached that of virus vaccinated cattle (van 
Bekkum et al, 1963,1969; Fish et al, 1969).
It was not possible to boost the immune response by 
second and third vaccinations over a period of 56 
days. Animals given one, two or three doses of 
vaccine could not be distinguished serologically. 
This is not too remarkable in view of the high 
circulating antibody titres present at the time, 
but it is at variance with the results of Francis 
et al (1985). However, their methods differed from 
those used in this study in a number of respects. 
For instance, their peptide was similar but not 
identical to the 0 peptide of this study and their 
vaccines were adjuvanted with Al(OH)g and 
administered intramuscularly.
The immune response was boosted in some groups of 
animals, notably rabbits vaccinated with KLH-0 
peptide, when they were revaccinated approximately 
one year after the initial vaccination, by which 
time circulating antibody titres had declined 
considerably. It is not clear why guinea-pigs were 
still generally non-responsive after this length of 
time. It may be that the mode of immunization was 
in some way responsible, or that the earlier 
vaccination schedule had induced a state of 
tolerance. Similar effects were observed in other 
species by Grob and Walter (1983), though no 
explanation was offered. Friedman and Cohen (1984) 
have reported that non-responsiveness in certain 
strains of mice was associated with the persistence 
of adjuvant/antigen depots, such as would be formed
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by the Freund's adjuvanted vaccines used here. 
Whatever the reason for the non-responsiveness of 
guinea-pigs, they were clearly different from 
rabbits in this respect. Whilst the relative 
susceptibility of rabbits and guinea-pigs to the 
induction of tolerance is not known, the phenomenon 
is certainly under genetic control (Benacerraf and 
Germain, 1978) and it is known that various strains 
of inbred mice differ in their abilities to resist 
the induction of tolerance (Fujiwara, 1977; 
Fujiwara and Kariyone, 1982). It is therefore 
quite possible, and consistent with the results 
described in chapter 5, that rabbits and guinea- 
pigs should differ in this important respect.
To conclude that boosting of the immune response to 
synthetic peptides by revaccination with synthetic 
peptides is critically dependent upon the nature of 
the peptide, the animal species, the interval 
between primary and secondary vaccination and, 
probably, the adjuvant used and the route of 
administration, is to some extent a statement of 
the obvious. However, it must be said that 
boosting of the immune response in the case of 
conventional FMD vaccines is considerably less 
critical (T.R. Doel, 1985, personal communication). 
The discrepancy between the results reported here 
and elsewhere (e.g. Francis et al, 1985) serves to 
emphasise the need to properly define the optimum 
conditions for the use of peptide vaccines.
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7. PRIMING THE IMMUNE SYSTEM OF MICE WITH KLH- 
PEPTIDE.
7.1. Introduction.
Results presented in the previous chapter indicated 
that peptide vaccines could, under some 
circumstances, prime the immune system for 
subsequent exposure to peptide. It would clearly 
be useful to know more about the conditions under 
which priming occurs, and to determine whether 
these peptide vaccines are able to prime for virus, 
as has been reported for similar vaccines (Emini et 
a l , 1983b; Francis et a l , 1985).
Various factors, including mode of immunisation and 
the presence of circulating antibody, may affect 
the in-vivo response to vaccination. collen et al 
(1984) have described a method by which antibody to 
aphthovirus may be induced in cultures of 
presensitized mouse splenocytes. This technique 
offered a means of examining the responses of 
splenocytes from peptide- or virus-vaccinated mice 
to stimulation with various antigens in a 
relatively well-defined situation.
This chapter describes a series of in-vivo and in- 
vitro experiments which examine the extent to which 
peptide vaccines are able to prime the immune 
system of mice for subsequent exposure to peptide 
or virus.
7.2 . Response of mice to vaccination and
revaccination with KLH-peptide.
C57B mice (a strain shown to respond well to
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peptide vaccines - see chapter 5 ) were vaccinated 
and revaccinated with a range of doses of KLH-0 
peptide or KLH-A peptide according to the schedule 
shown in Table 7.1. The results are shown in 
Figures 7.1 and 7.2.
Mice vaccinated initially with 4^g or less of KLH-0 
peptide showed no detectable antibody response, 
even after revaccination. Animals vaccinated 
initially with AOjig produced a weak antibody 
response prior to revaccination, after which 
moderate anti-peptide and anti-viral antibody 
titres could be detected in some groups.
Similarly, mice vaccinated with 4jig or less of KLH- 
A peptide did not produce a detectable response to 
the initial vaccination. Those vaccinated with 
0.04jig initially did not produce detectable 
antibody at any time, even after revaccination with 
up to 4jig of the conjugate. In contrast mice 
initially vaccinated with 4jig or 0.4jig of KLH-A 
peptide produced moderate anti-viral and low anti­
peptide antibody titres upon revaccination with 
doses as low as 0.04jig, doses which did not 
stimulate a response when given as the initial 
vaccination.
Those mice vaccinated initially with 40jig of KLH-A 
peptide produced moderate anti-viral and anti­
peptide antibody titres after 28 days. These 
titres did not change significantly following 
revaccination with 0.4 or 4jag of conjugate but were 
clearly boosted by revaccination with 40jjg. 
Neutralizing antibody was not detected in any of
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the groups, whether vaccinated with 0 or A peptide 
conjugates, at any stage of the experiment.
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Table 7.1. Schedule for the vaccination of C57B
mice with KLH-peptide.
Initial vaccination Second vaccination
(Day 0) (Day 28)
KLH-glutaraldehyde- KLH-glutaraldehyde
peptide, peptide.
0. 2ml, in FCA. 0 . 2ml, on Al (OH ) 3 .
Dose, in jig Dose, in jig
40 40
40 4
40 0.4
4 40
4 4
4 0.4
0.4 4
0.4 0.4
0.4 0.04
0.04 4
0.04 0.4
0.04 0.04
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Figure 7.1. The response of C57B mice to 
vaccination and revaccination with a range of doses 
of KLH-glutaraldehyde-0 peptide. Groups of fifteen 
mice were vaccinated with A) 40jig (A), B) 4jig 
( A ) ,  C) 0.4jig ( □ )  or D) 0.04jig ( ■ )  of the
conjugate in FCA. After 28 days each group was 
divided into three groups of five which were 
revaccinated with various doses of conjugate on 
A1 (0H )3 according to the schedule shown in Table
7.1. Animals were bled every 14 days and the anti­
viral and anti-peptide antibody titres of pooled 
sera were determined by ELISA. A single horizontal 
line indicates no response in a group of 15 mice to 
vaccination or revaccination.
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Figure 7.2. The response of C57B mice to 
vaccination and revaccination with a range of doses 
of KLH-glutaraldehyde-A peptide. Groups of fifteen 
mice were vaccinated with A) 40pg ( A ) ,  B) 4pg 
( A ) ,  c) 0.4^g ( □ )  or D) 0.04pg ( ■ )  of the
conjugate in FCA. After 28 days each group was 
divided into three groups of five which were 
revaccinated with various doses of conjugate on 
Al(OH)g according to the schedule shown in Table
7.1. Animals were bled every 14 days and the anti­
viral and anti-peptide antibody titres of pooled 
sera were determined by ELISA. A single horizontal 
line indicates no response in a group of 15 animals 
to vacination or revaccination.
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7.3. Response of mouse splenocytes to in-vitro
stimulation with virus or peptide antigens.
C57B mice were vaccinated and revaccinated with 2pg 
of virus or 40pg of KLH-peptide conjugate. 
Splenocytes from mice shown to have responded to 
vaccination were stimulated with various doses of 
the homologous virus, peptide, KLH-peptide and, in 
the case of conjugate-vaccinated animals, with KLH. 
Production of antibody after eight days was 
assessed by ELISA (Figures 7.3 to 7.8).
There was no major difference between the responses 
of cells from mice vaccinated with either virus, 
OlBFS or A24 Cruzeiro. Splenocytes from OlBFS- 
vaccinated mice (Figure 7.3) produced antiviral 
antibody in response to a wide range of 
concentrations of the inactivated virus. Optimum 
stimulation occurred when the concentration of 
virus in the tissue culture medium was between 0.03 
and 0.003pg/ml. The splenocytes did not produce 
detectable levels of anti-peptide antibody in 
response to virus.
Splenocytes from A24 Cruzeiro-vaccinated mice 
(Figure 7.6) also produced antibody in response to 
a wide range of virus concentrations. Optimum 
stimulation in this case occurred at or below 
O.l^g/ml of virus in the medium, though the exact 
optimum could not be determined precisely since the 
quantity of antibody produced saturated the assay- 
system. These splenocytes apparently produced low 
levels of anti-peptide antibody, though in view of 
the high levels of anti-viral antibody produced the
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result may have been due to cross-reacting anti- 
viral antibody rather than to the specific 
stimulation of anti-peptide antibody.
Splenocytes from mice vaccinated with either virus 
were not stimulated to produce detectable anti­
viral or anti-peptide antibody by either the 
homologous peptide or KLH-peptide.
Splenocytes from mice vaccinated with KLH-peptide 
did not produce any detectable antibody in response 
to the homologous virus or peptide (Figures 7.4 and 
7.7). However, when these splenocytes were 
stimulated with either KLH or KLH-peptide (Figures 
7.5 and 7.8) there was a weak and apparently non­
specific response, usually to the  higher
concentrations of antigen, resulting in low levels 
of anti-viral, anti-peptide and anti-KLH antibody. 
These results were largely confirmed when the 
metabolic activity of cultured splenocytes was 
assayed. Splenocytes from C57B mice vaccinated 
with A24 Cruzeiro or with KLH-A peptide were 
stimulated with A24 Cruzeiro, a  peptide, KLH-A 
peptide or KLH. Metabolic activity over the next 
four days was assessed by MTT reduction (Figures 
7. 9 and 7.10).
Splenocytes from A24 Cruzeiro-vaccinated mice 
(Figure 7.9) were stimulated strongly by virus, 
with an optimum of approximately O.l^g/ml virus in 
the culture medium. The splenocytes were also 
stimulated to a moderate extent by the higher 
concentrations of KLH-peptide or KLH, but were only 
weakly stimulated by peptide alone. Whilst the
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stimulation by peptide is probably indicative of a 
specific but weak secondary response it is less 
easy to explain the response to KLH or KLH-peptide. 
The effect is presumably due to KLH, but KLH is not 
reported to be a mitogen, so the activity observed 
may reflect increased metabolic activity on the 
part of phagocytic or antigen-presenting cells 
unconnected with a specific secondary response. 
Splenocytes from mice vaccinated with KLH-A peptide 
were strongly stimulated by KLH or KLH-peptide at 
the higher dose levels used, but were not 
stimulated at all by virus or peptide. Stimulation 
by KLH-peptide was indistinguishable from 
stimulation by KLH alone and in view of the failure 
of free peptide to cause any detectable stimulation 
it seems likely that the KLH moiety was the active 
component of the KLH-peptide conjugate.
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Figure 7.3. Production of antibody by C57B mouse 
splenocytes primed in-vivo with 01 BFS and 
stimulated in-vitro with a range of concentrations 
of 01 BFS (□) ,  0 peptide (O) or KLH-
glutaraldehyde-0 peptide (A). Anti-viral (upper 
panel) and anti-peptide (lower panel) antibody 
titres of the medium from eight-day old cultures 
were measured by ELISA according to the protocol 
described in section 2.10.4.. Titres are the means 
of duplicate tests and are expressed as the 
absorbance at 492nm after assay of the neat medium. 
Titres obtained from unstimulated cells (<-) or 
from cells stimulated with LPS (<+), a non-specific 
B-cell mitogen, are marked on the vertical axis.
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Figure 7.4. Production of antibody by C57B mouse 
splenocytes primed in-vivo with KLH-glutaraldehyde- 
0 peptide and stimulated in-vitro with a range of 
concentrations of 01 BFS ( □ )  or 0 peptide (O). 
Anti-viral (upper panel), anti-peptide (middle 
panel) and anti-KLH (lower panel) antibody titres 
of the medium from eight-day old cultures were 
measured by ELISA according to the protocol 
described section 2.10.4.. Titres are the means of 
duplicate tests and are expressed as the absorbance 
at 492nm after assay of the neat medium (anti-virus 
or -peptide) or medium diluted 1/2 (anti-KLH). 
Titres obtained from unstimulated cells (<-) or 
from cells stimulated with LPS (<+), a non-specific 
B-cell mitogen, are marked on the vertical axis.
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Figure 7.5. production of antibody by C57B mouse 
splenocytes primed in-vivo with KLH-glutaraldehyde- 
0 peptide and stimulated in-vitro with a range of 
concentrations of KLH ( A ) or KLH-glutaraldehyde-0 
peptide (■) .  Anti-viral (upper panel), anti­
peptide (middle panel) and anti-KLH (lower panel) 
antibody titres of the medium from eight-day old 
cultures were measured by ELISA according to the 
protocol described in section 2.10.4.. Titres are 
the means of duplicate tests and are expressed as 
the absorbance at 492nm after assay of the neat 
medium (anti-virus or -peptide) or medium diluted 
1/2 (anti-KLH).
Titres obtained from unstimulated cells (<-) or 
from cells stimulated with LPS (<+), a non-specific 
B-cell mitogen, are marked on the vertical axis.
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Figure 7.6. Production of antibody by C57B mouse 
splenocytes primed in-vivo with A24 Cruzeiro and 
stimulated in-vitro with a range of concentrations 
of A24 Cruzeiro ( □ ) ,  A peptide ( O ) or KLH- 
glutaraldehyde-A peptide ( A ). Anti-viral (upper 
panel) and anti-peptide (lower panel) antibody 
titres of the medium from eight-day old cultures 
were measured by ELISA according to the protocol 
described in section 2.10.4.. Titres are the means 
of duplicate tests and are expressed as the 
absorbance at 492nm after assay of the neat medium. 
Titres obtained from unstimulated cells (<-) or 
from cells stimulated with LPS (<+), a non-specific 
B-cell mitogen, are marked on the vertical axis.
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Figure 7.7. production of antibody by C57B mouse 
splenocytes primed in-vivo with KLH-glutaraldehyde- 
A peptide and stimulated in-vitro with a range of 
concentrations of A24 Cruzeiro { □  ) or A peptide 
(O). Anti-viral (upper panel), anti-peptide 
(middle panel) and anti-KLH (lower panel) antibody 
titres of the medium from eight-day old cultures 
were measured by ELISA according to the protocol 
described in the text. Titres are the means of 
duplicate tests and are expressed as the absorbance 
at 492nm after assay of the neat medium (anti-virus 
or -peptide) or medium diluted 1/2 (anti-KLH). 
Titres obtained from unstimulated cells (<-) or 
from cells stimulated with LPS (<+), a non-specific 
B-cell mitogen, are marked on the vertical axis.
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Figure 7.8. Production of antibody by C57B mouse 
splenocytes primed in-vivo with KLH-glutaraldehyde- 
A peptide and stimulated in-vitro with a range of 
concentrations of KLH (A) or KLH-glutaraldehyde-A 
peptide (■). Anti-viral (upper panel), anti­
peptide (middle panel) and anti-KLH (lower panel) 
antibody titres of the medium from eight-day old 
cultures were measured by ELISA according to the 
protocol described in section 2.10.4.. Titres are 
the means of duplicate tests and are expressed as 
the absorbance at 492nm after assay of the neat 
medium (anti-virus or -peptide) or medium diluted 
1/2 (anti-KLH).
Titres obtained from unstimulated cells (<-) or 
from cells stimulated with LPS (<+), a non-specific 
B-cell mitogen, are marked on the vertical axis.
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Figure 7.9. Activation of splenocytes from A24 
Cruzeiro vaccinated mice stimulated in vitro with 
A24 Cruzeiro, A peptide, KLH-A peptide or KLH as 
indicated in each panel. Splenocytes were cultured 
in the presence of a range of concentrations of 
antigen (either 10 (• ) ,  1 (O), 0.1 (■} ,  0.01
(A) or 0.001 ( A )  |ig/ml). Metabolic activity was 
assayed on the first four days in culture by 
measuring MTT reduction as described in section 
2.10.4. Activity is directly proportional to 
absorbance. Results are the means of duplicate 
assays and are expressed as a percentage of the 
activity of unstimulated splenocytes.
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Figure 7.10. Activation of splenocytes from KLH- 
glutaraldehyde-A peptide vaccinated mice stimulated 
in vitro with A24 Cruzeiro, A peptide, KLH-A 
peptide or KLH as indicated in each panel. 
Splenocytes were cultured in the presence of a 
range of concentrations of antigen (either 10 ( #), 
1 ( □ ) ,  0.1 ( ■ ) ,  0.01 ( A  ) or 0.001 ( A )  |ig/ml).
Metabolic activity was assayed on the first four 
days in culture by measuring MTT reduction as 
described in section 2.10.4. Activity is directly 
proportional to absorbance. Results are the means 
of duplicate assays and are expressed as a 
percentage of the activity of unstimulated 
splenocytes.
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7.4. Discussion.
A series of experiments were conducted in mice to 
examine the effect of vaccination and revaccination 
with various doses of KLH-peptide conjugates. 
Whereas results with the KLH-0 peptide were 
inconclusive, the responses of a number of groups 
of KLH-A peptide vaccinated mice were clearly 
boosted on revaccination. The effect was dose
dependent and was strongest in the group of mice 
given 40^g of the conjugate followed by a further 
40/jg at 28 days.
Two aspects of these results are of interest.
Firstly, the variation in response to the two 
peptides closely parallels the response in guinea- 
pigs, suggesting that the differences noted in 
chapters 4, 5 and 6 reflect real differences
between the peptides rather than an immunological 
feature peculiar to guinea-pigs. This reinforces 
the observations made at the end of chapter 4
concerning the differences between 0 and A vaccines 
generally.
Secondly, the response of the mice to the 0-peptide 
differs from that observed in chapter 4. In the 
previous experiment the mice produced lower anti­
viral titres than seen here and also produced 
detectable levels of neutralizing antibody. The 
reason for this is unclear, but probably reflects 
the individual variation noted in chapter 4. Emini 
et al (1985) have observed similar variations in 
response between groups of nominally identical 
rabbits vaccinated with poliovirus peptides.
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Splenocytes derived from virus- or KLH-peptide- 
vaccinated mice were stimulated in-vitro with 
virus, peptide, KLH-peptide or KLH. In contrast to 
the results obtained in-vivo there was no evidence 
that splenocytes from KLH-peptide vaccinated mice 
were primed to any antigen but KLH, although 
splenocytes from virus-vaccinated mice were clearly 
primed for subsequent exposure to virus. While 
there is no reason to doubt the in-vivo results 
which show that peptide vaccines are able to prime 
the immune system, the in-vitro results indicate 
that either the priming effect of peptide vaccines 
is very weak compared to priming by virus or that 
there is a major difference between the two 
antigens in the way that they stimulate antibody 
production.
The findings of Lamb et al (1983) provide a 
possible explanation. Synthetic peptides of the 
influenza haemagglutinin molecule specifically 
inhibited the proliferation of cloned influenza- 
immune human T-helper cells. This phenomenon could 
explain why KLH-peptide-primed splenocytes failed 
to respond to stimulation with peptide even though 
they were capable of producing peptide-specific 
antibody when stimulated with LPS. It would not, 
however, account for the slight blastogénie 
response observed when virus-primed splenocytes 
were stimulated with peptide.
Whatever the explanation, there are definite 
differences between the responses to peptide- and 
virus-vaccines, differences which are more complex
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than simple variations in the specificity of the 
antibodies produced. Little is known concerning 
cellular events in the immune response to 
aphthovirus or related viruses. There is obviously 
a requirement for antigen processing and 
presentation, and presumably some T-cell 
involvement, but the nature of these events remains 
obscure. Collen et al (1984) have described 
preliminary studies of some aspects of the cellular 
basis of immunity to aphthovirus. Further studies 
may well provide information of great value in the 
rational design of peptide vaccines.
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8. COMPARISON OF THE PROPERTIES OF PEPTIDE-INDUCED 
AND VIRUS-INDUCED ANTIBODY.
8.1. Introduction.
Results presented in the previous chapters 
indicated differences between the iminunogenicity of 
peptide and virus with respect to the induction of 
anti-viral antibodies. In order to investigate the 
functional basis of these differences two pools of 
anti-viral sera and two pools of anti-peptide sera 
were prepared, as shown in Table 8.1. All pools 
were assayed by ELISA for anti-viral and anti­
peptide antibody. The results are shown in Table
8.2. The anti-viral sera were highly specific for 
the homologous virus. Slight cross reactions with 
the heterologous virus were observed, probably due 
to the presence of 12S particles in the virus 
preparations. Neither anti-viral serum reacted 
strongly with the peptides. The pooled antisera to 
A24 Cruzeiro reacted slightly with the A peptide 
but not at all with the 0 peptide. The pooled 
antisera to OlBFS did not react detectably with 
either peptide. The two pools of anti-peptide sera 
were less specific, reacting strongly with the 
homologous peptide and slightly less strongly with 
the homologous virus. They also reacted weakly 
with the heterologous antigens.
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Table 8.1. Pooled guinea-pig sera - vaccination 
schedule.
Pool Antigen Schedule
1+ KLH-glutaraldehyde 200^g in FCA, day 0
A peptide 200jjg on A 1 (0H)3 , day 28
Bleed, day 56
2. A24 Cruzeiro Hyperimmune
3.' KLH-glutaraldehyde- 2mg in FCA, day 0
0 peptide 2mg on AlfOH)^ , day 28
Bleed, day 56
4. OlBFS 1860 Hyperimmune
In a duplicate group of five animals. all were
protected from challenge after 56 days.
 ^ In a duplicate group of six animals. none were
protected from challenge after 56 days.
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Table 8.2. ATtibo^ titres of the pooled guinea-pig sera (Ascribed in Table 
8.1.
PDOl Asssy^ % 1 0 Antibocÿ Titre
anti- anti- anti anti-
OlEES 0 p^ide A24 Cruz. A p^ icfe
1. Tbtal 2.18 <1.7 4.56 4.86
(anti- IgGl <1.7 <1.7 2.87 3.20
KLH-A p^ i(te) IgG2 <1.7 <1.7 3.35 3.56
lyxi <1.7 <1.7 2.65 3.13
2. Tbtal 3.13 <1.7 5.08 2.00
(anti- igsi <1.7 <1.7 2.77 <1.7
A24 Cruzeiro) lgG2 <1.7 <1.7 4.05 <1.7
2.18 <1.7 3.13 <1.7
3. TDtal 4.56 >5.03 2.65 2.18
(anti- igGl 2.34 4.02 <1.7 <1.7
KEH-Op^ icte) xgG2 3.18 4.10 <1.7 <1.7
igyi 2.65 4.08 <1.7 <1.7
4. TDtal 5.08 <1.7 3.13 <1.7
(anti-OlEES) igsi 2.53 <1.7 <1.7 <1.7
XgG2 3.39 <1.7 <1.7 <1.7
igM 2.65 <1.7 <1.7 <1.7
FT ISA, as (tescribed in secticns 2.8. and 2.9.
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8.2. Virus neutralization.
All four pools were assayed for virus-neutralizing 
antibody by a plaque reduction assay. The results 
are shown in Figure 8.1. The antibody titres 
varied from pool to pool, but the shapes of the 
neutralization curves were essentially similar, 
especially when neutralization by homologous anti­
viral and anti-peptide sera were compared. 
However, anti-peptide sera left a higher proportion 
of non-neutralized virus at low dilutions than did 
anti-viral sera.
Although the two anti-peptide sera had equivalent 
neutralizing activity in this assay it should be 
noted that the guinea-pigs from which the anti-0 
peptide sera were obtained were not protected from 
subsequent challenge, whereas those guinea-pigs 
from which the anti-A peptide sera were obtained 
were protected.
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Figure 8.1. Plaque reduction assays of guinea-pig 
antisera to 01 BFS (()), KLH-glutaraldehyde-0 
peptide ( #), A24 Cruzeiro { □ )  and KLH-
glutaraldehyde-A peptide ( ■ ) .  The protocol is 
described in section 2.9.4. and the results are the 
means of duplicate assays.
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8.3. The effect of complement upon neutralization. 
The effect of complement on neutralization was 
tested by assaying the sera after heating to 
inactivate complement and after the addition of 
fresh guinea-pig complement to heated sera. The 
results are shown in Figures 8.2 and 8.3. No major 
change in the neutralizing activity of any sera was 
observed after either treatment. There was some 
indication that the size of the non-neutralized 
virus fraction at low serum dilutions was increased 
in the absence of complement, most obviously in the 
case of the anti-OlBFS sera, but the effect was 
slight. In general, complement did not appear to 
be important in the neutralization of either virus 
in this assay.
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Figure 8.2. The effect of complement on the 
neutralization of 01 BFS by guinea-pig antisera to 
KLH-glutaraldehyde-0 peptide (A) or 01 BFS (B). 
Sera were assayed in a plaque reduction assay as 
normal ( O) or after heating for 1 hour at 56°C 
{ •). Heated sera were also assayed in the 
presence of an equal quantity of fresh guinea-pig 
serum containing 250 CH50units/ml (A ). The 
results are the means of duplicate assays.
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Figure 8.3. The effect of complement on the 
neutralization of A24 Cruzeiro by guinea-pig 
antisera to KLH-glutaraldehyde-A peptide (A) or A24 
Cruzeiro (B). Sera were assayed in a plaque 
reduction assay as normal ( □)  or after heating for 
1 hour at 56°C ( ■). Heated sera were also assayed 
in the presence of an equal quantity of fresh 
guinea-pig serum containing 250 CH50units/ml (A). 
The results are the means of duplicate assays.
- 229 -
100"
8 0
4 0 "
20"
û- 6 0 "
4 0 "
20 "
0 "
32 5
LOGio SERUM DILUTION
Figure 8.3.
- 230 -
8.4. The effect of competing peptide upon 
neutralization.
Each serum was assayed at a fixed dilution, 
selected to cause approximately 60% neutralization 
according to Figure 8.1. Each pool, at the 
selected dilution, was assayed in a plaque 
reduction assay in the presence of varying 
concentrations of the homologous peptide. The 
effect of the peptide on neutralization is shown in 
Figure 8.4.
The neutralizing activity of both anti-peptide sera 
was reduced over a wide range of peptide 
concentrations, resulting in an increased number of 
plaques compared to a peptide-free control. The 
inhibition of neutralization was greatest in the 
presence of from 1 to lOOjig/ml of either peptide. 
Above or below these limits the inhibitory effect 
was reduced or absent. In marked contrast, the 
neutralizing activity of both anti-viral sera was 
enhanced in the presence of peptide. This 
enhancement was strongest at the highest 
concentrations of peptide and diminished as the 
peptide concentration decreased, but enhancement 
was still detectable at peptide concentrations of 
O.ljug/ml or lower. These effects were not due to 
direct interaction of virus and peptide, for 
instance inhibition of the attachment of virus to 
cells, since the infectivity of virus was unaltered 
when it was assayed in the presence of peptide only 
(i.e. without immune serum).
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Figure 8.4. The effect of competing homologous 
peptide on the neutralization of 01 BFS (upper 
panel) or A24 Cruzeiro (lower panel) by homologous 
antiviral (open symbols) or antipeptide (closed 
symbols) guinea-pig sera. Sera were assayed, at 
concentrations causing approximately 60% plaque 
reduction (anti-01 BFS 1/1200, anti KLH- 
glutaraldehyde-0 peptide 1/300, anti-A24 Cruzeiro 
1/16000, anti KLH-glutaraldehyde-A peptide 1/200), 
in the presence of various concentrations of free, 
monomeric, homologous peptide. The results were 
expressed as a percentage of the plaques counted in 
simultaneously performed peptide-free assays. All 
results are the means of duplicate assays.
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8.5. The formation of immune complexes.
The ability of the sera to form immune complexes 
with virus was determined using density gradient 
centrifugation. Sera were assayed at a range of 
dilutions selected to span the neutralization . 
curves shown in Figure 8.1, and the results are 
shown in Figures 8.5, 8.6, 8.7 and 8.8.
All four sera aggregated virus strongly when 
assayed undiluted. However, as thesera were diluted 
each lost the ability to aggregate virus at a 
different rate. Both anti-peptide sera caused 
significant aggregation only when used neat, though 
the situation is slightly obscured with the anti-A 
peptide pool since the diluting horse serum was 
itself able to non-specifically aggregate a 
proportion of the A24 Cruzeiro virus. Indeed, it 
would appear that the anti-A peptide serum is able 
to inhibit this non-specific aggregation at a 
dilution of 1/100, indicating that antibody is 
still binding to the virus even though complexes 
are not formed.
The anti-viral sera lost their aggregating ability 
more slowly on dilution. The anti-OlBFS serum 
caused detectable aggregation at a dilution of 
1/1600, whilst the anti-A24 Cruzeiro serum could 
cause detectable specific aggregation at dilutions 
as great as 1/5000.
The conclusion that the aggregating activities of 
anti-peptide and anti-viral sera dilute out at 
different rates was confirmed when aggregation was 
expressed as a function of neutralizing activity
- 2 34 -
rather than dilution. As can be seen from figure 
8.9 each type of sera shows a distinct relationship 
between the two activities. This is clearest with 
the anti-OlBFS and anti-0 peptide sera, since the 
non-specific aggregation mentioned above obscures 
the situation for the other two sera. The virus- 
neutralizing activity of anti-peptide sera is 
independent of virus aggregation until some 80% of 
the virus is neutralized, at which point 
significant quantities of aggregated virus become 
detectable. There is a much closer relationship 
between virus-neutralization and aggregation in the 
case of anti-viral sera. significant aggregation 
was detectable when as little as 40% of the virus 
was neutralized.
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Figure 8.5. Complexing of 01 BFS by guinea-pig 
antisera to the virus. virus was incubated in the 
presence of various dilutions of serum and the 
resulting immune complexes were detected by density 
gradient centrifugation according to the protocol 
described in section 2.9.5.. Fraction 1 represents 
the base of the gradient, fraction 12 the top. The 
dilutions of serum tested are shown in each panel, 
together with the neutralizing ability of the serum 
at that dilution as determined by plaque reduction 
assay.. The final panel in the figure shows density 
gradient analysis of the virus alone.
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Figure 8.6. complexing of 01 BFS by guinea-pig 
antisera to KLH-glutaraldehyde-0 peptide. virus 
was incubated in the presence of various dilutions 
of serum and the resulting immune complexes were 
detected by density gradient centrifugation 
according to the protocol described in section 
2.9.5.. Fraction 1 represents the base of the 
gradient, fraction 12 the top. The dilutions of 
serum tested are shown in each panel, together with 
the neutralizing ability of the serum at that 
dilution as determined by plaque reduction assay.
- 238 -
1/30
807o
60
>907,
40
20
1/90 
77 7o
1/270
647o
<  60 
h-
40
1/810
157o
1/2430
07o
40 • *
20'"
FRACTION
Figure 8.6.
- 239 -
Figure 8.7. Complexing of A24 cruzeiro by guinea- 
pig antisera to the virus. Virus was incubated in 
the presence of various dilutions of serum and the 
resulting immune complexes were detected by density 
gradient centrifugation according to the protocol 
described in section 2.9.5.. Fraction 1 represents 
the base of the gradient, fraction 12 the top. The 
dilutions of serum tested are shown in each panel, 
together with the neutralizing ability of the serum 
at that dilution as determined by plaque reduction 
assay.. The final panel in the figure shows density 
gradient analysis of the virus alone.
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Figure 8.8. complexing of A24 cruzeiro by guinea- 
pig antisera to KLH-glutaraldehyde-A peptide. 
Virus was incubated in the presence of various 
dilutions of serum and the resulting immune 
complexes were detected by density gradient 
centrifugation according to the protocol described 
in section 2.9.5.. Fraction 1 represents the base 
of the gradient, fraction 12 the top. The dilutions 
of serum tested are shown in each panel, together 
with the neutralizing ability of the serum at that 
dilution as determined by plaque reduction assay.
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Figure 8.9. The relationship between the abilities 
of guinea-pig anti-viral sera and anti-peptide sera 
to neutralize virus and to aggregate virus into 
immune complexes. The aggregating ability of 
various dilutions of four pools of guinea-pig sera 
(anti-OlBFS, #  ; anti-KLH-glutaraldehyde-0 peptide, 
O ; anti-A24 Cruzeiro, ■  ; anti-KLH-glutaraldehyde- 
A peptide, □  ) was determined by sucrose density 
gradient analysis (Figs. 8.5., 8.6., 8.7. and
8.8.). The neutralizing ability of the four pools 
was determined by plaque reduction assay (Fig. 
8.1.). This figure shows the percentage of virus 
aggregated (i.e. virus in gradient fractions 1 to 
4) by a given dilution of serum as a function of 
the percentage of virus neutralized by that 
dilution of serum (as determined from Fig. 8.1.).
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8.6. The effect of competing peptide upon the 
formation of immune complexes.
Virus was incubated with anti-viral serum in the 
presence of the homologous peptide. ssrum and 
peptide concentrations were selected to span the 
concentrations used in the assays performed to 
determine the effect of competing peptide upon 
virus neutralization, though it should be noted 
that virus concentrations could not be similarly 
adjusted. The results are shown in Figures 8.10 
and 8.11.
Viral aggregation, by either anti-A24 Cruzeiro or 
anti-OlBFS sera, was unaffected by the presence of 
peptide under any of the conditions assayed. 
Aggregation was neither inhibited nor enhanced.
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Figure 8.10. The effect of competing homologous 
peptide upon the complexing of A24 Cruzeiro by 
guinea-pig antisera to the virus. virus was 
incubated in the presence of various dilutions of 
serum and A peptide, as follows:
A. serum 1/500, peptide free,
B. serum 1/500, peptide O.lpg/ml,
C. serum 1/500, peptide lOOpg/ml,
D. serum 1/8000, peptide free,
E. serum 1/8000, peptide O.ljig/ml,
F. serum 1/8000, peptide lOOpg/ml.
The resulting immune complexes were detected by 
density gradient centrifugation according to the 
protocol described in section 2.9.5. Fraction 1 
represents the base of the gradient, fraction 12 
the top.
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Figure 8.11. The effect of competing homologous 
peptide upon the complexing of 01 BFS by guinea-pig 
antisera to the virus. virus was incubated in the 
presence of various dilutions of serum and 0 
peptide, as follows:
A. serum 1/200, peptide free,
B. serum 1/200, peptide O.lpg/ml,
C. serum 1/200, peptide lOOpg/ml,
D. serum 1/1200, peptide free,
E. serum 1/1200, peptide 0.1/ig/ml,
F. serum 1/1200, peptide lOOpg/ml.
The resulting immune complexes were detected by 
density gradient centrifugation according to the 
protocol described in section 2.9.5. Fraction 1
represents the base of the gradient, fraction 12 
the top.
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8.7. Discussion.
The virus-neutralizing activities of the four pools 
of antisera were examined and two differences were 
noted. Firstly, anti-peptide sera left a greater 
proportion of non-neutralized virus than did anti­
viral sera and, secondly, the neutralizing 
activities of anti-peptide sera could be blocked by 
peptide whereas those of anti-viral sera were
enhanced.
Although the origin of the non-neutralized fraction 
is not completely understood, the evidence suggests
that in the case of picornaviruses non­
neutralization is the result of the interaction of
virus with low affinity antibodies. It was shown 
by Dulbecco et al (1956) that the presence of a 
non-neutralized virus fraction was characteristic 
of poliovirus. Similar results had previously been 
obtained with bacterial viruses and numerous 
subsequent studies found that non-neutralized 
fractions could be demonstrated with a wide range 
of viruses (for a review see Mandel, 1978).
Wagner and Cowan (1971) reported that significant 
heterogeneity existed in the virus neutralizing 
properties of guinea-pig, but not bovine, IgG and 
IgM antibodies to aphthovirus. Subsequently,
heterogeneous neutralizing activity in guinea-pig 
sera was also reported by Hardy and Moore (1981, 
1982) who observed that polyclonal, neutralizing 
guinea-pig antisera to aphthovirus included two 
populations of antibodies. One population of 
antibodies, specific for 146S virions, neutralized
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with high efficiency whereas a second population of 
antibodies cross-reactive with virions and 12S 
particles was relatively ineffective at 
neutralizing virus. The second population of 
antibodies bound to virus and formed immune 
complexes but a proportion of bound or complexed 
virus was not neutralized. Interestingly,
neutralizing antibody induced by VPl was entirely 
of this second type.
The results presented in this study indicate that 
peptide, too, may induce antibodies mainly of the 
second type. Thus, the anti-peptide sera examined 
were less specific than the anti-viral sera (Table 
8.2) and had a tendency to form infectious 
complexes with virus (Figure 8.1).
Heterogeneous neutralizing activity has also been 
observed in antisera to poliovirus. Ozaki (1968) 
and Lewenton-Kris and Mandel (1972) observed a 
correlation between early, low affinity, antibody 
and the non-neutralized state, in that early sera 
left a greater non-neutralized fraction than late 
sera. Lewenton-Kris and Mandel (1972) found in 
addition that early sera was able to inhibit 
neutralization by late sera. This second finding 
is of particular significance, demonstrating that 
non-neutralized virus may actually be protected 
from neutralization. Massey and Schochetman (1981), 
working with monoclonal antibodies to Kirsten 
sarcoma virus, showed unequivocally that some non- 
neutralizing antibodies not only bound to virus but 
could compete with and block the action of
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neutralizing antibodies.
The presence of antibodies similar to these may
account for the observation that peptide is able to 
enhance neutralization by anti-viral sera. 
Firstly, peptide apparently competes for a 
population of blocking antibodies in anti-viral 
serum. Secondly, the larger non-neutralized 
fractions observed with the anti-peptide sera 
suggest that the antibodies in these sera have a 
relatively low affinity for the virus. Assuming 
that peptide reacts with an equivalent antibody 
population in both anti-viral and anti-peptide 
sera, this suggests that there is a population of 
low affinity antibodies induced by virus which 
neutralize virus inefficiently and which block the 
action of more effective neutralizing antibodies. 
More importantly, it also suggests that a 
proportion of the anti-viral antibodies induced by
peptide may be able to protect the virus from
neutralization.
The third major difference observed between the
anti-viral and anti-peptide sera was in their 
ability to aggregate virus into immune complexes. 
Anti-viral sera were far more effective at 
aggregating virus, whether this was expressed as a 
function of dilution or of neutralizing ability. 
This is consistent with the conclusion that anti­
peptide sera has a lower affinity for virus than 
does anti-viral sera, since low-affinity antibodies 
would be expected to form complexes less 
efficiently (Steensgard et a l , 1977). The
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important feature of these results is that the 
relationship between neutralization and aggregation 
is different for anti-viral and anti-peptide sera. 
This implies either that aggregation is unimportant 
in the neutralization of aphthovirus or that the 
two types of sera neutralize aphthovirus by 
different means.
The available evidence generally supports the 
second hypothesis. The aphthovirus neutralizing 
monoclonal antibodies of Baxt et al (1984) acted in 
three distinct ways, one of which involved
aggregation of the virus. Brioen et al (1983) 
described a poliovirus neutralizing monoclonal 
antibody which acted solely by aggregating the 
virus, whereas Icenogle et al (1981, 1983) reported 
two monoclonals which neutralized poliovirus by two 
different mechanisms, both independant of
aggregation. Multiple neutralization mechanisms 
have also been described by Emini et al (1983c, 
1983d) who found that monospecific antisera to 
poliovirus capsid protein VP3 neutralized the virus 
in a manner distinct from neutralization by
monospecific antisera to VPl.
The observation that, whereas its neutralizing
ability was enhanced, the aggregating ability of 
anti-viral serum was unaffected by the presence of 
peptide could be taken to support the view that 
aggregation is unimportant in relation to 
neutralization. It is more likely, though, that 
this result reflects the nature of the peptide- 
reactive antibodies in anti-viral sera. Since, on
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the basis of the ELISA results, the proportion of 
these antibodies in such sera is low their removal 
would be detectable only if they exerted a 
disproportionate effect in some way. They
apparently do this with regard to neutralization by 
inhibiting the action of other antibodies, but 
there is no reason to expect them to have a similar 
effect on aggregation. Indeed, if these antibodies 
are analogous to the virus-reactive antibodies in 
anti-peptide sera then it is likely that their 
aggregating activity is a minor component of the 
total aggregating activity of the sera.
Complement had no apparent role to play in the
neutralization of virus by either anti-peptide or
anti-virus sera. It is difficult to assess the 
significance of this result, since it is known that 
results obtained in tissue culture assays of this 
kind are highly dependent upon several factors, 
including the cells used and the respective species
of origin of the antiserum and complement (Ferris
and Donaldson, 1983; Rweyemamu et a l , 1977. For a 
review see Cooper, 1979). However, under 
equivalent conditions there were no obvious 
differences in the requirements for complement of 
the four sera pools examined in this study. It 
seems likely that a requirement for complement is 
not an explanation for the other differences 
observed between anti-peptide and anti-viral sera. 
A number of workers have noted discrepancies 
between neutralizing antibody titres and protection 
(see section 1.5.2). The results of Bradish et al
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(1962) and Knudsen et al (1983) clearly showed 
that, for aphthovirus, neutralization in vitro and 
protection were discrete phenomena. Immune
complexes of aphthovirus which were infectious in- 
vitro were not infectious in vivo, or were of much 
reduced infectivity, when inoculated at a site 
where they would be accessible to phagocytosis.
It is apparent from the results reported both here 
and in preceding chapters that there is a similar 
discrepancy in the case of peptide vaccines. The 
A peptide induced antibody which was neutralizing 
and protective, whereas the 0 peptide induced 
antibody which was neutralizing but not protective. 
It follows that either the A peptide induces a 
spectrum of antibodies which is not equivalent to 
that induced by the 0 peptide, or that the two 
peptides induce equivalent antibodies but the two 
strains of virus differ in their susceptibility to 
these antibodies. The widely varying responses of 
guinea-pigs to the two peptides tends to support 
the former hypothesis, but there is also some 
evidence to support the second hypothesis. For 
cattle the neutralizing antibody titre 
corresponding to 90% protection following 
vaccination with an inactivated virus vaccine was 
much greater for an 0 serotype virus than for A or 
C serotype viruses (Pay et a l , 1983). Meloen and 
Barteling (1983) have reported finding fewer 
neutralizing epitopes on an 01 virus than on an AID 
virus. similarly, there are differences in the 
numbers and locations of neutralizing sites between
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polioviruses types 1 and 3 (see section 1.4.3). 
This situation is not strictly analogous, since the 
additional sites on poliovirus type 1 are located 
on capsid proteins VP 2 and VP3, but it does serve 
to show that there can be major differences between 
the neutralization of closely related
picornaviruses.
The possibility that there is such a difference 
between A and 0 serotype aphthoviruses, and
presumably among the other five serotypes as well,
is essentially the same point that was made in
chapter 4. When considered in conjunction with the
different activities of peptide-induced and virus- 
induced antibodies it emphasises how little is 
known of the mechanisms by which aphthovirus is 
neutralized.
The design of peptide vaccines to date has centered 
upon identifying and copying neutralizing 
determinants within viral capsid proteins. This 
approach has proved succesful, but there are 
clearly differences between the effects of peptide 
and viral vaccines. It is not surprising that 
peptide-induced antibodies have a different 
spectrum of activity to virus-induced antibodies, 
but this is clearly of crucial significance to the 
use of peptides as vaccines. Without a proper 
understanding of the functional basis of 
neutralization (and protection) there will always 
be a strong empirical element in the design of 
peptide vaccines.
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SUMMARY AND CONCLUSIONS
Ideally, synthetic peptide vaccines should provide 
a cheap, stable, innocuous product of standardised 
and defined composition (see section 1.6.4.). 
However, these expectations presuppose that such
vaccines are sufficiently immunogenic to confer an 
acceptable level of protection. This thesis has 
examined the immunogenicity of synthetic peptide 
vaccines against foot-and-mouth disease in a range 
of laboratory animals and in cattle, the most 
important of the domestic animals susceptible to 
the disease.
The peptides used in this study were the simplest 
form of synthetic antigen, corresponding to the 
sequence of a single linear antigenic region from 
the aphthovirus capsid protein, VPl. No attempt 
was made to control their secondary structure, for 
instance by the incorporation of cysteine residues, 
nor did the peptides attempt to mimic more complex 
antigenic sites by including other, non-contiguous, 
antigenic regions from the protein.
Preliminary studies (chapter 4) showed that the use 
of a carrier protein enhanced the immunogenicity of 
the peptides, a finding in agreement with several 
earlier reports (see section 4.5). Furthermore, it 
appears from the results presented here that the 
nature of the carrier and cross-linking agent are 
relatively unimportant. This indicates that there 
is a wide choice of potential carriers if these 
prove to be a necessary component of an effective
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vaccine.
Possibly the most interesting aspect of these 
results is that the two peptides were of quite 
distinct immunogenicity, despite copying 
corresponding regions of VPl (chapter 4). The 
possibility that the antigenic characteristics of 
the two parent viruses are not equivalent has
important implications for the development of
synthetic vaccines. If true, it might require the 
development of peptides specifically tailored for
each serotype or even each vaccine strain of
aphthovirus.
The immunogenicity of the peptides varied among the
species in which the tests were performed, and
there was marked variation between the responses of
individuals of the same species (chapter 5).
Similar results have recently been described by
other workers (see section 5.7) and if this proves
to be a common feature of peptide vaccines it could
be a major obstacle to their succesful development.
To overcome the problem of interspecies variation
either a suitable model for cattle and other
domestic animals must be established or vaccines
must be developed using the target species, most
probably cattle, for tests. Neither option is
particularly attractive but it cannot be assumed
that traditional small animal models for FMD can be
used uncritically to test synthetic vaccines. In
any case this would not solve the second problem,
that of a varying intra-species response. The
experiments described in chapter 5 were not
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designed to address this problem directly, so it is 
not possible to draw a firm conclusion. It may be 
that the problem can be solved simply, for instance 
by selection of an appropriate adjuvant or dosage, 
but it is equally possible that some individuals 
lack the Ir genes required to respond to the 
restricted set of epitopes presented on a 
particular peptide.
A more encouraging result was that the duration of 
the immune response to the peptide vaccines was 
comparable to the duration of the response induced 
by conventional vaccines (chapter 6). However, the 
ability of peptide vaccines to boost the immune
response appears to be restricted in some way 
(chapters 6 and 7), although the reason for this is 
not clear. Possibly this feature of the response 
is also a consequence of the restricted set of
epitopes on a peptide.
Of more fundamental importance are those results 
which indicate important qualitative differences 
between the antibodies induced by virus and peptide 
(chapter 8). It would be interesting to know 
whether such differences can be detected for other
peptide vaccines, since the assessment of such
differences could provide a simple means of 
screening potential peptide vaccines. The more 
closely the induced antibodies resemble virus 
induced antibodies, the more effective such a
vaccine might be expected to be.
Thus, to summarise, peptide vaccines of the type 
studied could be sufficiently immunogenic to confer
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protection. However there were important
differences between the peptide vaccines and 
conventional vaccines. There was marked inter- and 
intra-species variation in the response to the 
peptide vaccines and this was compounded by 
differences between the two peptides studied. 
There were also important qualitative differences 
between the antibodies induced by peptide and by 
virus. The immune response to peptide vaccines is 
not truly comparable with that to conventional 
vaccines and a better understanding of the reasons 
for this will be required if the design of peptide 
vaccines is to advance beyond its present, 
empirical, stage.
A.D. MURDIN, JULY 1985.
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